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SUMMARY
At the outset of this project Epstein-Barr virus (EBV) was associated with a 
proportion of cases of Hodgkin's disease (HD). Clonal EBV genomes were 
detected in HD tumour material however the localisation of EBV within the 
malignant cells had not been clearly demonstrated. Following the availability of 
monoclonal antibodies to the EBV latent genes, the expression of LMP-1 and 
EBNA-2 was investigated in a series of HD cases. EBV LMP-1 was expressed in 
Reed-Sternberg (RS) cells in the majority of cases studied, however there was a 
lack of expression of EBNA-2. The detection of LMP-1, which has been shown 
to have oncogenic potential, has strengthened the evidence that EBV is involved 
in the pathogenesis of a proportion of HD cases. These results indicated that a 
distinct pattern of EBV latent gene expression, designated Lat II, was observed 
in HD.
As LMP-1 has been shown to upregulate a number of cellular genes, the 
expression of CD23 and bcl-2 in HD were examined. CD23 and bcl-2 were 
rarely detected In RS cells. There was no correlation between LMP-1 expression 
and the presence of CD23 or bci-2. These results indicate that the role of EBV in 
HD is independent of the upregulation of CD23 and bcl-2.
Further evidence that EBV is localised to RS cells in HD was obtained following 
the detection of EBER RNA in RS cells using an in situ hybridisation technique. 
Comparison of techniques to detect EBV in HD tumour material indicated that the 
EBER RNA in situ hybridisation assay was the most useful and reliable method 
of determining EBV latent infection. We have categorised HD cases which were 
EBV-positive by in situ assays or using Southern blot hybridisation for the 
detection of clonal EBV genomes as EBV-associated.
XII
Using the above criteria the epidemiological features of HD were investigated 
with respect to EBV. Paediatric HD cases, in particular cases <10 years of age, 
older adults and cases of MCHD subtype were strongly EBV-associated. There 
was no evidence that EBV is a useful prognostic marker.
Although the epidemiological features of HD suggest that young adult HD is most 
likely to be caused by an infectious agent our results indicated that these cases, 
in particular NSHD, were seldom EBV-positive. We have speculated that 
another virus may be involved in this age group. In order to eliminate the 
possibility that other known DNA viruses may be involved in HD, we examined 
clinical samples from HD, NHL and reactive conditions for the presence of 
adenovirus, SV40, LPV and HHV-7. We have not detected any of the viruses in 
these clinical samples. The implications of these results will be discussed further 
in this thesis.
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Chapter 1 
General Introduction
1.1 Aim of study
A number of malignant diseases are known or suspected to have an infectious 
aetiology. For many years it has been suggested that the malignant lymphoma 
Hodgkin's disease (HD) may be caused by a virus. Recently a proportion of HD 
cases have been associated with the lymphotropic herpesvirus Epstein-Barr virus 
(EBV). The role of EBV in the pathogenesis of HD is unclear and at the initiation of 
the work presented in this thesis few studies had investigated the localisation of 
EBV within the affected tissues in HD. This study examined the localisation of EBV 
within Reed-Sternberg (RS) cells and the reactive infiltrate.
In order to gain some insight into the role EBV plays in HD, the presence of the B- 
cell activation antigen, CD23 and proto-oncogene bcl-2 was investigated in RS cells. 
These cellular genes have been shown to be upregulated by EBV, in vitro. The 
EBV status of HD cases was further correlated with the epidemiological features of 
the disease. A range of HD cases and non-Hodgkin's lymphomas (NHL) were also 
analysed for the presence of other oncogenic DNA viruses.
1.2 Classification of lymphomas
Classification systems for malignant lymphomas are complicated (Lukes & Collins, 
1975, 1977, Gerard-Marchant et al., 1974, Rosenberg, 1982, Bennett et a!., 1991). 
New disease categories have now been recognised as more detailed information 
concerning lymphomas becomes available (Harris et a!., 1994). The Kiel 
classification system of non-Hodgkin's lymphoma (NHL), which was recently 
updated, subdivided lymphomas into low and high grade classes of either B- or T- 
cell origin (Stansfeld et al., 1988). Categorisation of lymphomas based on
immunophenotyping as a single entity is not ideal as the normal counterpart of 
many neoplastic cells has not been identified. Harris et al. (1994) has suggested 
that other features such as treatment category and clinical aggressiveness of NHL 
should be included in classification systems. In contrast to the NHL classification 
system the subdivision of HD using the Rye classification system has remained 
stable and is generally accepted as pathologically relevant (Bennett eta!., 1991, see 
section 1.3.3).
1.3 Hodgkin's disease
Hodgkin's disease (HD), an unusual disease of lymph nodes, was first described by 
Thomas Hodgkin in 1832 (Hodgkin, 1832). It was not until the latter half of the last 
century that Sternberg and Reed described the large bilobed or multinucleated giant 
cells, which are now termed Reed-Sternberg (RS) cells (Sternberg, 1898, Reed, 
1902). Early investigators suggested that HD was a form of Mycobacterium 
tuberculosis (Sternberg, 1898), or was a chronic immunological disorder. The 
malignant nature of HD has now been established (Kaplan, 1980, 1981, Rosenberg, 
1989).
1.3.1 Clinical features of HD
The clinical features of HD include lymphadenopathy; the most common sites of 
presentation are in the neck and mediastinal lymph nodes (Mauch, 1993). In 
addition constitutional B symptoms i.e. pyrexia, night sweats or weight loss have 
been observed (Selby & McElwain, 1987).
1.3.2 Histopathological classification and definition of HD
The histopathological features of HD have been examined by Lukes and Butler 
(1966). The diagnosis of HD is dependent on the identification of Reed-Sternberg 
(RS) cells or a morphological variant of this cell, within an appropriate histological 
background (Lukes, 1971). The cellular infiltrate is heterogeneous in HD consisting 
of lymphocytes, plasma cells, histiocytes, eosinophils and polymorphonuclear 
leukocytes. The diagnosis of HD requires the presence of RS cells within the 
context of this cellular background as RS-like cells have been Identified in other 
conditions including infectious mononucleosis and NHL (Strum ef a/., 1970, Tindle et 
a/., 1972),
The most commonly used classification system of HD, proposed at an International 
meeting in Rye, New York (Lukes et a/., 1966) simplified the Lukes and Butler 
system as shown in Table 1.1. The Rye classification system incorporates the 
proportion of RS cells and the nature of the cellular infiltrate within a lesion and this 
system forms the basis for the division of HD into four subgroups; nodular sclerosis 
(NSHD), mixed cellularity (MCHD), lymphocyte depleted (LDHD) and lymphocyte 
predominant (LPHD) (Lukes et a/., 1966, Butler, 1992). These four histological 
subtypes differ in their histopathological appearance (reviewed by Krajewski & 
Jarrett, 1994), age and sex distribution (McKinney et a!., 1989, Alexander et al., 
1989, 1991a) and prognosis (reviewed by Ultmann, 1992). These pathological 
features are summarised in the following sections 1.3.2.1-1,3.2.4.
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1.3.2.2 Nodular sclerosis HD
Nodular sclerosis HD (NSHD) is the most common form of HD invoiving 70% of 
cases (Holman ef a/., 1983). The majority of cases are adults less than 40 years of 
age. A variant form of the RS cell, the lacunar cell is seen in NSHD. The diagnosis 
of NSHD requires the presence of classical RS cells, lacunar cells and nodular 
formation with orderly bands of biréfringent collagen that partially or entirely 
subdivides abnormal lymphoid tissue into isolated nodules (Bennett et a/., 1991, 
Figures 1.2a). NSHD has been further subdivided into good and poor prognostic 
categories, NS-1 and NS-2, respectively (MacLennan etaL, 1989, Figure 1.2.b).
1.3.2.1 Lymphocyte predominance HD
Lymphocyte predominance HD (LPHD) involves between 5% and 10% of cases of 
HD and has been divided Into nodular lymphocytic and histiocytic predominance
(NLPHD) and diffuse lymphocytic and histiocytic predominance (DLPHD) types. 1
■This subtype of HD presents mainly in young adult (15-34 years of age) mates.
■LPHD is characterised by the presence of the L & H type of RS cell, or "popcorn" ....
cells, with very few classical RS ceils (Wright, 1989, Butler, 1992, Figure 1.1).
Cases of LPHD have a distinct phenotype CD45+, GDIS', cytoplasmic J chains and 
B-cell-associated antigens^ (GDI 9, GD20, GD22) suggesting that the L & H cells 
are of B-cell origin (Poppema et a!., 1979a, 1979b, Stein ef a/., 1986, Timens et a!.,
1986, Nicholas et a!., 1990). These cases tend to be described as a distinct clinical 
entity (Pinkus & Said, 1988, Nicholas etaL, 1990, Mason e tal., 1994).
Figure 1.1 Lymphocyte predominance HD 
Haematoxylin & eosin-stained section
(Magnification x250)
Lymphocyte predominance HD case. L & H type of Reed-Sternberg cells are 
present in the section.
(kindly provided by Dr AS Krajewski, University of Edinburgh Medical School)
Figure 1.2a Nodular sclerosis HD 
Haematoxylin & eosin-stained section
(Magnification xlOO)
Figure 1.2b Nodular sclerosis HD, NS-2 
Haematoxylin & eosin-stained section
(Magnification x250)
(kindly provided by Dr AS Krajewski, University of Edinburgh Medical School)
1.3.2.3 Mixed cellularity HD
The mixed cellularity HD (MCHD) subtype accounts for between 20% and 40% of 
cases (Colby ef a/., 1982). This subtype is more common in maie patients and aiso 
within the older age category. Criteria for inclusion in this category are not always 
clear as cases which do not fulfil the morphological appearance of NSHD or LPHD 
tend to be classified as MCHD. RS cells are easily detected and the background 
cell population is mainly composed of small lymphocytes, plasma cells, neutrophils 
and eosinophils (see Figure 1.3).
1.3.2.4 Lymphocyte depleted HD
Lymphocyte depleted HD (LDHD) is the least common type of HD and represents 
<5% of cases (Kant et al., 1986). This subtype generally presents in the older age 
group (>49 years) and has been shown to be the most aggressive type of HD with 
the shortest median survival period. Two subtypes of LDHD are recognised, diffuse 
fibrosis and reticular (Lukes & Butler, 1966). On microscopical examination there is 
an overall cellular depleted appearance with disordered fibrosis and RS cells are 
present in almost every high power field.
1.3.3 Immunophenotyping and genolyping of HD cases
The cellular origin of the RS cell is still under debate (Hsu, 1990, Drexler et ai, 
1992). The characterisation of RS cells has proven difficult due to the small number 
of malignant cells present in HD lesions. In addition studies to determine the 
phenotype of the cells have been limited due to the small numbers of lineage 
specific reagents available for use on routinely fixed tissue. Many different cell
Figure 1.3 Mixed cellularity HD 
Haematoxylin & eosin-stained section
(Magnification x250)
Mixed cellularity HD case. Reed-Sternberg cells are present in the biopsy 
(kindly provided by Dr AS Krajewski, University of Edinburgh Medical School)
types have been proposed as the normal counterparts of RS cells including B- and 
T-lymphocytes, macrophages, monocytes, myeloid cells and interdigitating reticulum 
cells (Drexler & Leber, 1988). Recent immunophenotyping studies on frozen and 
fixed HD tissue have been extensively reviewed by Drexler (1992).
Evidence for a lymphoid origin for RS cells is limited; variable percentages of 
positivities of the T-ceii markers (CD2, CDS or CD4) and B-cell markers (CD19, 
CD20 and CD22) have been found on the NSHD, MCHD and LDHD cases (Faiini et 
al., 1987, Casey eta!., 1989, Kadin eta!., 1988, Schmid eta!., 1991).
The classical histological subtypes, NSHD, MCHD and LDHD, showed expression 
of CD15+/-, but there was a lack of CD45 expression on RS cells (Stein eta!., 1991). 
With the exception of LPHD, the majority of HD cases from the remaining 
histological subtypes expressed the activation markers, CD30 (Ki-1), CD25 
(interleukin-2 receptor), CD74 (HLA-associated), HLA-DR and CD71 (transferrin 
receptor). These studies have enabled the distinction between MCHD and NHL, in 
particular peripheral T-cell lymphoma and T-cell rich and histiocyte rich B-cell 
lymphoma (Krajewski etal., 1988, Harris, 1992).
A number of immunohistochemical studies have reported negative data which failed 
to support the notion that RS cells may have been derived from interdigitating 
reticulum or dendritic reticulum ceils (Kadin, 1982, Carbone et a!., 1987, Kornstein 
etal., 1986, Kennedy etal., 1989). Curran and Jones (1977) implied that the origin 
of the RS cell may be follicular dendritic reticuium ceiis. In a more recent study, 
Delsol et al. (1993) reported expression of CD21 in a large proportion of HD cases. 
As CD21 is strongly expressed in follicular dendritic reticulum cells, it was suggested
that there may be a relationship between follicular dendritic reticulum cells and RS 
cells in HD.
Studies to investigate the presence of Immunoglobulin (Ig) and T-cell receptor 
(TCR) genes in HD have been used to determine the histogenesis of RS cells.
These studies have been reviewed by Drexler (1992) and Diehl et al., (1990). 
Rearrangement of Ig genes has been detected in a proportion of HD cases (Weiss 
etal., 1986, Knowles etal., 1986, Griesser etal., 1987, Gledhill et al., 1990). One 
report detected Ig gene rearrangements in 9 of the 35 HD cases studied (Gledhill et ft
al., 1991). A high incidence of TGRp chain gene rearrangements was reported in 
two studies (Griesser et al., 1987, Herbst et al., 1989), however other studies have 
failed to confirm these findings (Schmid et al., 1991, Gledhill et al., 1990).
1.3.4 Epidemiology of HD
HD is a rare malignancy, representing only 1% of cancers diagnosed in the UK 
(Cartwright et al., 1990). HD is uncommon in children of four years or younger 
(Kung, 1991).
In contrast to other malignancies, epidemiological studies have shown a bimodal 
age incidence curve for HD (MacMahon, 1966). This age incidence curve varies 
depending on the economic status of the countries studied. Correa & O'Conor 
(1971) described three epidemiological patterns of HD. In developing countries, a 
type I pattern is evident; the first age incidence peak occurs in childhood between 
the ages of 7 and 12 years and there is low incidence in young adulthood. The type 
III pattern is observed in developed countries. In this pattern the age incidence 
rises through childhood and the first peak is seen between the ages of 15 and 34
years. In both developed and developing countries, the incidence of HD increases 
in older age (Glaser & Swartz, 1990), however, in a recent study in the UK a plateau 
from 45 years of age was observed (McKinney et al., 1989, Correa & O'Conor, 
1971). An intermediate pattern of age incidence, designated type II, in which the 
childhood peak moves to a slightly older age, has been observed in countries 
undergoing socio-economic development and in rural areas of developed countries 
(Correa & O'Conor, 1971, Merk etal., 1990, Alexander etal., 1991b, Figure 1.4).
The proportion of the four histological subtypes of HD varies between age groups; 
NSHD predominates from the age of 11 years into young adulthood whereas MCHD 
is relatively more common in children under 1 0  years of age and in the older adult 
age group (McKinney etal., 1989, Correa & O'Conor, 1971, Glaser & Swartz, 1990). 
In comparison with the NSHD subtype, when taken together, the other histological 
subtypes generally show a gradual increasing incidence with increasing age (Figure 
1.5).
A high male:female ratio has been noted in children and is also present in older 
adults (Spitz et ai, 1986, McKinney et al., 1989, Glaser & Swartz, 1990). In the 
young adult age group there are similar rates of female and male HD cases.
On the basis of the above epidemiological data, a number of hypotheses have been 
suggested to account for the aetiology of HD. MacMahon (1966) proposed that the 
three distinct age groups 0-14 years, 15-34 years and >49 years may have different 
aetiologies. He further suggested that HD in young adults may be caused by an 
infectious agent. Recent studies have supported the "two-disease" hypothesis in 
adult HD. The factors associated with the development of HD are different in young
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Figure 1.5 Age-specific rates of Hodgkin's disease by
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adult HD cases from those observed in older cases (Cole et a/., 1968, Alexander et 
a/., 1991a).
The risk of developing HD in young adults has been associated with good living 
conditions during childhood, but this finding was not substantiated for older age HD 
cases (Gutensohn, 1982, Gutensohn & Cole, 1980, Paffenbarger et al., 1977, 
Abramson et al., 1978). Other epidemiological studies have indicated that high 
maternal education, small family size and early birth order children also increased 
the risk of developing HD (Gutensohn & Cole, 1981, Vianna & Polan, 1978). 
Abramson (1974) noted that the geographical distribution of HD was comparable to 
that of an infection which was subsequently controlled by vaccination - i.e. paralytic 
poliomyelitis (PP).
An analogy has been drawn between the epidemiological features of PP and HD - 
the polio model (Dauer, 1955, Gutensohn & Cole, 1977, Melnick, 1990). Prior to 
vaccination, environmental conditions determined the age at which infection with the 
polio virus was likely to occur and this subsequently determined the possible 
outcome of infection. In developing countries, exposure to common infectious 
agents was widespread in childhood and most individuals developed immunity 
before young adulthood. Children were infected early in life thus paralytic 
symptoms were observed in this age group. In developed countries infection in 
childhood was rare and therefore on exposure to the infectious agent older children 
and young adults were more likely to be infected. Infection in the latter age groups 
leads to a greater risk of developing paralytic manifestations of the infection.
HD in young adults, therefore, may be related to the age of exposure to infectious 
agents which in turn is determined by the socio-economic conditions encountered at
10
that time, in contrast to MacMahon's hypothesis, the polio model therefore predicts 
that the same infectious agent is involved in paediatric cases in developing 
countries and young adult cases in developed countries. These features are 
discussed further in Chapters 5 and 6 .
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1.4 Involvement of viruses in malignant disease
Both RNA and DMA viruses have been associated with the development of tumours 
in animals and less frequently in humans (Table 1.2). In particular the RNA virus 
family Retroviridae, subfamily Oncovirinae and the DNA virus families, 
Herpesviridae, Hepadnaviridae and Papovaviridae, which contains the subfamily 
Papillomavirinae, have all been associated with malignant disease in humans.
1.4.1 Herpesviruses
The family Herpesviridae represents a group of over 100 viruses characterised by 
the presence of a linear double stranded DNA genome ranging from 120 to 235 
kilobase pairs (kbp) (Roizman & Baines, 1991). On examination by electron 
microscopy, the herpesvirions are enveloped particles of 120 to 300 nm in diameter 
(reviewed in Roizman & Furlong, 1974). Structurally, the virion consists of a core 
containing the linear double stranded DNA (Furlong et a/,, 1972), an 
icosadeltahedral capsid of 1 0 0 - 1 2 0  nm in diameter containing the viral nucleic acid 
(Wildy & Watson, 1963), an amorphous tegument which surrounds the capsid 
(Roizman & Furlong, 1974) and an envelope from which viral glycoprotein spikes 
project from the surface.
Herpesviruses are classified according to the biological behaviour of the virus. The 
nature of the host range, cell tropism and site of latency are taken into consideration 
within the classification system (Roizman et al., 1992). On the basis of these 
biological properties three subfamilies of herpesviruses, alpha, beta and gamma 
have been described.
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Table 1.2 Viruses associated with tumours
Taxonomic group Associated cancer
RNA viruses
1 . Retroviruses
Oncoviruses Hematopoietic cancers involving 
lymphoid, myeloid or erythroid 
cells, various sarcomas and 
carcinomas
2 . Flaviviruses Hepatocellular carcinoma
DNA viruses
3. Hepadnaviruses Hepatocellular carcinoma
4. Polyomaviruses Various solid tumours
5. Papillomaviruses Papillomas and carcinomas
6 . Adenoviruses Various solid tumours
7. Herpesviruses Lymphomas and carcinomas
8 . Poxviruses Myxomas and fibromas
Reproduced from Benjamin T, Vogt PK (1990) Cell transformation by viruses. In: 
Virology, edited by Fields BN and Knipe DM, New York: Raven Press, p 381
The alphaherpesviruses have a wide host range, short replication cycle (18-20 
hours) and establish latency in neuronal ganglia or lymphoid tissue. Members of 
this subfamily include herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV- 
2), varicella zoster virus (VZV), pseudorabies virus (PRV), equine herpesvirus-1 
(EHV-1) and equine herpesvirus-4 (EHV-4).
In contrast the betaherpesviruses display a more restricted host range. Viral 
replication is slow and latency is observed in lymphoid cells, kidneys and salivary 
glands. Members of this subfamily include human cytomegalovirus (HCMV), and 
the recently identified human herpesviruses (HHV), HHV- 6  and HHV-7, have also 
been assigned to this group.
Gammaherpesviruses have a limited host range in vivo. All members of this 
subfamily have been shown to replicate in lymphoblastoid cells in vitro and some 
may cause lytic infection in some types of epithelial and fibroblastoid cells. In 
addition, these viruses have the ability to immortalise either B-lymphocytes (7 I 
subgroup) or T-lymphocytes (7 2  subgroup) and some can cause iymphoproliterative 
disease in the host. Latency usually occurs in lymphoid tissue. The 7 I subgroup of 
gammaherpesviruses includes EBV.
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1.4.2 Herpesvirus life cycle
There are two distinct phases of the herpesvirus life cycle - lytic and latent phases. 
Primary infection by herpesviruses occurs in a number of stages in which the virus 
gains entry to the host cell and results in the release of progeny virus and death of 
the host cell. The virus also has the ability to establish a state of latency in the host. 
In order to initiate infection, the virus attaches through its envelope glycoproteins to 
receptors on the surface of the host cell. The receptor for EBV is the C3d 
(complement, CD21) receptor (Nemerow et a/., 1986). Following binding, 
penetration is complete in 1-2 hours (Fingeroth et al., 1984). In the case of HSV-1 
and HSV-2 the receptors are heparan sulphate proteoglycans (Wudunn & Spear,
1989). The virus penetrates by fusion of the viral envelope with the plasma 
membrane of the cell. Once the virus enters the cell, the capsids are released into 
the cytoplasm and are transported to the nuclear pores and the DNA-protein 
complex is released from the nucleocapsid into the nucleus. Upon release, the 
linear viral genome circularises by ligation of the terminal sequences. On entry to 
the nucleus, transcription and replication of viral DNA occurs (Honess & Roizman, 
1974). Finally viral DNA and structural proteins are assembled into progeny virions. 
Both the core and capsid are assembled within the nucleus and the capsid is 
enveloped by budding through internal membranes (Roizman & Furlong, 1974). In 
the lytic cycle, host cell DNA and protein synthesis can be shut-off and this leads to 
host cell death (Wagner & Roizman, 1968).
The ability to establish latent infection is a characteristic of herpesviruses (Roizman, 
1982). In latently infected cells, the viral genome is present as a circular or linear 
concatameric molecule (Rock & Fraser, 1985, Hurley & Thorley-Lawson, 1989). In 
the case of EBV, closed episomal forms have been detected (Lindahl et al., 1976).
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During this latent process only a limited number of viral genes are expressed. 
Latent gene expression of EBV is discussed in detail in sections 1.4.3.1-1.4.3.5. 
Herpesviruses can remain latent for long periods of time and thus avoid detection by 
the host immune system. Despite much study, the process of reactivation from 
latency remains elusive.
1.4.3 Epslein-Barr virus (EBV)
EBV was first isolated by Epstein et at. (1964) from cells cultured from Burkitt's 
lymphoma (BL) material. In the virion the EBV genome consists of a linear duplex 
DNA molecule of -172 kbp (Baer et al., 1984). This virus has been associated with 
a number of non-maiignant and malignant diseases including infectious 
mononucleosis (IM), oral hairy leukoplakia, BL, nasopharyngeal carcinoma (NPC), 
NHL and lymphomas in immunosuppressed persons.
Primary infection with EBV usually occurs via the oral route in childhood. The virus 
Is ubiquitous and -90% of adults are infected (reviewed by Evans & Niederman,
1989). The virus shows a specific tropism for B-cells (Jondal & Klein, 1973, 
Greaves et al., 1975). If infection is delayed until adolescence or young adulthood 
IM is observed In approximately half of the cases (Henie et al., 1968). The clinical 
features of IM include lymphadenopathy, fever and pharyngitis all of which have 
been attributed to the host immune response to proliferating B-cells (Brown et al., 
1984).
Early studies suggested that EBV infected oropharyngeal epithelial cells In the first 
Instance (Sixbey et al., 1984, Wolf et al., 1984). EBV was thought to spread from 
the oropharyngeal epithelium to B-cells (Allday & Crawford, 1988). Recent studies
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have shown that patients with IM who were treated with acyclovir showed a 
reduction of EBV shedding from the oropharynx while the number of EBV-positive 
B-cells remained constant (Yao et al., 1989a, 1989b). In addition treatment with 
irradiation and drugs following bone marrow transplantation resulted in the 
elimination of EBV from the patient through the destruction of haemapoietic tissue 
suggesting that this was an important site of EBV latency (Gratama et al., 1988). 
From these data, Niedobitek and Young (1994) proposed that B-cells were 
Important in primary infection and persistence of EBV.
EBV has the ability to transform human B-lymphocytes in vitro and thus produce 
lymphoblastoid cell lines (LCLs) (Pope et al., 1968). It has been reported that only 
one particle of EBV is required to immortalise a B-lymphocyte (Henderson et al., 
1977). The viral genome is present in multiple episomal copies and has a restricted 
range of gene expression (reviewed by Speck & Strominger, 1989). The method of 
immortalisation of B-cells by EBV is not completely understood, however a number 
of gene products have been Identified in LCL (reviewed by Kieff & Liebowitz, 1990). 
These latent genes include six EBV nuclear antigens, EBNA-1, EBNA-2, EBNA-3A,- 
3B,-3G and leader protein (LP), three membrane-associated proteins designated 
LMP-1, LMP-2A and LMP-2B and two small non-translated RNA molecules named 
EBV-encoded RNAs (EBER-1 and EBER-2 ).
Intensive research has been carried out to ascertain the role that these EBV latent 
genes play in the immortalisation process. To date, at least three of these viral 
genes have been shown to be required for immortalisation of B-cells: EBNA-1, 
EBNA-2, and LMP-1 (reviewed by Ring, 1994).
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1.4.3.1 EBNA-1
The biological properties of the EBNA-1 protein have been identified. EBNA-1, a 
specific DNA binding protein, is required for the maintenance of the virus in 
episomal form through binding to the EBV plasmid origin of replication (or/P) (Yates 
et al., 1984). The EBNA-1 gene is thus required to enable early proliferation of 
infected B-cells (Yates et al., 1984, 1985). EBNA-1 is detected in all EBV-infected 
cells. A difference in promoter usage at different time points has been identified for 
different tumours. Expression of EBNA-1 in BL and in BL-derived cell lines appears 
to be driven from a promoter identified as Fp (Sample et al., 1991, Schaeffer et al., 
1991). in LCL, Cp is the dominant promoter during transcription of all of the EBNA 
genes (Woisetschlaeger et a!., 1990). Recent studies of EBNA-1 expression in 
transgenic mice suggest that EBNA-1 is directly involved in malignant 
transformation (Wilson & Levine, 1992, J. Wilson, personal communication).
1.4.3.2 EBNA-2
Studies using the immortalisation-deficient mutant P3HR-1 (Hinuma et al., 1967) in 
which the EBNA-2 gene and part of EBNA-LP is deleted (Rowe et al., 1985), have 
shown that the EBNA-2 gene is required for immortalisation of B-lymphocytes in 
vitro (Cohen et al., 1989, Hammerschmidt & Sugden, 1989). The réintroduction of 
the sequences deleted in P3HR-1, by homologous recombination, restored the 
ability to immortalise B-cells in vitro.
Two strains of EBV have been now been demonstrated: Types 1 and 2 or Types A 
and B, which differ in the EBNA-2, EBNA-3A, -3B, -3C gene loci (Adldinger et al., 
1985, Rowe etal., 1989). These two antigenically distinct forms are represented by
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B95/8 and AG876, respectively (Dambaugh et al., 1984, Adldinger et al., 1985, 
Rowe et al., 1985, Zimber-StrobI et al., 1986). Type 2-infected LCL In vitro show a 
poorer survival of individual cells, a lower growth rate and a lower saturation density 
than lines established with Type 1 virus (Rickinson et al., 1987). EBV Type 1 virus 
has the ability to transform B-lymphocytes in vitro more readily than EBV Type 2 
virus (Rickinson etal., 1987). Following the réintroduction of EBNA-2 genes into the 
P3HR-1 genome, Cohen et al. (1989) showed that the differences in growth 
phenotype of LCL immortalised by Type 1 and Type 2 EBV strains are determined 
by the EBNA-2 type expressed.
Geographical differences between the two subtypes have indicated that EBV Type 1 
is predominantly found in Western countries whereas Type 2 virus has been 
restricted to Papua New Guinea and Africa (Zimber-StrobI et al., 1986, Young et al., 
1987). In a recent study from the US, EBV Type 2 virus was detected in the 
oropharyngeal epithelial cells of healthy persons (Sixbey et al., 1991). EBV Type 2 
virus has also been associated with endemic BL, NPC and to a lesser extent 
sporadic BL (Young etal., 1987, Goldschmidts etal., 1992).
The role of EBNA-2 in the immortalisation process is not fully understood. However, 
EBNA-2 has the ability to increase the expression of LMP-1 (Abbot et al., 1990) and 
the B-cell activation antigens, CD21 and CD23 (Cordier et al., 1990, Wang et al.,
1990). Both EBNA-2 and LMP-1 can lead to the induction of CD23 expression, 
either individually of co-operatively (Wang et al., 1990). CD23 is detectable at high- 
levels in EBV immortalised B-lymphocytes (Kintner & Sugden, 1981, Thorley- 
Lawson et al., 1985) and is also expressed after B-cell activation by interleukin-4 or 
mitogen stimulation (Defrance et al., 1987). The induction of this B-cell activation 
molecule appears to be a critical event in the immortalisation of B-cells by EBV.
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Only EBV-infected B-lymphocytes which express CD23 have the ability to produce 
immortalised cells lines (Thorley-Lawson & Mann, 1985). During the infection of 
EBV-negative B-lymphoma cell lines with the immortalising EBV strain, B95/8, high 
levels of CD23 are expressed, however when these experiments are repeated using 
the non-transforming EBV strain P3HR-1, CD23 antigen is not induced (Calender et 
a/., 1987). The role of CD23 in HD is discussed further in Chapter 3.
1.4.3.3 EBV latent membrane protein (LMP-1)
EBV LMP-1, a 62 kd membrane protein, is located in discrete patches in the plasma 
membranes of immortalised B-cells (Liebowitz et al., 1986, Hennessy et al., 1984, 
Mann et al., 1985). Structurally, the EBV LMP-1 protein is thought to consist of a 
short hydrophilic amino terminus, six hydrophobic transmembrane domains and a 
long hydrophilic acidic carboxy terminus (Mann et al., 1985). This structure shows 
similarity to ion channels and the p-adrenergic and rhodopsin receptors (Fennewald 
et al., 1984). Single-gene transfer of LMP-1 to EBV-negative BL cell lines 
reproduces many of the altered growth effects seen in the latent EBV infection of 
primary B-lymphocytes; growth in tight clumps, increased villous projection and 
increased expression of activation molecules (Wang et al., 1988). Kaye et al. 
(1994) have recently confirmed these early experiments and shown that LMP-1 is 
essential for EBV-mediated transformation of primary B-lymphocytes. LMP is the 
only virus encoded protein which has been shown to have transforming ability, in 
isolation. In transfection experiments, the LMP-1 gene can transform the rodent 
fibroblast cell line, Rat-1 and the transformed cells induce tumours in nude mice 
(Wang et al., 1985). Deletion experiments suggest that all regions of LMP-1 are 
essential for transformation of Rat-1 fibroblasts (Moorthy & Thorley-Lawson, 1993).
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A recent study indicated that EBNA-2 is required for the expression of LMP-1 in 8 - 
cells (Abbot et al., 1990). However, EBNA-2 is not expressed in all situations in 
which LMP-1 Is expressed (Fahraeus et al., 1988, Pallesen et al., 1991a). LMP-1
has the ability to induce a number of cellular genes including CD23 (Wang et al.,
1990), CD30, CD40, the cellular oncogene, bcl-2 (Henderson et al., 1991) and the 
cellular adhesion molecules LFA-1, LFA-3 and IGAM-1.
LMP-1 protein expression has been detected by immunohistochemical analysis in 
50% of cases of NPC (Young et al., 1988). A role for LMP-1 in malignancies of 
epithelial origin has been supported by studies showing that LMP-1 can induce 
transformation in human kératinocytes (Fahraeus et al., 1990) and the abnormally 
controlled differentiation of epithelial cells (Dawson et al., 1990). The detection of 
LMP-1 in B-cell proliferations in transplant patients also indicates that LMP-1 may 
be involved in the pathogenesis of lymphoproliferative disease In vivo. EBV latent 
gene expression in HD is described in detail in Chapter 3, section 3.4.
Role of other EBV gene products in the Immortalisation process
1.4.3.4 EBNA-3A,-3Br3C
EBNA-3A,-3B,-3C are present in latently infected B-cells (Petti et al., 1990), and 
there is homology in the amino acid sequence of all three latent genes between 
Type 1 and Type 2 virus (Sample et al., 1990). The role of these EBNAs was 
investigated by Tomkinson & Kieff (1992) using mutant recombinant EBV generated 
by homologous recombination. EBNA-3A and EBNA-3C are required for 
Immortalisation of B-cells, whereas EBNA-3B is not required (Tomkinson et al.,
1993). There is accumulating evidence to suggest that EBNA-3C is a trans­
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activator of LMP-1 and the cellular genes, CD23, CD21 and vimentin (Wang et al., 
1990, Allday etal., 1993).
1.4.3.5 EBV-encoded RNAs (EBERS)
The expression of two small, non-translated, RNA polymerase III transcribed RNAs, 
EBER-1 and EBER-2, was recognised by Jat & Arrand (1982). These RNAs are 
located in the nucleoplasm of EBV transformed lymphocytes (Howe & Steitz, 1986, 
Wu et a!., 1990) where they assemble into ribonucleoprotein particles that are 
complexed with the La autoantigen (Lerner et al., 1981, Howe & Steitz, 1986). 
However, using high resolution confocal laser scanning microscopy there is clear 
evidence for the presence of both EBERs in the cytoplasm of Raji Burkitt's 
lymphoma cells and EBV-immortalised LCL (Schwemmie etal., 1992).
In latently Infected cells, the EBERs are actively transcribed and it is estimated that 
there are up to 5 x 10^ copies per cell (Howe & Shu, 1989, Clemens, 1993). In a 
recent In vitro study, EBV mutants in which the EBER genes were deleted did not 
differ from the wild-type EBV in their ability to immortalise B-cells (Swaminathan et 
al., 1991). These results suggest that the EBER genes are not essential in the 
immortalisation of B-cells by EBV.
Evidence for a possible function for these small RNAs is now emerging. There is a 
similarity between the cellular U6  small nuclear RNA and the EBER RNAs indicating 
that they may play a role in RNA processing (Glickman et al., 1988). Recently, a 
cellular protein, EBER-associated protein (EAR), which has been shown to be the 
ribosomal protein L22, has been shown to bind to EBER-1 (Toczyski et al., 1991,
1994). The significance of EBER-1 binding to the L22 protein on cellular growth
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control has been raised following a report of a chromosomal translocation invoiving 
the gene for L22 in some forms of myelodysplasia (Nucifora et al., 1993). The 
ability of the EBERs to bind L22 is reminiscent of other viral proteins e.g. SV40 large 
T antigen and adenovirus El A, which interact with the anti-oncogenic products i.e. 
p53 or retinoblastoma (Rb) gene (Levine, 1990, Shenk & Flint, 1991). It has been 
suggested that these RNAs may play a role in cell transformation.
..
The abundance of these RNAs during latent infection makes them good targets for
%the detection of EBV using in situ hybridisation. The application of this technology
'Jto the detection of EBV in HD biopsies is discussed further in Chapter 4.
1.4.3.6 Patterns of EBV latent gene expression
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In B-cells three distinct patterns of expression of the latent gene products have been 
described (Rowe et al., 1992). A restricted pattern of expression is found in BL in 
which only the EBNA-1 gene is detectable (Rowe et al., 1987). In contrast LCL 
display the full complement of latent genes. An intermediate pattern of latency has 
now been identified in which only EBNA-1, LMP-1 and LMP-2 are expressed. 
These patterns of latent gene expression have been designated as Lat I, Lat III and 
Lat II expression, respectively. The pattern of latent gene expression in various 
EBV-associated malignancies has been examined. In BL the latency pattern 
corresponds to Lat I and in lymphomas in immunosuppressed persons to Lat III. 
An intermediate pattern or Lat II expression pattern has been observed in NPC in 
vivo.
1.4.4 Human Herpesviruses-6 and -7
Human herpesvirus- 6  (HHV-6 ) was first isolated from patients with AIDS, AIDS- 
related lymphomas and other lymphoproliferative diseases (Salahuddin et al., 
1986).
As the virus was shown to have B-cell tropism in cord blood lymphocytes it was 
initially named human B-lymphotropic virus (HBLV). Molecular analysis of the viral 
genome confirmed HBLV as a new herpesvirus (Josephs et al., 1986). Following 
reports that the target cell population for HBLV in cord blood lymphocytes was CD4+ 
T-lymphocytes rather than B-cells the virus was renamed HHV- 6  (Lusse et al., 1987, 
Tedder etal., 1987).
The HHV- 6  genome is a linear, dsDNA molecule of 162 kbp (Martin et al., 1991). 
HHV- 6  is most closely related to HCMV (Lawrence et al., 1990). Two subtypes of 
HHV- 6  have been identified by restriction site polymorphisms; HHV- 6  variant A and 
HHV- 6  variant B which have been shown to have distinct biological, immunological 
and molecular properties (Jarrett et al., 1989, Schirmer et al., 1991, Aubin et al., 
1991, Ablashi et al., 1991, 1993).
HHV- 6  is widespread within the general population (Briggs et al., 1988). The virus 
has been shown to be the causative agent of the childhood illness exanthem 
subitum (Yamanishi etal., 1988).
HHV- 6  has the ability to transform NIH 3T3 cells and these cells have been shown 
to cause tumours in experimental animals (Razzaque, 1990). An association 
between HHV- 6  and human malignancy has been proposed foliowing detection of
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the virus in some human malignancies (Josephs et a/., 1988, Jarrett et al., 1988, 
Gompels et a!., 1992, Torelli et a!., 1991,1992).
The adenoviruses have been classified into six groups, A-F, based on the 
oncogenic potential of the virus (Horwitz, 1990). All six subgroups have the ability to 
transform primary rat cells in vitro (Freeman et ai., 1967, Graham et ai., 1974). 
Subgroup A consists of types 12,18 and 31 which have been shown to be highly 
oncogenic and cause tumours in animals (Trentin et ai., 1962), subgroup B includes 
types 3,7 ,11,16, and 35 and which have been described as moderately oncogenic 
and type 5 belongs to subgroup C which are essentially non-oncogenic (Baum,
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■IMore recently, the isolation of a novel human herpesvirus from purified CD4+ T- 
lymphocytes of a healthy individual was reported by Frenkel et ai. (1990). This virus 
has been shown to be distinct from other human herpesviruses and has been 
designated human herpesvirus-7 (HHV-7). There is only limited sequence 
homology between the DNA from HHV-6 , HCMV or HHV-7 (Berneman et ai., 1992). 
Serological studies have shown that HHV-7 is prevalent within the population and 
infects early in childhood (Wyatt et ai., 1991, Clark et ai., 1993). :§
i:1.4.5 Adenovirus
Adenoviruses are non-enveloped viruses with a double stranded DNA genome of 
between 30-35kbp in size (Green et ai, 1967). A number of serotypes of 
adenovirus have been identified and these are associated with a range of diseases 
in humans including acute respiratory disease in children (Brandt et ai., 1969), 
conjunctivitis (Bennett et ai., 1957) and gastrointestinal disease (Yolken et ai.,
1982).
1984). The virus has the ability to remain latent in adenoidal tissue and also in B 
lymphocytes (Abken eta!., 1987).
1.4.5.1 Adenovirus genes involved in transformation
The El domain of adenovirus, encoding an intermediate early transcript, is divided 
into two regions, El A and E1B. This region has been implicated in transformation 
by adenovirus (Sambrook et a!., 1974) and both El A and E1B are required for 
oncogenesis (Byrd et a/., 1988). The El A gene, E1B gene of adenovirus and the 
polyoma middle T antigen has been shown to be sufficient for transformation of 
primary rodent cells (Ruley, 1983, Gallimore et al., 1985, Moran & Mathews, 1987). 
The El A and E1B gene products co-operate in transformation; one function of El A 
is to bind the Rb protein thus inactivating its function (Whyte et a/., 1988) and 
pushing cells into cycle (Howe & Bayley, 1992) whereas the 19 kd and 55 kd 
products of E1B have an anti-apoptotic function. Despite the above biological 
properties of adenovirus, there are no reports of an association between adenovirus 
infection and malignant disease in humans.
1.4.6 Papovavirus
The family Papovaviridae contains the subfamilies Polyomavirinae and 
Papiliomavirinae. Members of the subfamily Polyomavirinae include the simian 
virus 40 (SV40), human polyomaviruses, BKV and JCV and lymphotropic 
papovavirus (LPV). The genomes of the polyomaviruses are dsDNA molecules of 
~5 kbp. These viruses have the ability to cause tumours in species other than their 
natural hosts; SV40 virus causes tumours in newborn hamsters. The polyoma and 
SV40 large T antigens have the ability to immortalise cells in culture (Colby &
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Shenk, 1982). Large T antigen binds the Rb protein (Larose et ah, 1991) and p53 
thus exerting an anti-apoptotic effect and pushing the cells into cycle (Zhu et a/., 
1991, Kierstead & Tevethia, 1993). Using serological techniques, the reactivity with 
antibodies against the polyomaviruses, SV40 and LPV has been identified in human 
serum following immunisation with poliovirus vaccines (Horvâth, 1972, Shak & 
Nathanson, 1976, Brade etaL, 1980, Takemoto etal., 1982).
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1.5 Malignant diseases associated with EBV
EBV is associated with an ever growing range of malignant conditions, including BL, 
NPC, HD and NHL.
1.5.1 Burkitt's lymphoma
BL is a malignant lymphoma which is classified as a high grade lymphoma, small 
non-cleaved cell group (Rosenberg, 1982). There are two forms of BL distinguished 
by their geographical distribution - endemic or African BL (eBL) and non-endemic or 
sporadic BL (sBL). The peak incidence of eBL occurs in children, 6 - 8  years, 
however the peak incidence of sBL is in older children of 10-12 years in Africa and 
adults in other parts of the world. The incidence of eBL mimics the distribution of 
malarial infection. Both the chronic antigenic stimulation and immunosuppressive 
effect of malarial infection are thought to contribute to tumour development. The 
distribution of sporadic BL is unrelated to that of malaria.
The most characteristic feature of both forms of BL is a chromosomal translocation 
involving the c-myc locus (Shiramizu et a!., 1991). In the majority of cases the 
translocation juxtaposes the IgH gene on chromosome 14 with the c-myc locus. 
Other translocations involve the rearrangement of c-myc to immunoglobulin light 
chain (IgL) lambda or IgL chain (kappa) loci (Cory, 1986)
Cofactors associated with the development of tumours have been observed in BL. 
Serological and molecular studies have supported the role of EBV in eBL and to a 
lesser extent in sBL. There are increased antibody titres to EBV in African patients 
with BL compared to a control group (Henie et a/., 1969) and EBV DNA is detected
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in 98% of tumour biopsies from these eBL patients (Nonoyama etaL, 1973). In sBL, 
EBV DNA was detected in 20% of cases studied (Ziegler, 1977).
1.5.2 Nasopharyngeal carcinoma
NPC, an epithelial tumour, is distributed world-wide, however there is a much higher 
prevalence in South East China (de-Thé et al., 1989). Undifferentiated NPC Is 
characterised histologically by malignant cells with indistinct cytoplasmic bands 
(Gaffey & Weiss, 1990).
The suggestion that NPC may have an infectious aetiology has been borne out by 
the detection of EBV in the majority of undifferentiated NPC cases (zur Hausen et 
a!., 1970, Klein, 1979). The EBV genomes in undifferentiated NPC are clonal, thus 
suggesting that EBV plays a direct role in the pathogenesis of the disease (Raab- 
Traub & Flynn, 1986).
As with BL, other factors are likely to be involved in the development of NPC. The 
geographical distribution of NPC and BL do not mirror the prevalence of EBV in the 
community. Both genetic and environmental factors have been suggested as 
additional factors (de-Thé et al., 1989). Dietary factors such as nitrosamines in 
salted fish, which affect EBV latency, have been linked to an increased incidence of 
NPC (Yu eta!., 1986).
1.5.3 Lymphomas in immunosuppressed persons
The presence of B-cell lymphomas in immunosuppressed persons has been linked 
to EBV. The role of EBV in these malignancies is not entirely clear, however the
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immunosuppressive nature of the host is likely to enable the EBV-infected B-celis to 
proliferate in an uncontrolled manner.
The association between EBV and post-transplant lymphoma has been documented 
(Purtilo et al., 1981). The prevalence of post-transplant lymphoproliferative disease 
after renal or liver transplant ranges from 1% to 2.3%, respectively (Ho et al., 1985, 
Hanto et al., 1985). In heart-lung transplant patients this figure increases to 
between 5% and 9% (Cleary et al., 1984). EBV has been detected in a substantial 
proportion of these post-transplant lymphomas (reviewed by Purtilo etal., 1992).
9
Acquired immunodeficiency has been linked to the increased development of 
malignant lymphoma. Malignant lymphoma has been observed in an increasing 
number of cases following infection with human immunodeficiency virus (HIV). 
These tumours have been designated as acquired immunodeficiency disease- 
related NHLs (ARLs). Morphologically these tumours are high grade B-cell NHL of 
large cell or Burkitt (small non-cleaved cell) type (Hamilton-Dutoit et al., 1991). EBV 
has been associated with a proportion of ARLs. EBV is present in almost all primary 
central nervous system ARLs (MacMahon et al., 1991), in most systemic 
immunoblast rich/large cell ARLs, however in only 30-40% of BL type ARLs 
(Hamilton-Dutoit et al., 1993a,1993b). The presence of EBV in the tumour cells 
correlated with the tumour morphology and primary site of the lymphoma (Hamilton- 
Dutoit etal., 1993).
In sporadic high grade NHLs of B-cell origin, EBV has been detected in the tumour 
cells in 5% of cases. In peripheral T-cell lymphomas, EBV has been detected in a 
greater proportion of cases (10%) than in the B-cell type (4%) (G. Pallesen, 
personal communication). The significance of EBV in these lymphomas is not clear.
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1.5.4 Hodgkin's disease
The association between an infectious agent and HD has been debated. Both 
serological and molecular techniques have identified EBV in HD cases. Initial 
serological studies showed that patients with HD have elevated levels of antibody to 
EBV compared with control cases (Levine et al., 1971, Henderson et al., 1973, 
Hesse et al., 1977). These increased antibody titres were present in HD patients 
with a past history of IM (Evans & Gutensohn, 1984) and occurred prior to diagnosis 
of HD (Mueller etal., 1989).
Early studies failed to detect EBV genomes in HD biopsies (Pagano et al., 1973, 
Lindahl etal., 1974). In 1987 Weiss etal. reported the detection of EBV genomes in 
HD tumour material in 4 out of 21 cases using Southern blot hybridisation (Weiss et 
al., 1987a). Since that first report the proportion of EBV-positive HD cases has 
been shown to vary between 17-41 % (Weiss et al., 1987a, Anagnostopoulos et al., 
1989, Boiocchi etal., 1989, Gledhili et al., 1991, Jarrett etal., 1991a).
Analysis of the terminal repeat region of the EBV genomes indicated that in the 
majority of cases examined a single infectious event had taken place (Weiss et al., 
1987a, Gledhili et al., 1991, Anagnostopoulos et al., 1989, Jarrett et al., 1991a). 
These above results support the suggestion that, in a proportion of HD cases, the 
EBV had infected a single cell, which had clonally expanded.
At the start of this study two research groups had published data on the localisation 
of EBV within the malignant cells of HD, the Reed-Sternberg (RS) cells. DNA in situ 
hybridisation studies indicated that EBV genomes were localised to the RS cells in 
seven out of the ten cases tested (Anagnostopoulos et ah, 1989, Weiss et al.,
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1989). However signal to noise ratios were not good and it was not possible to 
examine large numbers of cases, or archival material, using this technique.
Epidemiological features of HD have suggested an infectious origin for some groups 
of HD (see section 1.3.5). The association between EBV and age at diagnosis in 
HD has been investigated using Southern blot analysis (Jarrett et al., 1991a). 
Paediatric and older age cases were shown to be more likely to be EBV positive 
than young adult HD cases. In addition MCHD cases are more likely to be EBV 
positive than NSHD cases (Weiss et al., 1987a, Staal et al., 1989, Boiocchi et al., 
1989, Gledhili et al., 1991). The relationship between EBV status, age and 
histological subtype in HD is further investigated in Chapters 5 and 6  of this thesis.
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1.6 Proving a relationship between a virus and cancer
Proving a relationship between a virus and cancer is difficult particularly where 
tumours in humans are concerned. It is only possible to try to get close to 
establishing a causal relationship. Prevention of the tumour by vaccination against 
the infectious agent provides proof that the virus is necessary for the tumour 
development but at the present time this is not a practical possibility In the 
investigation of most cancers.
Viruses can cause tumours by direct and indirect mechanisms, however the 
following discussion relates only to direct mechanisms of oncogenesis. Direct 
mechanisms have been described as systems in which part or all of the virus is
present in the malignant cell at some stage during transformation. There are few
examples of viruses which cause transformation by a single hit; one such example 
is polyoma virus infection of hamster cells where the titre of the infecting virus is
directly related to the number of transformed foci.
In most cases in which viruses are involved in tumour development viral 
Involvement Is likely to be one step in a multi-step process. Thus other factors, 
either genetic or environmental, are likely to be involved in the development of 
tumours. In transplant patients, the presence of EBV-associated B-cell 
lymphoproliferative disease may be a rare example of a tumour which is directly 
associated with the virus alone. In these cases even monoclonal tumours, can 
recede following withdrawal of immunosuppressive treatment and initiation of anti­
viral therapy (Starzl etal., 1970).
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In the early 1800s Koch proposed a set of criteria designed to prove that a micro­
organism was involved in a given disease, as described in section 1.6.1-1.6.4. 
These criteria would appear to be too stringent to establish a relationship between a 
virus and cancer and would fail to recognise important pathogenetic associations 
(Hall & Lemoine, 1991). The methods used to demonstrate a link between a virus 
and a tumour are described in the following sections. Examples are given to show 
the use and the problems associated with each method.
1.6.1 Demonstration of virus or viral nucleic acid within tumour cells
Strong evidence that the virus may be involved in tumour development is provided 
by the demonstration of the virus in all cells of a tumour. Tumours caused by a hit 
and run mechanism would not fulfil this criterion. One example of the latter 
mechanism of tumourigenesis is exhibited by bovine papillomavirus (BPV)-4. 
Bovine cells infected with BPV-4 cause metastatic tumours when transplanted into 
immunocompromised mice (Campo et al., 1985, Gaukroger et al., 1993). Viral 
nucleic acid cannot be detected within these tumours thereby providing evidence for 
a hit and run method of transformation in an experimental system. Due to the 
difficulty in proving a hit and run mechanism it is not clear whether this could be an 
important way in which viruses operate.
Viruses can be detected within tumours by electron microscopy or by demonstration 
of viral nucleic acid or protein. Viral particles are usually detected by electron 
microscopy after culture of tumour cells in the laboratory. Some tumours, such as 
cervical cancers associated with HPV-16, contain defective viral genomes and are 
unable to produce viral particles. At present, molecular analyses such as PCP, 
Southern blotting and in situ hybridisation are frequently used to detect viral
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genomes within affected tissues. Expression of viral proteins within tumour cells 
provides evidence of viral infection and may help to explain the role of the virus in 
disease pathogenesis. The demonstration of expression of viral genes or proteins, 
particularly those known to have oncogenic potential, in tumour cells provides good 
evidence that the virus is contributing to tumour development.
1.6.2 Serological studies
Serological studies provide important clues to the association between a virus and 
cancer. In the case of HTLV-1, the distribution of adult T-cell leukaemia (ATL) and 
tropical spastic paraparesis (TSP), both of which are known to be causally 
associated with the virus, follows the distribution of the virus as determined by 
serological studies (Robert-Guroff et af., 1982, Gessain et aL, 1985). In contrast to 
control cases almost all cases of ATL and TSP are HTLV-1 seropositive (Hinuma et 
al., 1982, Clark et al., 1985). Serological studies therefore played an important role 
in establishing the relationship between HTLV-1 and these very different diseases. 
The association between hepatocellular carcinoma (HOC) and Hepatitis B virus 
(HBV) has been demonstrated using serological techniques (Beasley et al., 1981, 
1982).
Serological studies of EBV are more complex since most adults are EBV 
seropositive, however in eBL EBV titres tend to be raised suggesting an association 
between the virus and the lymphoma (HenIe et al., 1969, de-Thé et al., 1978). The 
situation regarding EBV titres in HD is complicated and not fully resolved.
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Several tumours associated with viruses show a restricted geographical distribution, 
e.g. NPC. In these cases the distribution of cases appears to follow the distribution 
of co-factors and not that of the virus (see sections 1.5.1 and 1.5.2).
The ability to demonstrate transformation by a virus in vitro provides supportive 
evidence for the rote of a virus in oncogenesis, however in many cases it has not 
proven possible to propagate tumour viruses in cell culture. This may either be due 
to the lack of an appropriate system to culture the target population or to the 
presence of defective viruses. Conversely, genomes or parts of genomes from 
several viruses have been shown to have transforming properties in vitro but have 
not been associated with any naturally occurring tumours (reviewed by MacNab, 
1987).
1.6.4 Tumour induction in experimental animals
The restricted host range of some viruses e.g. HTLV-1, EBV, HBV, has presented 
difficulties in establishing animal models In circumstances where it is possible to 
produce viral infection e.g. HTLV-1 infection of rabbits (Miyoshi, 1992), it has not 
been possible to reproduce the human disease.
These examples highlight the difficulty in laying down criteria for demonstrating an 
association between a virus and cancer. Current efforts should attempt to establish 
close links between virus and particular malignancies. Viruses may provide a single 
hit, or one of several hits, which ultimately lead to malignant transformation. 
Additionally, viruses may provide a single hit resulting in pre-matignant change and
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1.6.3 Transformation by viruses in vitro
a greatly increased risk of tumour development. Therefore any evidence showing 
the presence or expression of viral genes at any stage in tumour development may 
provide important evidence for an association between a virus and cancer.
1.6.5 Viruses and Hodgkin's disease
There are two difficulties associated with the demonstration of an association 
between viruses and HD. First, RS cells in HD are rare, representing <1% of the 
tumour population and therefore any method used to demonstrate the presence of 
virus must be both sensitive and, in the case of common viruses, permit cellular 
localisation of the virus to the tumour cells. Methods of localising EBV to RS cells 
are described in detail in Chapters 3 and 4.
Secondly, epidemiological evidence suggests that viruses linked to HD are likely to 
be common viruses which infect many individuals at a young age (see Chapters 5 
and 6). EBV is associated with some cases of HD. Most healthy adults are 
persistently infected with EBV and lymphoid cells are latently infected (Niedobitek et 
al., 1992, Hummel et al., 1992). Thus, the detection of EBV in any lymphoid tumour 
raises the possibility that it is merely a passenger virus. Examination of the terminal 
repeats of the viral genome provides a means to assess the number of infectious 
events that have taken place within a cell population. This data provides an indirect 
assay for the clonality of the cells with respect to the virus (Raab-Traub & Flynn, 
1986). The ability to demonstrate monoclonal EBV genomes with a tumour 
population mitigates against the presence of a passenger virus and lends support to 
the argument that a virus is playing some role in tumour causation.
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The relationship between oncogenic DNA viruses and HD is the subject of this 
thesis.
I
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Chapter 2 
General Materials and Methods
38
This chapter describes the materials and methods that have been routinely used 
throughout the work described in this thesis. Any additional material and methods 
required to conduct the experiments described in individual chapters are 
summarised within the appropriate chapters.
2.1 Materials
The chemical reagents used were purchased from The Sigma Chemical Company 
Limited (Poole, Dorset, UK) or BDH (Poole, Dorset, UK) except where specifically 
stated in the text. Deionised water obtained from a reverse osmosis system 
(Millipore) was used for to make up buffers and solutions. Deionised, filtered water 
(MilliQ water filtration system, Millipore) was used for all enzymatic reactions and 
the resuspension of DNA.
2.2 Preparation of samples
2.2.1 Preparation of high molecular weight DNA
Extraction of high molecular weight DNA from tissue samples was carried out in a 
Containment level II facility within a Class II microbiological safety cabinet. Biopsy 
samples were disrupted mechanically in TNE buffer (Appendix I), in a Stomacher 
(Colworth). The cells were pelleted by centrifugation at 2500 revolutions per minute 
(rpm) (MSE Mistral 1000 centrifuge) for five minutes and further washed in TNE 
buffer. The cell pellet was resuspended in five millilitres (mL) of TNE buffer. 
Proteinase K and sodium dodecyl sulphate (SDS) were added to a final 
concentration of lOOpg/mL and 0.5% respectively and the suspension incubated at 
55°C for one hour, or at 37°C for 16-20 hours. In order to remove the protein an
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equal volume of phenol (Rathburn Chemical Company, Walkerburn, UK) was added 
and the phases mixed gently by inversion. The aqueous phase was removed 
following centrifugation at room temperature. An equal volume of chloroform was 
added and the phases mixed thoroughly. Following centrifugation the aqueous 
phase was transferred into 99.7% ethanol. High molecular weight DNA was 
spooled onto a plastic (polypropylene) Pasteur pipette and placed into a sterile 
microfuge tube (Scotlab Bioscience Limited, Coatbridge, UK). The DNA pellet was 
washed in 70% ethanol then 95% ethanol and allowed to dry for 2-3 hours. The 
DNA was resuspended in TE buffer (Appendix I) and incubated at 37^C for 16-20 
hours to enable the DNA to dissolve thoroughly. The concentration of DNA was 
estimated by measuring the OD260nm ^nd OD280nm and determining the quantity of 
DNA using the equation ODggonm of 1 0 is equal to 50p,g/mL of double stranded (ds) 
DNA. The ratio between the readings at 260nm and 280nm (OD2 6 0 /OD2 8 0 ) 
provides an estimate of the purity of the nucleic acid. Pure preparations of DNA and 
RNA have an OD2 6 0 /OD2 8 0  ratio of 1.8 and 2.0, respectively (Sambrook et a!., 
1989).
2.2.2 Cytospin preparations
Cell lines were maintained in RPMI 1640 medium containing 10% heat-inactivated 
foetal bovine serum (FBS; heat inactivated at 560(), 400pg/mL streptomycin, 
400U/mL penicillin and 2mM L-glutamine (all obtained from Life Technologies Inc., 
Paisley, UK). Cells were split at a ratio of 1:5 twice weekly, gassed with 5% CO2  
and incubated in sealed tissue culture flasks (Costar, High Wycombe, UK) at 37^C. 
Prior to splitting the cells, a one millilitre aliquot was removed, centrifuged and 
washed three times in Hank's buffered saline solution (HBSS, Life Technologies 
Inc., Paisley, UK) containing 2% FBS. The number of cells was counted using a
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haemocytometer (Fisons, Loughborough, UK) and the cells resuspended at a 
concentration of 1 x 10^ cells/mL. A 50pL volume of the cell suspension was 
centrifuged onto a glass slide (Fisons, Loughborough, UK) at 400rpm (Shandon 
Cytospin 2) for 5 minutes. The cytospin preparations were air dried and fixed in ice- 
cold acetone or methanol for 30 minutes. Cell preparations were stored at -20°C.
2.2.3 Paraffin-embedded tissue samples
Three to five micrometre sections from paraffin-embedded biopsy tissues were 
mounted on 3-aminopropyltriethoxysilane (APES) coated slides (Appendix VI) and 
stored at room temperature. Prior to analyses, tissue sections were dewaxed in two 
changes of a xylene substitute, Citroclear (National Diagnostics, Atlanta, Georgia), 
for a minimum of five minutes. The Citroclear was removed from the tissue sections 
by washing in two changes of ethanol (99.7%) for five minutes each and then 
washing in distilled water. Sections which were fixed in a mercuric chloride-based 
fixative (e.g. formal sublimate) were treated with Lugol's iodine solution (Appendix 
II) for 1-2 minutes and rinsed in water. The iodine/mercury complex was removed 
using a 5% solution (w/v) of sodium thiosulphate in deionised water. The sections 
were rinsed thoroughly in water. Prior to immunohistochemical analyses (section
2.3), the sections were placed in TBS pH 7.6 (Appendix II). In order to examine the 
localisation of viral nucleic acid using in situ hybridisation (section 2.4), following 
pretreatment with pronase (see sections 2.4.1 and 4.2.3.1), the tissue sections were 
dehydrated and air dried at room temperature.
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2.3 Immunohistochemical methods 
2.3.1 Pretreatment of samples
Paraffin-embedded tissue sections were dewaxed and rehydrated as described in 
section 2.2.3. The sections were washed in two changes of TBS pH 7.6 (Appendix 
II) for five minutes each. Cell preparations which had been stored at -20°C were 
allowed to return to room temperature and rehydrated in TBS pH 7.6 for 10 minutes.
2.3.2 Enzymatic digestion
Pretreatment of formalin-fixed, paraffin-embedded tissue with proteolytic enzymes 
enabled a clearer demonstration of certain antigens. The sections were pre­
warmed in TBS pH 7.6 at 37°C for 5-10 minutes. The slides were placed in a 0.1 % 
trypsin/0.1 % calcium chloride solution pre-warmed to 37°C over a time period of 20 
minutes (section 3.2.2.3). The duration of proteolytic digestion depended on the 
nature of the fixative and antigen under consideration. The enzymatic reaction was 
stopped by washing the sections in deionised water and then TBS pH 7.6 for five 
minutes. Cell preparations fixed in acetone or methanol did not require enzymatic 
digestion for the detection of antigens.
2.3.3 Microwaving
As an alternative to proteolytic digestion, a microwave oven method for antigen 
retrieval was utilised. Sections were immersed in 0.01 M citrate buffer, pH 6.0 at 
room temperature. These tissues were heated in a household microwave oven 
(Swan, compact microwave oven; model 20701) at 750W for 10-20 minutes. After
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the heating period, the slides were removed from the hot buffer and placed into 
deionised water at room temperature.
2.3.4 Primary monoclonal antibody
Care was taken to ensure that the sections did not dry out during the 
immunohistochemical staining procedure. In order to reduce non-specific staining, 
filtered normal sheep serum (NSS) at a dilution of 1:5 in TBS pH 7.6 was applied to 
the tissue sections for 15-30 minutes. Excess NSS was blotted from the tissue 
sections and the primary monoclonal antibody solution added for a minimum of one 
hour at room temperature or overnight at 4^C, The optimal working dilution of the 
monoclonal antibody preparation was assessed for each antibody and each 
individual tissue tested (section 3.2.2.4). The antibody was diluted in TBS pH 7.6.
2.3.5 Indirect Immunohistochemical staining method
Following incubation of the monoclonal antibody preparation (section 2.3.4), the 
sections were washed in TBS pH 7.6 for three minutes. The secondary antibody, 
sheep anti-mouse IgGI (isotype specific; The Binding Site, University of 
Birmingham, Birmingham, UK) at a dilution of 1:25 was applied to the tissue 
sections for 30 minutes. After further washes in TBS pH 7.6 over 10 minutes, a 
donkey anti-sheep Ig conjugated with alkaline phosphatase (AP) (The Binding Site, 
University of Birmingham, Birmingham, UK) prepared at a dilution of 1:50 was 
placed on the tissue sections for 30 minutes. Following further washing in TBS pH
7.6 for 10 minutes, bound alkaline phosphatase (AP) was detected using Fast red 
TR salt as substrate. This was used at a final concentration of Img/mL in AP 
substrate solution (Appendix II) and filtered directly onto the slides and incubated
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for 20 minutes. The enzymatic reaction was stopped by washing in distilled water 
and the tissue counterstained in aqueous haematoxylin (Mayer's haematoxylin, 
Appendix II). The haematoxylin stain was differentiated in Scott's Tap Water 
Substitute (STWS) (Appendix II) and the tissues were mounted using aqueous 
mountant (Aquamount, BDH). A positive reaction was demonstrated by a red 
reaction product visualised using light microscopy.
2.3.6 Immunohistochemical staining using an avidin-biotin method
These staining procedures were carried out at room temperature. After incubation 
of the monoclonal antibody preparation (section 2.3.4), the sections were washed in 
TBS pH 7.6 for three minutes. The secondary antibody, biotinylated sheep anti­
mouse immunoglobulin (isotype-specific) (The Binding Site, University of 
Birmingham, UK), at a dilution of 1:200, was applied to the tissue sections for 30 
minutes. After further washes in TBS pH 7.6 over 10 minutes, the avidin-biotin 
complex conjugated with alkaline phosphatase (ABC-AP) (Dako Limited, High 
Wycombe, UK) prepared at a dilution of 1:50 was placed on the tissue sections for 
30 minutes. As described in section 2.3.5, bound alkaline phosphatase (AP) was 
detected using Fast red TR salt as substrate and the tissue sections were 
counterstained in aqueous haematoxylin (Mayer's haematoxylin, Appendix II).
2.3.7 Immunohistochemical staining using an alkaline phosphatase anti- 
alkaline phosphatase (APAAP) method
The preparation of tissue samples, enzymatic digestion and primary antibody 
titrations are described in sections 2.3.1, 2.3.2, and 2.3.4.
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2.4 RNA in situ hybridisation using oligonucleotide probes
2,4.1 Pretreatment of samples
Three to five micrometre paraffin-embedded tissue sections were processed as 
described in section 2.2.3. All solutions were made up in diethylpyrocarbonate 
(DEPC) treated water (Appendix V).
The digestion of paraffin-embedded lymph node tissue sections using pronase 
(Boehringer Mannheim Limited, Lewes, UK), diluted in the appropriate buffer 
(Appendix III), was optimised at 1 mg/mL for five minutes at room temperature. The 
proteolytic enzyme reaction was stopped by immersing the sections in glycine buffer 
(Appendix III). Sections were dehydrated by placing in 70%, 85% and 99.7% 
ethanol for five minutes each and air dried at room temperature.
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Following incubation with the primary monoclonal antibody preparation, the tissues 
were briefly washed in TBS pH 7.6 for three minutes. Using the methodology 
described by Cordell et al. (1984), the secondary antibody, rabbit anti-mouse 
immunoglobulin (Dako Limited, High Wycombe, UK) at a dilution of 1:25 was 
applied to the tissue sections for 30 minutes at room temperature. After washing in 
TBS pH 7.6, the APAAP complex (Dako Limited, High Wycombe, UK) diluted 1:50 
was added to the tissue and incubated for 30 minutes at room temperature. The 
secondary antibody and APAAP complex steps, with intervening washing In TBS pH
7.6 as described above, were repeated but with a reduction of incubation times to 
15 minutes each. Positive reactivity was visualised using Fast red TR salt as 
described in section 2.3.5. The tissue sections were counterstained in aqueous 
haemoatoxylin (Mayer's haematoxylin. Appendix II).
2.4.2 3 -end labelling of oligonucleotide probe
Oligonucleotide probes incorporating a biotin molecule at the 5'-end (Alta 
Bioscience, University of Birmingham) were synthesised on an automated 
oligonucleotide synthesiser. The concentration of oligonucleotide was calculated by 
determining the CD 260nm ^nd CD 280nm. The concentration of the probe was 
calculated using the formula OD260nm is equal to 30pg/mL for a single stranded (ss) 
DNA molecule. In a total reaction volume of 50pL, 3.5pg of probe was added to 
10fxL 5x TdT buffer (0.5M potassium cacodylate pH 7.1, lOmM cobalt chloride, ImM 
Dithiothreitol (DTT)), 1.5pL terminal transferase (TdT) enzyme (stock solution 
15U/pL, Life Technologies Inc., Paisley, UK) and 16.7|o.L biotin-11-dUTP (stock 
solution 0.3mM in Tris pH 7.5, The Sigma Chemical Company, Poole, Dorset, UK). 
The labelling reaction was carried out at room temperature for four hours. The 
reaction was stopped by placing on ice. The labelled probe was separated from 
unincorporated nucleotides using a commercially prepared sephadex-G50 NICK 
column (Pharmacia Limited, Milton Keynes, UK). The probe was diluted to a final 
concentration of 8.75ng/pL assuming complete recovery of the oligonucleotide.
2.4.3 Hybridisation of oligonucleotide probe
The optimal hybridisation temperature was calculated as 37°C for the EBV EBER-1 
oligonucloeotide probe (see section 4.2.3.2). The tissue sections were incubated 
with pre-hybridisation buffer (Appendix III) for two hours at 37°C. A final probe 
concentration of 0.25ng/pL was experimentally-determined to be optimal (section
4.2.3.3) and this was diluted in the hybridisation buffer (Appendix III). The sections 
were subsequently hybridised for 16-20 hours at 37oc .
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2.4.4 Detection of biotinylated probes
All post-hybridisation wash steps were carried out at room temperature. The 
sections were washed in two changes of 2 x SSC (Appendix I) for 15 minutes each.
Two further washes were carried out in 1 x SSC for 15 minutes each.
f
Bound probe was detected using avidin-biotin complexes conjugated with alkaline 
phosphatase (ABC-AP). The antibody was prepared in the appropriate buffer 
(Appendix III) at a dilution of 1:500. This solution was placed on the tissue sections 
for two hours and incubated at 37°C. The tissue sections were washed three times 
in wash solution 1 (Appendix III) for three minutes each. An additional wash with 
solution 2 (Appendix III) was carried out for three minutes. The nitro blue 
tetrozolium (NBT) at a final concentration of 0.33mg/mL (Appendix III) and bromo- 
chloro-indolyl phosphate (BCIP) at a final concentration of 0.16mg/mL (Appendix III) 
in substrate buffer pH 9.0 (Appendix III) were added to the sections for 30-60 
minutes. The development of the substrate solution was observed by naked eye 
and the reaction was stopped by placing the sections in deionised water. The 
sections were mounted in aqueous mountant (Aquamount, BDH) and in the majority 
of cases the sections were not counterstained. A positive reaction was identified as 
a blue-black reaction product visible under light microscopy.
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2.5 Growth of bacteria and extraction of plasmid DNA
2.5.1 Transformation of competent cells
Competent bacteria (Life Technologies Inc., Paisley, UK), Escherichia co//HB101 or 
DH5a strains, were thawed on ice and fOOpL placed in a Falcon tube (Code no. 
2059, Becton Dickinson UK Limited, Cowley, UK). Between ten and one hundred 
nanograms (ng) of plasmid DNA were added to the cells which were then placed on 
ice for 30 minutes. Bacteria and plasmid DNA were heat shocked at 42°C for 45 
seconds and then placed on ice for 2-3 minutes. After the addition of SOOpL of L- 
broth (Appendix IV) or SOC (Appendix IV), the Falcon tube was placed in a shaking 
incubator set at 3?oc for one hour. One hundred microlitres of the bacteria were 
plated onto L-agar plates (Appendix IV) containing the appropriate antibiotic (e.g. 
ampicillin at 50p,g/mL) and incubated at 37^C overnight.
2.5.2 Preparation of plasmid DNA
2.5.2.1 Alkaline lysis method
A single bacterial colony was inoculated into 5mL of L-broth (Appendix IV) 
containing the appropriate antibiotic (e.g. ampicillin 50pg/mL) and incubated 
overnight at 37°C in the shaking incubator (Fisons, Loughborough, UK). The 
bacterial culture was then added to 500mL of L-broth (Appendix IV) containing the 
appropriate antibiotic and further incubated with shaking at 37^0 for 16-20 hours.
Bacteria were pelleted using a JS-7.5 rotor (Beckman J2-21 centrifuge, Beckman 
Instruments Limited, High Wycombe, UK) at 7000rpm for 10 minutes at 4^0. The
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supernatant was discarded and the bacterial cells were washed in lOOmL STE 
buffer (Appendix IV). The supernatant was removed after further centrifugation at 
7000rpm for 10 minutes. In order to digest the bacterial cell wall, the pellet was 
resuspended in 4mL of a 0.5% lysozyme solution (solution 1; Appendix IV) and 
allowed to stand at room temperature for five minutes. The bacterial membrane 
was lysed and DNA was denatured by adding 16mL of an alkaiine solution 
containing detergent (soiution 2; Appendix IV). The mixture was vortexed and 
incubated on ice for 10 minutes. Plasmid DNA was reannealed by neutralising the 
solution with 12mL of potassium acetate solution pH 4.8 (solution 3; Appendix IV). 
The mixture was placed on ice for a further 10 minutes. The lysed bacteria were 
pelleted by centrifugation at 19000rpm in a JA-20 rotor (Beckman J2-21 centrifuge, 
Beckman Instruments Limited, High Wycombe, UK) for 30 minutes at room 
temperature. The supernatant was distributed between two glass Corex tubes. In 
order to precipitate the plasmid DNA, 0.6 volumes of isopropyl alcohol were added 
and mixed thoroughly. The resultant solution was centrifuged for 30 minutes at 
lOOOOrpm in a JA-20 rotor (Beckman JS-21 centrifuge, Beckman Instruments 
Limited, High Wycombe, UK) at room temperature. The supernatant was removed 
and 5mL of 70% ethanol were added to the pellet in order to remove the salt from 
the precipitated plasmid DNA. This solution was centrifuged at lOOOOrpm in a JA- 
20 rotor (Beckman J2-21 centrifuge, Beckman Instruments Limited, High Wycombe, 
UK) for 15 minutes at room temperature. The pellet was allowed to dry for a 
maximum of 10 minutes and was then resuspended in 5mL of TE buffer (Appendix 
I).
The plasmid DNA was purified in a caesium chloride/ethidium bromide gradient. 
Caesium chloride and ethidium bromide were added at a final concentration of 
Img/mL and 740|ug/mL, respectively. The solution was transferred to Beckman
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"Quick Seal" centrifuge tubes (Beckman Instruments Limited, High Wycombe,UK). 
DNA was separated on a density gradient by centrifugation in a Vti 65.2 rotor 
(Beckman L-8 M uitracentrifuge, Beckman Instruments Limited, High Wycombe, UK) 
at 49000rpm for 16-20 hours at 20°C. DNA bands were visualised using a hand 
held UV lamp (UVP Inc., San Gabriel, GA, USA, Model UVGL-58) and the 
supercoiled plasmid identified as the lower band on the gradient. This band was 
removed using a needle and syringe and was diluted with TE buffer (Appendix I) to 
a final volume of 5mL. The ethidium bromide was removed with water saturated 1- 
butanol. When the aqueous phase was colourless, the plasmid DNA was 
precipitated in 2 volumes of 99.7% ethanol at -20^0 for 2 hours. The DNA was 
pelleted by centrifugation at lOOOOrpm for 30 minutes at 4°C in a JA-20 rotor 
(Beckman J2-21 centrifuge, Beckman Instruments Limited, High Wycombe, UK). 
The pellet was washed in 70% ethanol, allowed to dry and resuspended in TE 
buffer.
DNA, for use as probe, was digested with the appropriate restriction endonuclease 
(Life Technologies Inc., Paisley, UK) and electrophoresed on a 0.8% agarose gel in 
TAE buffer (Appendix I). Ethidium bromide at 0.5|ug/mL was added to the gel. The 
DNA was visualised using a hand held UV lamp (UVP Inc., San Gabriel, GA, USA, 
Model UVGL-58). Appropriate DNA fragments was purified using DEAE membrane 
or using a Gelase protocol.
2.5.3 Elution of DNA from DEAE membrane
Using a scalpel blade a small cut was made in the gel directly below the DNA 
fragment of interest. DEAE membrane (Schleicher & Schuell, West Germany) was 
placed in the gel space. The gel was run at 50V/cm until the DNA migrated onto the
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DEAE membrane. The excess membrane was trimmed and placed in elution buffer 
(Appendix I) and was incubated at 65°C for one hour. An equal volume of PC19 
(Appendix IV) was added, the mixture was vortexed and then centrifuged at 
13000rpm (MSE microcentrifuge, Rsons, Loughborough, UK). DNA was 
precipitated by addition of 2 volumes of 99.7% ethanol and incubated for two hours 
at -20°C. The precipitated DNA was collected by centrifugation, washed in 70% 
ethanol and air dried. The pellet was resuspended in TE buffer (Appendix I). The 
concentration of DNA was estimated by electrophoresis of an aliquot of the fragment 
on an agarose gel and comparison with a DNA sample of known concentration.
2.5.3.1 Gelase procedure
The recovery of intact DNA from a 1% low melting point agarose gel (Life 
Technologies Inc., Paisley, UK) was carried out using a commercial enzyme 
preparation, Gelase (Cambio Limited, Cambridge, UK). The gel slice containing the 
DNA fragment of interest was excised from the low melting point agarose gel, 
weighed and melted at 70°C for 20 minutes with Gelase buffer. The DNA solution 
was equilibrated by placing at 45°C for 10 minutes. The Gelase enzyme was added 
to the DNA (stock solution 1U/|j,L; 1 unit of Gelase enzyme was added for every 
lOOmg of molten 1% low melting point-agarose gel in TAE buffer) and incubated for 
one hour at 45°C. The eluted DNA was precipitated using 2.5M ammonium acetate 
(stock soiution, 5M ammonium acetate) and centrifuged at lOOOOrpm in a JA-20 
rotor (Beckman J2-21 centrifuge, Beckman Instruments Limited, High Wycombe, 
UK) for 30 minutes at room temperature. The pellet was resuspended in TE buffer. 
In order to determine the concentration of DNA, a comparison with DNA of known 
concentration was performed as outlined above (see section 2.5.3).
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2.5.4 Radioactive labelling of dsDNA using random priming
Twenty five nanograms of linear dsDNA were denatured by boiiing for five minutes 
and cooled on ice. Radioactive labelling using the Multiprime Kit (Amersham 
International pic, Little Chalfont, UK) was carried out according to the manufacturers 
instructions. In a total reaction volume of 50[uL, 10pl of buffer solution containing 
dATP, dGTP, dTTP, 5\xL of primer solution with random hexanucieotldes, 3MBq 
<%32p dCTp (800Ci/mmol: Amersham Internationai pic, Little Chalfont, UK) and 2U 
of the Klenow fragment of DNA polymerase I (stock solution 1 U/p-L) were Incubated 
for four hours at room temperature. Unincorporated radioactive nucleotides were 
removed by sephadex column separation. Sephadex-G50 solution (Pharmacia 
Limited, Milton Keynes, UK) was pipetted into columns and then equilibrated with 
TE buffer (Appendix I) to enabie the sephadex to settle. The multiprime labelling 
reaction was added and a Geiger counter used to monitor the column. The 
radioactively labelled DNA probe was detected as the first peak of radioactivity 
eluted from the column and the unincorporated nucleotides were monitored as the 
second radioactive peak. The radioactively labelled DNA probe was collected and 
stored at -20°C.
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2.6 Analysis of high molecular weight DNA
2.6.1 Restriction endonuclease digestion of high molecular weight and 
plasmid DNA
2.6.2 Agarose gel electrophoresis
Restriction endonuclease digested high molecular weight DNA was separated on a 
0.8% agarose gel in TBE buffer (Appendix I). The DNA samples and one tenth 
volume of gel running dye (Appendix I) were loaded into the wells. The high 
molecular weight DNA marker, Lambda DNA digested with Hind III (Life 
Technologies Inc., Paisley, UK), was loaded adjacent to the sample DNA to enable 
sizing of the fragments. The samples were electrophoresed at 32V/cm for 16-20 
hours and the gel was immersed in ethidium bromide at a final concentration of
O.Spg/mL. The DNA was visualised on a transilluminator (Spectroline
transilluminator, Model TC-254A) and photographed with a Polaroid MP4 Land 
Camera with Polaroid Type 57 high speed film (Genetic Research Instrumentation 
Limited, Dun mow, UK).
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Ten micrograms of high molecular weight DNA were digested with the appropriate 
restriction endonuclease (Life Technologies Inc., Paisley, UK) in a 50pL volume 
containing restriction enzyme reaction buffer at the manufacturers recommended 
concentration and spermidine at a final concentration of 3mM. Five units of 
restriction enzyme were added per pg of DNA. In a lOpL volume, one microgram of 
plasmid DNA was digested with a restriction endonuclease. The reactions were 
incubated at 37^0 for 16-20 hours for high molecular weight DNA and for 1-2 hours 
for digestion of plasmid DNA.
2.6.3 Southern blotting procedure
High molecular weight DNA was transferred to nylon membrane (Hybond-N, 
Amersham International pic, Little Chalfont, UK) using a modified Southern blotting 
procedure. After photography, the DNA was denatured by placing in alkali buffer 
(Appendix I) for one hour at room temperature. This solution was replaced by 
neutralising buffer (Appendix I) and incubated for a further one hour. The gels were 
placed in transfer buffer, 10 x SBC (Appendix I). The DNA was blotted downward 
using capillary action assisted by gravity. The nylon membrane and gel were placed 
on a layer of absorbent material and overlaid with a sponge soaked in transfer 
buffer. The blots were sealed in plastic bags to avoid evaporation and left for 16-20 
hours. The nylon membrane was rinsed in 3x SBC to remove any extraneous 
material and the DNA was irreversibly bound to the membrane by cross-linking with 
UV light (UV Btratalinker 1800, Btratagene Limited, Cambridge, UK).
2.6.4 Hybridisation of Southern blots
The nylon filters were soaked in 3x SBC, 0.1% SDB and placed, with the bound 
DNA facing inside, in a glass tube suitable for the hybridisation oven (Techne 
Hybridiser HB-1, Philip Harris Scientific, Clydebank, UK). The filters were 
prehybridised with lOmL of the hybridisation buffer for 4 hours at 65°C with 
continuous rotation. The labelled probe (see section 2.5.4) was boiled for five 
minutes and cooled rapidly on ice. The 32p-iabelled probe was added to the 
hybridisation buffer and the filters were rotated at 65°C for 16-20 hours. The filters 
were washed initially in two changes of 2x SBC, 0.1% BDB at room temperature for 
five minutes each. The filters were washed in two changes of 0.5x SBC, 0.1% BDB 
at 65°C for 30 minutes each. The filters were wrapped in Baran wrap (Genetic
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Research Instrumentation Limited, Dunmow, UK) and autoradiographed in a 
cassette containing an intensifying screen. The autoradiographs at -70^C were 
developed after exposures of 1-21 days as required.
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Chapter 3
Expression of the EBV encoded latent gene product LMP-1 In 
Hodgkin's disease; lack of correlation with GD23 and bcl-2
expression
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3.1 Introduction
The human herpesvirus, EBV has been linked with a number of malignant 
conditions including BL (Henie et al., 1969, zur Hausen ef a/., 1970, Nonoyama 
ef a/., 1973, 1974), lymphomas in immune deficient persons (Purtilo et aL, 1985, 
Loning et aL, 1987), NPC (zur Hausen et aL, 1970, Nonoyama et aL, 1973) and 
more recently HD.
Using molecular techniques EBV genomes have been detected in HD biopsies 
from 17-41% of cases (Weiss et aL, 1987a, Anagnostopoulos et aL, 1989, Staal 
et aL, 1989, Boiocchi et aL, 1989, Jarrett et aL, 1991a). Although EBV was 
detected in lesions in a proportion of HD cases, it was unclear what role, if any, 
the virus was playing in the disease process. In order to address this issue the 
clonality of the EBV-infected ceils was examined. Analysis of the terminal repeat 
region of the EBV genomes indicated that in the majority of cases examined the 
EBV was monoclonal (Weiss et aL, 1987a, Anagnostopoulos et aL, 1989, 
Gledhill et aL, 1991, Jarrett et aL, 1991a). These above results support the 
suggestion that in a proportion of HD cases the EBV had infected a single cell, 
which had clonally expanded.
At the initiation of this work the localisation of EBV within the affected tissues of 
HD had not been fully determined. Furthermore, there were no data regarding 
the expression of EBV latent gene products in HD biopsies with the exception of 
one early case report. Poppema et aL (1985) used human sera to demonstrate 
expression of an EBV nuclear antigen in HD. Recently monoclonal antibodies 
became available for EBV latent gene products LMP-1 and EBNA-2 (Rowe et aL, 
1987, Young et aL, 1989).
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LMP-1 is the only virus encoded protein which has been shown to have 
transforming ability, in isolation. In B-cell lines, LMP-1 is known to upregulate 
the cellular adhesion molecules, LFA-1, LFA-3 and ICAM-1 and the activation 
antigen CD23 (Wang e ta i, 1988, 1990).
Recent data suggest that the expression of LMP-1 can protect B-cells from 
programmed cell death, apoptosis (Gregory etal., 1991). This effect is mediated 
by the LMP-1 induced upregulation of the bcl-2 gene (Williams et aL, 1990, 
Henderson et aL, 1991). The t(14;18) translocation, which is present in more 
than 85% of follicular lymphomas, is also thought to cause an increased 
expression of the bcl-2 gene (Weiss et aL, 1987b, Cotter, 1990). One report has 
indicated that this translocation occurs in 32% of HD cases (Stetler-Stevenson et 
aL, 1990). It was therefore speculated that bcl-2 expression, induced by either 
LMP-1 or by the transiocation t(14;18), might play a role in HD.
This study was designed to further investigate the role of EBV in HD through the 
examination of EBV latent genes in RS cells. Using immunohistochemical 
methods, the localisation of the EBV latent gene product LMP-1 was examined 
in a series of HD cases previously analysed for the presence of EBV genomes. 
In a limited number of cases the expression of EBNA-2 was also studied. The 
expression of EBV LMP-1 was subsequently correlated with the expression of 
the activation antigen, CD23 and bci-2 protein.
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3.2 Materials and Methods
3.2.1 Clinical samples
Lymph node biopsies from HD patients were referred to the Leukaemia 
Research Fund (LRF) Virus Centre from a number of clinical centres for 
virological analyses. Thirty four HD cases were included in this study. Paraffin- 
embedded lymph node biopsy material was available from all of the cases. 
Frozen material, stored at the Department of Pathology, University of Edinburgh 
Medical School, was available from eleven cases. DNA from these samples had 
been examined previously for the presence of EBV genomes using Southern blot 
analysis. In the EBV positive cases the clonality of the EBV-infected celis was 
assessed (Gledhill et al., 1991, Jarrett et al., 1991a). Selection for this study 
was based on the EBV status of cases; seventeen cases contained clonal EBV 
genomes and seventeen cases were EBV negative. Following histological 
review, the cases were classified according to the Rye ciassification (Lukes et 
al., 1966). The series comprised 12 nodular sclerosis HD (NSHD), 18 mixed 
ceilularity HD (MCHD), 2 lymphocyte depleted HD (LDHD) and 2 lymphocyte 
predominant HD (LPHD) cases. Three reactive nodes were included as 
negative controls.
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3.2.2 Immunohistochemical analysis
3.2.2.1 Monoclonal antibodies
The cocktail of monoclonal antibodies, CS1-4, specific for EBV LMP-1 was kindly 
provided by Professor L.S. Young, University of Birmingham, Birmingham, UK. 
The Individual monoclonal antibodies, CS1, CS2 and the combined CS3 and 
CS4 were shown to recognise three different epitopes on the EBV LMP-1 protein 
(Rowe et a/., 1987). A monoclonal antibody specific for LMP-1, S I2, which 
recognises an epitope distinct from those recognised by the CS1-4 monoclonal 
antibodies was provided by Professor D. Thorley-Lawson (Mann et a/., 1985). 
The PE2 monoclonal antibody specific for the EBNA-2 protein was also donated 
by Professor L.S. Young (Young et a!., 1989). The monoclonal antibody bcl-2 
100 was kindly provided by Dr D.Y. Mason, LRF Immunodiagnostics Unit, John 
R add iff e Hospital, Oxford, UK (Pezzella et a/., 1990). The monoclonal antibody 
BU38 specific for the CD23 molecule was obtained from The Binding Site, 
University of Birmingham, Birmingham, UK.
3.2.2.2 Detection of EBV LMP-1
Using the monoclonal antibodies, CS1-4, a series of experiments was carried out 
to ascertain whether these antibodies could be used on paraffin-embedded 
lymph node material. Optimisation experiments were carried out on cytospin 
preparations of L591, an EBV-positive HD derived ceil line and J-Jhan, a T-cell 
line (prepared as in section 2.2.2) and subsequently on paraffin-embedded 
sections from a case of NSHD shown to be EBV-positive using the CS1-4 
antibodies in early experiments.
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3.2.2.S Enzymatic digestion
As described in section 2.3.2, the trypsin digestion of paraffin-embedded lymph 
node sections was tested over time point varying from 0-20 minutes. The 
intensity of staining within RS cells using the CS1-4 antibody in paraffin- 
embedded tissue was considerably greater without trypsin digestion. Recent 
experiments using heat treatment of paraffin-embedded lymph node tissue in a 
microwave oven for 10 minutes (see section 2.3.3), prior to addition of the CS1-4 
antibodies, resulted in a clearer demonstration of LMP-1 expression in RS cells.
3.2.2.4 Primary antibody
Non-specific staining was observed in initial experiments therefore the 
monocional antibody CS1-4 was purified by pre-adsorbing with HL60 celis which 
was kindly performed by Dr G. Brown at the Department of Immunology, 
University of Birmingham). During the following analyses, both the unpurified 
and purified monoclonal antibody preparations were compared. The cell 
preparations/sections were incubated for one hour with a series of dilutions of 
the monoclonal antibody cocktaii (CS1-4) from 1:10-1:100. Optimal staining 
conditions were observed when the tissue sections were incubated with the 
purified CS1-4 monoclonal antibodies at a dilution of 1:50 for 60 minutes at room 
temperature.
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3.2.2.S Detection of antibody using immunohistochemical methods
Due to problems with background staining four different methods of detecting the 
antigen/antibody complex were investigated (Figure 3.1).
1. an indirect staining procedure (section 2.3.5) using sheep anti-mouse IgGI 
(isotype specific) as secondary antibody and detection with donkey anti-sheep Ig 
conjugated with alkaline phosphatase (AP) (The Binding Site, Birmingham, UK).
2. an ABC method using a biotinylated anti-mouse IgGI (The Binding Site, 
Birmingham, UK, see section 2.3.6) as secondary antibody and detected with an 
avidin-biotin-AP complex (Dako Limited, High Wycombe, UK).
3. a standard APAAP method (Dako Limited, High Wycombe, UK, as described 
in section 2.3.7 and Cordell et aL, 1984) using rabbit anti-mouse immunoglobulin 
(Ig) as secondary antibody.
4. a modified APAAP method using an isotype-specific secondary antibody (anti­
mouse IgGI, The Binding Site, Birmingham, UK).
The standard APAAP method as described above (section 2.3.7) and the avidin- 
blotin alkaline phosphatase method (ABC-AP, see section 2.3.6) incorporating 
the isotype-specific secondary antibody (The Binding Site, Birmingham, UK) 
were equally sensitive methods of detecting reactivity with the monocionai 
antibody cocktail, CS1-4. The ABC-AP method was the most specific method of 
detecting LMP-1 in paraffin-embedded tissue sections. The IgGI-specific
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secondary antibody increased the specificity of the staining. In subsequent 
analyses reactivity was thus detected using this methodology.
Selected cases (cases 74 and 75) were also stained with the 812 monoclonal 
antibody (isotype lgG2a) which recognises another epitope on the LMP-1 
molecule, using an APAAP technique as described in section 2.3.7.
3.2.2.6 Controls
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The LMP-1 positive NSHD case, identified in initiai experiments, was included in 
each assay as a positive control. One section from each case was stained in 
parallel with a monoclonal antibody to rotavirus (RC3.6, kindly provided by Dr G. 
Brown, University of Birmingham) in order to control for non-specific staining. 
Where excess non-specific staining was encountered the procedure was 
repeated with 0.1% bovine serum albumin added to the wash buffer, TBS pH 7.6
3.2.3 Detection of EBNA-2
ir
The expression of EBNA-2 was examined on frozen material from two cases 
(cases 390 and 387) of HD using the PE2 monoclonal antibody and an APAAP 
method (section 2.3.7). Paraffin-embedded tissue sections from a further three 
cases of HD (cases 387, 938 and 954) were examined for EBNA-2 expression 
following reports of enhanced staining with the PE2 antibody after microwave 
treatment. The tissue sections were incubated in 0.01 M citrate buffer pH 6  in a 
microwave oven for 10 minutes (see section 2.3.3). Cytospin preparations and 
paraffin-embedded cell pellets of Raji, an EBV-infected cell line and J-Jhan cells 
were included as positive and negative controls, respectively.
3.2.4 Detection of CD23
Sections from paraffin-embedded material were investigated for the expression 
of CD23 using the monoclonal antibody BU38 and an APAAP method as 
described in section 2.3.7.
As described in section 3.2.2.3, prior to incubation with the monoclonal antibody 
BU38, paraffin-embedded sections were trypsin digested. Optimal staining was 
obtained foiiowing trypsin digestion for 20 minutes at 37°C. Incubation with the 
primary antibody, BU38 at a dilution of 1:50, was carried out overnight at 4^0. A 
section from each case was assayed using the antibody to rotavirus as a 
negative control.
A subset of eleven cases from which frozen material was available were 
analysed for the expression of CD23 using the monoclonal antibody MHM6  and 
an immunoperoxidase method. This assay was carried out at the Department of 
Pathology, University of Edinburgh Medical School.
3.2.5 Detection of bcl-2
Prior to microwave treatment of paraffin-embedded material, staining of paraffin- 
embedded tissue using the bci- 2  monoclonal antibody, bci- 2  1 0 0 , was unreliable. 
The expression of bcl-2 was assayed in eleven cases from which frozen material 
was available. Frozen sections were stained, at the Department of Pathology, 
University of Edinburgh Medical school, using an indirect immunoperoxidase 
technique and a monoclonal antibody to bcl-2 protein (bcl-2 100) (Salter et aL, 
1985).
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3.3 Results
3.3.1 Expression of EBV LMP-1
The correlation between EBV status, assessed by Southern blot analysis, and 
LMP-1 expression in 34 HD cases is summarised in Tables 3.1 and 3.2. EBV 
LMP-1 was present in the RS celis and in mononuclear variants in 15 cases 
(Figures 3.2a and 3.3). In many cases the staining was focai. The pattern of 
staining was predominantly cytoplasmic although some ceils showed a staining 
pattern consistent with the membrane distribution of the LMP-1 protein. 
Considerable variation was observed in the proportion of abnormal cells which 
stained posltiveiy within an individuai biopsy. In some cases only a minority of 
the RS cells showed reactivity with the LMP-1 antibodies. Staining was intense 
even when LMP-1 expression was limited to a few cells in the biopsy. EBV LMP- 
1 was not detected in the smali iymphocytes or other cell types in the reactive 
infiltrate. No reactivity was noted in sections from the three reactive nodes or in 
controi sections iabelled with the antibody to rotavirus (Figure 3b).
3.3.1.1 Southern blot positive HD cases
Seventeen cases containing clonal EBV genomes were analysed for the 
presence of the EBV LMP-1 protein. This EBV encoded latent gene product was 
detected in twelve of the EBV-positive HD cases (Table 3.1).
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Table 3.1 Expression of EBV LMP-1, EBNA-2, CD23 and bcl-2 in Hodgkin's
disease
Southern blot positive HD cases
LRF case 
number
Age
(years)
HD
subtype
Southern blot 
result
LMP-1 EBNA-2 CD23 bcl-2
70 36 LP C ++ NT - NT
79 48 MC C ++ NT - NT
386 80 MC c ++ NT - +
387 14 MC c ++ - - +
390 68 NS c ++ NT - -
937 14 MC c ++ NT + -
938 6 NS c ++ - - NT
940 5 MC c ++ NT - NT
954 31 MC c ++ - - NT
960 59 NS c NT - NT
962 54 NS c - NT - NT
974 82 NS c ++ NT - -
981 85 MC c 4—h NT + +
982 78 MC c - NT - -
987 65 LP c - NT - NT
990 67 LD c ++ NT - +/-
998 7 MC c ++ NT - NT
C, clonal EBV genomes; NT, not tested; ++, strongly positive; +, positive; -, 
negative
NS, nodular sclerosis HD; MC, mixed ceilularity HD; LD. lymphocyte depleted HD; 
LP, lymphocyte predominance HD
Table 3.2 Expression of EBV LMP-1, CD23 and bcl-2 in Hodgkin's disease
Southern blot negative HD cases
LRF case 
number
Age
(years)
HD
subtype
LMP-1 CD23 bcl- 2
71 2 2 NS - - NT
74 2 0 MC ++ - NT
75 25 NS ++ - NT
420 19 LD - - NT
430 67 NS - - NT
237 25 MC - - NT
939 7 NS - - NT
951 2 1 MC - - -
955 24 MC - - NT
956 25 MC - NT
959 30 MC - - NT
963 54 NS - - NT
964 56 NS - - NT
979 61 MC - - NT
983 60 MC - - ++
984 82 MC - -
995 39 NS - - NT
NT, not tested, ++ strongly positive, + positive, - negative
NS, nodular sclerosis HD; MC, mixed ceilularity HD; LD, lymphocyte depleted HD; 
LP, lymphocyte predominance HD
Figure 3.2a: EBV-LMP-1 expression In HD:Case 390
Paraffin-embedded lymph node biopsy section from a 6 8  year oid MCHD case. 
Clonal EBV genomes. Reactivity with LMP-1 monoclonal antibody (CS1-4) is 
detected. Clonal EBV genomes were detected. Alkaline phosphatase and Fast red 
salt, counterstained with haematoxylin.
Figure 3.2b: Immunohistochemical staining with rotavirus monoclonal antibody 
(RC3.6):Case 390
Paraffin-embedded lymph node section from a 6 8  year old MCHD case. 
Immunohistochemical staining using rotavirus monoclonal antibody (RC3.6) as 
negative control. Alkaline phosphatase and Fast red salt, counterstained with 
haematoxylin.
Figure 3.2a Expression of EBV LMP-1 in HD 
Case 390
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(Magnification x50)
Figure 3.2b Immunohistochemical staining with rotavirus 
monoclonal antibody (RC3.6)
Case 390
(Magnification x25)
Figure 3.3 Expression of EBV LMP-1 in HD 
Case 954
m
(Magnification xlOO)
Paraffin-embedded lymph node section from a 31 year old MCHD case. Reactivity 
with the LMP-1 monoclonal antibody (CS1-4) is detected in RS cells. Clonal EBV 
genomes were detected. Alkaline phosphatase and Fast red salt, counterstained 
with haematoxylin.
3.3.1.2 Southern blot negative HD cases
The expression of LMP-1 was investigated in seventeen EBV negative HD 
cases. Two of these, cases 74 and 75, had detectable EBV LMP-1 in the RS 
cells of the biopsy (Figures 3.4 and 3.5, Table 3.2). Staining of cells in these 
cases was also observed using the SI 2 monoclonal antibody confirming the 
specificity of the staining.
3.3.2 Expression of EBNA-2
Sections from five HD cases were investigated for the presence of EBNA-2 
expression. Staining was not detected in any of the five HD cases using the PE2 
monoclonal antibody (Tables 3.1 and 3.3). A distinct nuclear pattern of reactivity 
was observed in EBV-positive celis in positive control material.
3.3.3 Expression of CD23
Sections from all cases were analysed for the presence of CD23 but staining of 
RS cells was not observed using paraffin-embedded biopsy material (Tables 3.1 
and 3.2). In many cases strong staining was observed within the germinal 
centres of residual follicles (Figure 3.6) thus providing an internal positive 
control. Using frozen biopsy material, CD23 was detectable in the RS cells in 
two of the eleven cases examined (Table 3.3).
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Figure 3.4 Expression of EBV LMP-1 in HD 
Case 75
(Magnification x100)
Paraffin-embedded lymph node section from a 24 year old NSHD case. Reactivity 
with LMP-1 monoclonal antibody (CS1-4) is detected in RS cells. EBV-negative by 
Southern blot hybridisation. Alkaline phosphatase and Fast red salt,
counterstained with haematoxylin.
Figure 3.5 Expression of EBV. LMP-1 in HD 
Case 74
3
(Magnification xlOO)
Paraffin-embedded lymph node section from a 20 year old MCHD case. Reactivity 
with the LMP-1 monoclonal antibody (CS1-4) is detected in RS cells. EBV-negative 
by Southern blot hybridisation. Alkaline phosphatase and Fast red salt, 
counterstained with haematoxylin.
Table 3.3 Detection of EBV LMP-1, EBNA-2, CD23 and bcl-2 in RS cells in 
frozen biopsy material available from 11 cases of Hodgkin's disease
LRF case 
number
Age
(years)
HD
subtype
Southern blot 
result
LMP-1 EBNA-2 CD23 bcl-2
386 80 MC C ++ NT - +
387 14 MG C ++ - - +
390 6 8 NS c ++ - - -
937 14 MC c ++ NT + -
951 2 1 MC - - NT - -
974 82 NS c ++ NT - -
981 85 MC c H—h NT + +
982 78 MC c - NT - -
983 60 MC - - NT - +
984 82 MC - - NT - +
990 67 LD c ++ NT - +/-
C, clonal EBV genomes; ++, strongly positive; +, positive; +/-, equivocal; -, negative; 
NT, not tested
NS, nodular sclerosis HD; MC, mixed cellularity HD; LD, lymphocyte depleted HD
Figure 3.6 Immunostaining of paraffin-embedded HD biopsy material using the 
BU38 monoclonal antibody specific for CD23
(Magnification x100)
Staining of paraffin-embedded HD biopsy material using the BU38 monoclonal 
antibody. Intense staining within the germinal centres of residual follicles is 
detected, however no staining is observed in the RS cells. Alkaline phosphatase 
and Fast red salt, counterstained with haematoxylin.
3.3.4 Expression of LMP-1 and CD23
The correlation between LMP-1 and CD23 expression was analysed for the 
subset of 11 HD cases from which there was frozen biopsy material available 
(Table 3.4a). CD23 expression was observed in two of seven cases in which 
EBV LMP-1 had been detected. In comparison there was no detection of CD23 
expression in the RS cells in the EBV negative cases.
3.3.5 Expression of bcl-2
Sections from eleven HD cases were analysed for the expression of bcl-2 
(Tables 3.1, 3.2 and 3.3). Cytoplasmic staining of RS cells was seen in five 
cases. In these cases variable numbers of bci-2 positive and negative RS cells 
were present. Small lymphocytes stained with bcl-2 in all the cases examined 
and, where present, there was no staining in the germinal centres.
3.3.6 Expression of LMP-1 and bcl-2
bcl-2 expression was found in four of the eight cases in which clonal EBV 
genomes had been detected previously. However, bcl-2 expression was 
detected in two of the three cases which were EBV negative by Southern blot 
analysis. The relationship between LMP-1 and bci-2 expression was analysed 
and Is shown in Table 3.4b. From seven LMP-1 positive cases, three cases 
expressed the bcl-2 protein within the RS cells.
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Table 3.4a Correlation between the expression of EBV LMP-1 and CD23
in RS cells
CD23 status HD cases LMP-1
positive
LMP-1
negative
positive 8 2 0
negative 3 5 4
Total cases 11 7 4
Table 3.4b Correlation between the expression of EBV LMP-1 and bcl-2
in RS cells
bcl-2 status HD cases LMP-1
positive
LMP-1
negative
positive 8 3 2
negative 3 4 2
Total cases 11 7 4
3.4 Conclusions
The main finding from this study is that immunohistochemicai staining using 
antibodies against the LMP-1 protein clearly shows that EBV is localised to the 
RS cells in HD. Furthermore, an EBV encoded latent gene product with known 
oncogenic potential (see section 1.4.3.3), is expressed by RS cells. Previous 
reports of EBV genomes in HD have now been confirmed by the presence of 
LMP-1 exclusively in the RS cell population. These results are the first indication 
that the presence of EBV in HD is likely to be an important step in the 
pathogenesis of the disease.
During the course of this work two similar studies were published in which EBV 
LMP-1 was detected in RS cells in frozen biopsy material from a proportion of 
HD cases. Using the cocktail of monoclonal antibodies CS1-4, Pallesen et aL 
(1991a) investigated 84 HD cases and demonstrated LMP-1 in RS cells in 40 
cases (48%). In a similar study, LMP-1 expression was detected in 18 of 47 HD 
cases (38%) using a polyclonal rabbit antisera directed against LMP-1 (Herbst et 
al., 1991). Although the biochemical activity of LMP-1 is unknown the presence 
of a translated latent gene within the malignant ceils of a proportion of HD cases 
has led us to speculate that EBV is aetiologically involved in these HD cases.
Using the PE2 antibody on frozen biopsy tissue from a small number of HD 
cases, EBNA-2 expression was not detected in RS cells. These results have 
been confirmed by other groups (Pallesen et a!., 1991a, Herbst et ai., 1991a). 
Cattoretti et a!., (1993) recently reported a microwave method of antigen 
unmasking which enabled the use of a number of antibody preparations on 
formalin-fixed, paraffin-embedded tissue sections. Following microwave
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treatment, enhanced staining using the PE2 antibody has been documented (G. 
Niedobitek, personal communication). Further study of HD cases using this 
method of antigen retrieval and the PE2 antibody confirmed the above findings.
Selection of cases for this study on the basis of Southern blot results has 
enabled the correlation of the immunohistochemicai analysis with EBV status 
(Jarrett et a/., 1991a, Giedhiil et aL, 1991). In the majority of cases in which 
clonal EBV genomes were detected LMP-1 was expressed in RS cells. 
However, there were four cases in this category in which the LMP-1 protein was 
not detected. Explanations for the failure to detect expression include that LMP- 
1 may not have been expressed or was expressed at low levels in the malignant 
cells and the differences in fixation may have resulted in the negative LMP-1 
status of these cases. Cases were referred from various pathological centres 
thus fixation was not standard.
In addition we identified two cases (cases 74 and 75) which were negative by 
Southern blot analysis but expressed LMP-1 in RS cells. It would seem unlikely 
that the detection of EBV in these cases would have been below the detection 
limit of the Southern blot technique as it is possibie to detect a single EBV 
genome in <0.45% of the cells using this method. These cases were reviewed 
independentiy by Dr A.S. Jack, Consultant Pathologist, University of Leeds. In 
case 74 a large reactive component was described in the biopsy. This would 
suggest that the numbers of RS cells in this sample may have been insufficient 
to allow detection of virai genomes by the Southern blot method. In case 75 
large numbers of abnormal cells were noted in sections from this biopsy. The 
most likely explanation for the discrepancy between the Southern biot and 
immunohistochemicai results was that sampling error may have occurred.
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Overall, there was a good correlation between the detection of EBV using 
immunohistochemicai analysis and Southern blot hybridisation. The correlation 
between the detection of EBV using Southern blot analysis and 
immunohistochemicai techniques is discussed further in Chapter 4.
Using sensitive immunohistochemicai methods, we have demonstrated that the 
antibody cocktail CS1-4 could be reliably used in archival paraffin-embedded 
biopsy material to detect LMP-1 within RS ceils, particularly when the numbers 
of RS cells are low. Pallesen et aL (1991a) examined a small number of 
paraffin-embedded sections and reported weak reactivity with the LMP-1 
antibodies in RS cells. In the present study the percentage of LMP-1 positive 
HD cases detected in paraffin-embedded tissue was comparable to that seen in 
studies using frozen biopsy material (Pallesen et aL, 1991a, Herbst et aL, 
1991a). Murray etaL (1992a) confirmed our findings with the detection of LMP-1 
protein in RS ceils in 22 out of 46 HD cases (48%) in paraffin-embedded biopsy 
material.
LMP-1 has also been shown to be a potential target for cytotoxic T cells (Murray 
et aL, 1988). In a normal functioning immune system one would expect these 
cells would have been removed by cytotoxic T-ceils. Therefore, the presence of 
cells expressing LMP-1 in HD suggests either an impairment or lack of antigen 
presentation or a defect in cell-mediated immunity.
The Identification of LMP-1 protein in RS cells led us to investigate the 
expression of CD23 and bcl-2, both of which have been shown to be upregulated 
by LMP-1. LMP-1 is known to induce the expression of CD23 in B cells in vitro. 
CD23 expression was not detected in RS ceils in paraffin-embedded sections,
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but was detected in the malignant cells in a small number of cases using frozen 
biopsy material. From these results it is clear that the latter assay is more 
sensitive. However, these results do suggest that CD23 is present in RS cells in 
only a minority of cases and is not expressed at high levels (Jarrett et aL, 
1991b). These findings are consistent with those of other studies (Pallesen, 
1987, Herbst et aL, 1991a, Sandvej et aL, 1993). In contrast, a prior study by 
Rowlands et aL (1990) indicated that CD23 was expressed in RS cells in 13 out 
of 15 HD cases in paraffin-embedded tissue. From our data and those of other 
groups we suspect that there is an over-estimation of CD23 expression within 
the malignant cells in these particular cases.
Further analysis of the correlation between LMP-1 and CD23 expression was 
limited due to the small numbers of cases investigated using the frozen section 
assay. Both of the CD23 positive cases were LMP-1 positive therefore we 
cannot rule out the possibility that in a small proportion of cases the expression 
of LMP-1 upregulates CD23 in RS ceils. Transfection of the EBV-negative BJAB 
ceil line with both EBNA-2 and LMP-1 resulted in increased levels of CD23 
compared with cells expressing EBNA-2 and LMP-1 individually (Wang et aL, 
1990). Failure to up-regulate CD23 in RS cells may therefore be due to the lack 
of EBNA-2 expression.
Previous studies have examined the presence of the t(14;18) translocation in HD 
cases using the polymerase chain reaction (PGR). The bcl-2-associated 
translocation has been detected in 5-32% of HD cases (Stetler-Stevenson et aL,
1990, Masih et aL, 1991, Reid et aL, 1993), however other laboratories have 
failed to detect the presence of the translocation in HD material (Said et aL,
1991, Louie et aL, 1991). In our laboratory, the t(14;18) translocation was
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identified in only three of fifty HD cases studied (Alice Gallagher, personal 
communication). The expression of bcl-2 was examined in most of the cases 
included in the molecular analyses. In the present study, the bcl-2 protein was 
detected in RS cells in approximately half of the cases examined. The presence 
of bcl-2 in RS cells did not correlate with LMP-1 positivity. bcl-2 expression in 
RS cells has been described previously in a variable proportion of HD cases. 
Two groups failed to detect bci-2 staining in RS ceiis (Pezzeia etaL, 1990, Louie 
et aL, 1991); weak bci-2 staining was detected in RS celis in five of nine HD 
cases (Zutter etaL, 1991) and Bhagat et aL (1993) detected bci-2 protein in RS 
cells in eight of thirteen HD cases which had been previously analysed for 
t(14;18) translocation. In the latter study, the expression of bcl-2 in RS cells did 
not correlate with the presence of EBV LMP-1. Bhagat et aL, (1993) analysed 
the clinical features and histological subtype, EBV-positivity and t(14;18) 
translocation with bcl- 2  expression and showed no association between any of 
these factors.
From the results of this and other studies, we conclude that the LMP-1 protein is 
present in approximately 40% of HD cases however, there is no evidence of 
EBNA-2 expression in HD tissues (Pallesen et aL, 1991a, Herbst et aL, 1991a). 
These results indicate that a distinct pattern of EBV latent gene expression 
exists for HD. Rowe et al. (1992) described three patterns of EBV latent gene 
expression, in vitro (section 1.4.3.6 ). In BL cell lines only EBNA-1 is detected 
(Rowe etal., 1987). In LCL ail of the latent proteins are observed (Young et at.,
1989). These latency patterns have been defined as latency (Lat) I and Lat III 
patterns, respectively. The pattern of expression in HD appears to be similar to 
that seen in NPC in which LMP-1 is expressed in the absence of EBNA-2 and is 
described as a Lat II expression pattern.
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The role of LMP-1 in HD remains unresolved but the results of this study suggest 
that it is Independent of EBNA-2 expression and the upregulation of CD23 and 
bcl-2. The demonstration of an EBV encoded protein with oncogenic potential 
expressed in the RS cells suggests that EBV plays a role in the pathogenesis of
HD.
Chapter 4
Definition of EBV-assooiation in Hodgkin's disease: 
a molecular analysis
-
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4.1 Introduction
At the initiation of this work, the majority of studies had used Southern blot 
hybridisation to detect EBV in HD biopsy material (Weiss et a!., 1987a, 
Anagnostopolous et al., 1989, Weiss et aL, 1989, Staal et aL, 1989, Boiocchi et aL, 
1989, Giedhiil etal., 1991, Jarrett et aL, 1991a). The EBV BamHl-W probe, which 
identifies the major internal repeat sequence, can be used to detect a single EBV 
genome if it is present in <0.45% of a DNA sample derived from 1 x 1 0  ^cells (Jarrett 
et aL, 1991a). The sensitivity of this assay should enable the detection of EBV 
genomes present within RS cells in the majority of HD cases. In addition the 
examination of the terminal repeats of the viral genome using Southern blot analysis 
can be used to assess the clonality of the EBV-infected population (Raab-Traub & 
Flynn, 1986, see section 1.6.5). The EBV genomes in HD biopsies have been 
shown to be clonal which is consistent with the expansion of a single infected cell 
(Weiss etal., 1987a, Boiocchi etal., 1989, Jarrett etal., 1991a).
Using DNA in situ hybridisation, EBV genomes had been detected within RS cells 
(Anagnostopolous et aL, 1989, Weiss et aL, 1989). However, these studies have 
been criticised due to a lack of sensitivity and poor signal-to-noise ratios. When 
applied to routinely fixed and processed material this technique often gives 
unsatisfactory results (Anagnostopolous et aL, 1989). Consequently, this is not a 
practical method for screening large case series and archival samples.
The use of the polymerase chain reaction (PGR) to detect EBV in large series of HD 
cases has the obvious advantages of ease and sensitivity. However, the sensitivity 
of this technique increases the likelihood of detecting EBV within the reactive 
infiltrate.
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As described in the previous chapter, immunohistochemicai studies have localised 
the EBV LMP-1 to RS cells (Pallesen et aL, 1991a, Armstrong et aL, 1992a, 
Brousset et aL, 1993b). As the EBV LMP-1 protein has been shown to have 
oncogenic potential (Wang et aL, 1985), these results indicated that EBV may be 
important in the disease process of HD. Further evidence to support this concept
has been derived from the presence of EBV EBER RNA within RS cells (Wu et aL,
1990).
These small non-polyadenylated EBER RNAs (as described in detail in section 
1.4.3.5), which are abundantly transcribed, are found within the nuclei of latently- 
infected cells (Howe & Steitz, 1986). Using an in situ hybridisation assay, Wu et aL 
(1990) reported the presence of EBER RNA within the RS cells in 6  of the 8  cases 
which were positive by Southern blot analysis.
In this study the optimal method of detecting EBV in HD for use in epidemiological 
studies was determined. The comparison of four methods, Southern blot analysis, 
PCR, immunohistochemicai techniques and in situ hybridisation studies is 
described. The most practical method of determining the true incidence of EBV- 
association in HD is described.
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4.2 Materials and Methods
4.2.1 Clinical samples
HD biopsies from a number of clinical centres were referred to the LRF Virus centre, 
University of Glasgow and examined for the presence of EBV. In total, 71 cases of 
HD were evaluated. Samples from 44 of the cases had been examined previously 
using Southern blot analysis and the EBV BamHI-W probe (Jarrett et aL, 1991a). 
Cases were selected on the basis of EBV status as assessed by Southern blot 
analyses and PCR and, where possible, these cases were investigated using 
immunohistochemicai and in situ hybridisation methods.
4.2.1.1 Southern blot positive cases
Seventeen cases were EBV positive by Southern blot analysis. In sixteen of these 
cases we had demonstrated the clonality of the EBV genomes (Jarrett et aL, 
1991a). The EBV-infected population in the remaining case (case 960) did not 
appear to be clonal (Jarrett et aL, 1991a). During the course of the present study, 
using a slightly altered strategy, the clonality of the EBV genomes in this case was 
demonstrated (Armstrong et aL, 1992b). In order to determine the cellular 
localisation of the EBV, paraffin-embedded tissue sections from these cases were 
analysed by immunohistochemistry (see Chapter 3) and in situ hybridisation.
4.2.1.2 Southern blot negative cases
Samples from 27 Southern blot negative cases were examined to determine 
whether EBV could be detected using more sensitive techniques. DNA samples
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from 15 cases were examined for the presence of EBV genomes using PCR. The 
expression of LMP-1 protein and EBER-1 RNA was examined in 22 cases. As DNA 
samples from 1 2  cases had been handled in the laboratory in which plasmids 
containing EBV DNA fragments were used it was not possible to further analyse 
these cases by PCR because of the risk of contamination. Paraffin-embedded 
material from four cases was not available.
The association between expression of LMP-1, CD23 and bcl-2 in a proportion of 
these cases is reported in the previous chapter of this thesis.
4.2.1.3 Non-selected cases
Samples from 27 non-selected cases were examined for the expression of LMP-1 
and EBER-1 in order to compare further the techniques used to detect these two 
EBV latent gene products.
4.2.2 Immunohistochemicai analyses
EBV LMP-1 expression was investigated in paraffin-embedded HD sections using a 
cocktail of monoclonal antibodies (CS1-4) reactive with LMP-1 (Rowe et aL, 1987) 
as described in section 2.3.6 and 3.2.2.2-3.2.2.6.
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:4.2.3 RNA in situ hybridisation
Three to five micrometre paraffin-embedded sections were processed as described 
in section 2.2.3. All solutions were made up in diethyl pyrocarbonate (DEPC) 
treated water (Appendix V).
4.2.3.1 Pronase digestion
The proteolytic digestion of paraffin-embedded tissue is a critical step in the in situ 
hybridisation protocol. The digestion of paraffin-embedded lymph node tissue 
sections using pronase (Boehringer Mannheim UK, Lewes, UK) was tested at 
concentrations of 100pg/mL, SOOpg/mL and 1mg/mL over the time periods two, five 
and ten minutes. Optimal proteolytic digestion of lymph node tissue using pronase 
was achieved at a concentration of 1mg/mL for five minutes at room temperature. 
These parameters varied depending on the proteolytic enzyme used and tissue type 
examined. Therefore for each tissue type examined the concentration of pronase 
and time of incubation were assessed. The proteolytic enzyme reaction was 
stopped by immersing the sections in glycine buffer (Appendix III). Sections were 
dehydrated by placing in 70%, 85% and 99.7% ethanol for five minutes each and air 
dried at room temperature.
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4.2.S.2 Oligonucleotide probes
The in situ protocol was described by Weiss et ai. (1990) and modified for the 
detection of EBV using an oligonucleotide probe specific for the EBER-1 sequence. 
An oligonucleotide probe complementary to the EBER-1 RNA was synthesised with 
a biotin molecule at the 5' end:
5 -AGA CAC CGT CCT CAC CAC CCG GGA CTT GTA-3'
Tissues infected with herpes simplex-1, human papilloma virus-16 and adenovirus 
did not show hybridisation with this oligonucleotide probe (Weiss etal., 1991).
A nonsense oligonucleotide probe with base composition identical to that of the 
probe of interest was synthesised with a biotin molecule at the 5'-end.
5 -ATG GTG AGC CGG AGT CCT TAC GTC CGC GAA-3'
These probes were 3'-end labelled with biotin as described in section 2.4.2.
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4.2.3.3 Hybridisation of oligonucleotide probe
The melting temperature (Tm) of the hybrid between the probe and target sequence 
is dependent on several factors; ionic strength, base composition and denaturing 
agents. These factors are all considered in the following formula:
T^=  81.5 + 16.6(logioM)+ 0.41 (%G+C)-0.72 (F)-500/L
where T ^  = temperature at which 50% of duplexes are dissociated 
M = concentration of monovalent cation 
%G + C = proportion of guanidine and cytidine nucleotides 
F = % of form amide 
L = length of duplex in base pairs
When calculating the optimal hybridisation temperature for RNA-DNA hybrids 
several factors are considered. The stability of RNA-DNA hybrids is greater in 50% 
formamide than that of a DNA duplex of similar base composition (Bishop, 1972). 
This allows RNA-DNA hybrids to form whilst preventing DNA duplex formation. The 
maximum rate of RNA-DNA hybridisation has been shown to be obtained at 10- 
15°C below the T ^  of the hybrids. Thus using the above equation, the T ^  of the 
EBER-1 oligonucleotide following hybridisation to a perfectly matched sequence is 
equal to 47.75°C under conditions of 50% formamide and 3x SSC (salt 
concentration, 0.45M). The optimal hybridisation temperature was calculated to be 
approximately 37°C for the EBV EBER-1 oligonucleotide probe.
The sections were incubated with pre-hybridisation buffer (Appendix III) for two 
hours at 37°C. The probe was tested at a range of probe concentrations between
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0.125-1 Ong/pL. A final probe concentration of 0.25ng/pL was optimal and this was 
diluted in hybridisation buffer (Appendix III). The sections were subsequently 
hybridised for 16-20 hours at 37^0 .
4.2.3.4 Detection of biotinylated probes
All post-hybridisation wash steps were carried out at room temperature. The 
detection of biotinylated oligonucleotide probes was carried out as described in 
section 2.4.4.
4.2.3.5 Controls
A series of controls were included in each of the in situ hybridisation assays. In 
each assay an EBV-positive HD-derived cell line, L591, and the T-cell line, J-Jhan, 
embedded in paraffin wax, were included as positive and negative controls, 
respectively. In some studies these controls were not available thus a positive case 
identified during previous experiments was included as a positive control. The 
nonsense oligonucleotide probe (see section 4.2.3.2) was included during the 
optimisation of the assay on paraffin-embedded tissue from different clinical centres 
In order to assess non-specific staining. In order to determine the integrity of RNA 
in the tissue samples some negative cases were probed with a 30 base pair 
oligonucleotide dT probe, using altered hybridisation conditions: 25% formamide 
hybridisation buffer and 3x SSC at 37°C.
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4.2.4 PCR analyses
DNA samples were assayed using primers derived from the EBV BamH1-W 
sequence (Deacon et aL, 1991), the EBNA-2 gene (Sample et aL, 1990) and the 
LMP-1 gene (Brooks et aL, 1992) (Table 4.1). The EBV genome can be subtyped 
into Types 1 or 2 using the EBNA-2 primers (Sample etal., 1990).
A standard polymerase chain reaction was performed. Two micrograms of DNA 
were assayed in a 50pL total reaction mixture containing IpM primers (SOpmol), 
1.5mM magnesium chloride, 50mM potassium chloride, lOmM Tris pH 8.2, 0.05% 
NP40, 200pmol/L of each deoxynucleotide triphosphate, and 1U of Amplitaq 
(Perkin-Elmer, Applied Biosystems, Warrington, UK). The reaction mixture was 
overlaid with mineral oil to prevent evaporation during thermal cycling. Initial 
dénaturation of target DNA was carried out at 95°C for seven minutes in a thermal 
cycling machine (Perkin-Elmer Instruments). Following a ramp time of one minute, 
primers were denatured at 94°C for 10 seconds. The temperature was reduced to 
550C over two minutes and the primers were annealed at this temperature for 1 0  
seconds. The temperature was increased to 72°C over one minute and held at this 
temperature for 30 seconds to allow extension of the annealed primers using Taq 
polymerase. Forty cycles of amplification were performed. An extension time at 
72°C for 7 minutes was performed and the samples were finally brought to a 
temperature of 6 °C.
DNA from the EBV-positive cell line B95-8 and three Southern blot positive HD 
samples were used as positive controls. A negative control, consisting of either 
water or placental DNA, was included after each sample. Identical aliquots of the
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DNA samples were tested using the (3-giobin primers (Table 4.1), in order to check 
that amplifiable DNA was present.
Ten microlitres of the amplified products were subjected to polyacrylamide gel 
electrophoresis, electroblotted onto nylon membranes and hybridised with specific 
probes (Table 4.1). These assays were performed by Alice Gallagher.
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4.3 Results
The RS cells within a proportion of HD cases showed reactivity with the C81-4 
antibodies and hybridised with the EBER-1 probe (Tables 4.2 and 4.3). The pattern 
of labelling with the CS1-4 antibodies was predominantly cytoplasmic, but 
occasional cells showed membrane positivity (Figure 4.1). As illustrated in Figures 
4.2a and 4.3, the EBER-1 RNA was detected within the nuclei of positive cells. No 
specific staining was detected in the tissue sections following hybridisation with the 
nonsense (control) oligonucleotide probe (Figure 4.2b). Hybridisation with the 
EBER-1 probe was not restricted to RS cells as staining of small lymphocytes was 
also observed (Figure 4.4).
4.3.1 Southern blot positive cases
In 13 of the 17 cases in which clonal EBV genomes had been detected, RS cells 
were stained by the CS1-4 antibody cocktail. RS cells in three of the remaining four 
cases hybridised with the EBER-1 oligonucleotide probe. The cellular localisation of 
EBV was not established in case 962 and further investigation showed that sections 
from this case did not hybridise with an oligonucleotide dT probe. These results 
suggested that the RNA was degraded. The majority of these cases had been 
subtyped into EBV types 1 and 2 using a PCR strategy (Tables 4.2 and 4.3) (Jarrett 
etal., 1991a).
4.3.2 Southern blot negative cases
PCR analyses were performed on 15 samples within this group and positive results 
were obtained in 13 cases (Table 4.3). Quantitative PCR was not performed but
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Table 4.2 Detection of EBV in selected Hodgkin's disease cases
Southern blot positive HD cases
LRF case 
number
Histological
subtype
Age
(years)
EBV
subtype
*LMP-1 *EBER-1
70 LP 36 1 + +
79 MC 48 1 + +
386 MG 80 1 + +
387 MC 14 1 + +
390 NS 6 8 1 + ND
937 MC 14 1 + +
938 NS 6 ND + +
940 MC 5 1 + +
954 MC 31 1 + +
960 NS 59 ND - +
962 NS 53 1 - -
974 NS 82 1 + +
981 MC 85 1 + +
982 MC 78 1 - +
987 LP 65 1 -• +
990 MC 67 1 + +
998 MC 7 1 + +
NS, nodular sclerosis HD; MC, mixed cellularity HD; LP, lymphocyte predominance 
HD.
+. positive result; - negative result; ND not done; * EBV detected in RS cells
Table 4.3 Detection of EBV in selected Hodgkin's disease cases
Southern blot negative HD cases
LRF case 
number
Histological
subtype
Age PGR EBV
subtype
LMP-1 EBER-1
71 NS 2 2 + 1 - -
74 MC 2 0 ++ - + +
75 NS 24 ++ 1 + +
420 LD 19 + 1 - -
430 NS 67 ++ 2 - -
924 NS 19 + 1 - -
926 NS 26 ++ 1 -
382 NS 23 + 1 - -
384 NS 28 + 1 ND -
385 NS 31 + - - -
929 LP 17 " - ND ND
930 NS 32 - - ND ND
931 NS 42 + 1 - -
932 NS 25 ++ 1 ND ND
934 NS 2 1 -t- 1 ND ND
939 NS 7 ND ND - -
951 MC 2 1 ND ND - -
955 MC 24 ND ND - -
956 MC 25 ND ND - +
959 MC 19 ND ND - -
963 NS 54 ND ND - -
964 NS 56 ND ND - ~
979 MC 61 ND ND - -
983 MC 60 ND ND - -
984 MC 82 ND ND - -
995 NS 39 ND ND - -
999 NS 18 ND ND - -
NS, nodular sclerosis HD; MC mixed cellularity HD; LP, lymphocyte predominance HD; 
LD, lymphocyte depleted HD.
+, positive result; ++, positive result on ethidium-bromide stained gels; -, negative 
result; ND not done. *EBER-1 detected in RS cells
Figure 4.1 Expression of EBV. LMP-1 in HD 
Case 390
n
%
m
(Magnification x250)
Paraffin-embedded lymph node section from a 68 year old NSHD case. Reactivity 
with the LMP-1 monoclonal antibody (CS1-4) is detected in RS cells, multinuclear 
cells and mononuclear variants. EBV genomes were clonal. Alkaline phosphatase 
and Fast red salt, counterstained with haematoxylin.
Figure 4.2a: EBER RNA in situ hybridisation: Case 981
Paraffin-embedded lymph node section from a 85 year old MCHD case. Clonal EBV 
genomes were detected. EBV LMP-1 was not expressed. EBER RNA is detected 
in RS cells. Note nuclear localisation of EBER RNA. Alkaline phosphatase and 
NBT, lightly counterstained with haematoxylin.
Figure 4.2b: In situ hybridisation using nonsense oligonucleotide probe as negative 
control: case 981
Paraffin-embedded tissue section from a 85 year old MCHD case. Hybridisation of 
biotin-labelled nonsense oligonucleotide probe as negative control. Alkaline 
phosphatase and NBT not counterstained.
Figure 4.2a EBER RNA in situ hybridisation 
Case 981
(Magnification x100)
Figure 4.2b In situ hybridsation using nonsense 
oligonucleotide probe as negative control 
Case 987
(Magnification x 50)
Figure 4.3 EBER RNA in situ hybridisation 
Case 982
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(Magnification x250)
Paraffin-embedded lymph node section from a 78 year old MCHD case. EBER RNA 
is detected in RS cells. Clonal EBV genomes were detected. LMP-1 was not 
detected in RS cells. Alkaline phosphatase and NBT, not counterstained.
Figure 4.4 EBER RNA in situ hybridisation 
Case 926
(Magnification x100)
Paraffin-embedded lymph node section from a 26 year old NSHD case. EBV- 
positive by PCR on ethidium bromide stained PAGE gels. EBV-negative by 
Southern blot hybridisation. LMP-1 was not detected. Note staining of small 
lymphocytes. Alkaline phosphatase and NBT, counterstained with haematoxylin.
samples were scored as strongly positive (++) if specific products were detectable 
on ethidium bromide-stained gels and positive (+) if hybridisation were required. 
Five of the above samples scored (++). Previous experimental procedures have 
concluded that samples which are positive for EBV on Southern blot analysis are 
usually strongly positive using PCR.
As expected, the assay using primers derived from the EBV Bam HI-W sequence, 
the viral internal repeat, was most sensitive but there was good concordance 
between the results of the three PCR assays. One sample (case 385) was positive 
in only the assay using BamH1-W primers. DNA from case 74 did not amplify with 
EBNA-2 primers and the viral genome in this case is under further investigation in 
order to determine whether it is defective. Of the eleven samples which were 
successfully subtyped using EBNA-2 primers, ten were subtype 1 and the remaining 
case (case 430) was subtype 2.
Immunohistochemical staining for LMP-1 was performed on sections from 22 cases 
and in two cases (cases 74 and 75) the RS ceils were stained by the OS 1-4 
antibody cocktail (see Chapter 3, Figures 3.4a and 3.5). Expression of EBER-1 
RNA was detected in RS cells within sections from these 2 cases and from a third 
case in this group (case 956). The latter case was originally scored as negative in 
the immunohistochemical analysis, but on histological review a few abnormal cells 
showed weak reactivity with the CS1-4 antibodies.
in two cases (cases 430 and 926, see Figure 4.4), scattered lymphocytes hybridised 
with the EBER-1 probe.
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4.3.3 Non-selected cases
From the results of the above analysis the EBER-1 RNA in situ hybridisation 
analysis appeared to be the preferred method for evaluating the EBV status of HD 
tumours. The immunohistochemical and in situ hybridisation methods were 
compared in a fresh series of 27 cases. The RS cells within nine cases showed 
expression of EBV latent gene products; eight cases reacted with the LMP-1 
antibodies and in eight cases the RS cells hybridised with the EBER-1 
oligonucleotide probe (Figure 4.5). In samples positive by both assays the number 
of cells showing hybridisation with the EBER-1 probe was greater than that stained 
with the antibodies to LMP-1.
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Figure 4.5 EBER RNA in s/ft/ hybridisation 
Case 1221
(Magnification x250)
Paraffin-embedded lymph node section from a non-selected 25 year old MCHD 
case. Note detection of EBER RNA in RS cells. Using an immunohistochemical 
method, LMP-1 was detected in RS cells. Alkaline phosphatase and NBT, 
counterstained with haematoxylin.
4.4 Conclusions
This study evaluates the assays which have been used to detect EBV within biopsy 
samples from HD patients. In agreement with previous studies, the EBV latent gene 
products EBER-1 and LMP-1 were detected in RS cells (Pallesen et al., 1991a, 
Weiss et al., 1991, Murray et al., 1992, Brousset et al., 1993b). Although the 
function of the EBER RNAs is not fully understood (see section 1.4.3.5), the high 
abundance and expression of these RNAs during latent infection provides a useful 
tool for localising EBV to RS cells in HD.
From this study, EBV gene products were detected within RS cells of only 3/23 
cases which were negative on Southern blot analysis. However, EBV was localised 
to RS cells in only 2/13 Southern blot negative, PCR positive samples. In many of 
the remaining cases scattered small lymphocytes within the tissue sections 
hybridised with the EBER-1 probe. In previous studies, the use of PCR to detect 
EBV genomes in HD greatly increased the proportion of EBV-positive cases 
identified. EBV-positivity rates of between 18-79% were observed in HD biopsy 
material following PCR analysis (Uhara et al., 1990, Herbst et al., 1990, Wright et 
al., 1991, Weiss et aL, 1991, Knecht et al., 1991, Masih et al., 1991, Brocksmith et 
al., 1991). Therefore, PCR analysis alone may lead to an over-estimation of the 
number of cases in which EBV is involved.
The results of this study and other studies support the suggestion that EBV is 
present within small lymphocytes and was responsible for the increased numbers of 
EBV-positive HD cases as shown by PCR analysis (Weiss et al., 1991, Brousset et 
al., 1993b). The significance of these EBV-positive small reactive lymphocytes in 
the pathogenesis of HD is not known. However the presence of these cells may be
a consequence of immune dysfunction in HD patients (Slivnick et al., 1990). Thus 
PCR may only prove useful if performed quantitatively and in combination with 
localisation assays. In addition, a number of variables including the number of RS 
cells within a biopsy and the viral copy number must be taken into account during 
the interpretation of these assays.
Overall these data suggest that there is a relationship between the amount of EBV 
DNA present in the tumour and the cellular localisation of the EBV. Southern blot 
analysis has a good positive predictive value for the presence of EBV in RS cells, 
but is not sufficiently sensitive to detect EBV in all cases.
EBV is likely to play a direct role in the pathogenesis of HD in those cases in which 
the RS cells represent clonal expansions of an EBV-infected cell. Two assays, the 
immunohistochemical analysis and In situ hybridisation, permit localisation of EBV to 
the abnormal cell population. There is a good correlation between the presence of 
EBER and LMP-I expression in RS cells (reviewed by Drexler, 1992, Hummel etal., 
1992, Brousset et al., 1993b). In addition. Southern blot analysis permits 
demonstration of clonality and has a good correlation with the in situ techniques. 
Samples from 37 cases were analysed by all three methods and 19 cases were 
scored as positive in at least one assay. The EBER-1 in situ hybridisation assay 
was positive in 18 of these cases, clonal EBV genomes were demonstrable in 16 
cases by Southern blot analysis and the immunohistochemical assay was positive in 
15 cases. Thus, the RNA in situ hybridisation assay appears to be the most 
sensitive method for detecting EBV present in RS cells. The relative stability of 
EBER-1 RNA renders this assay suitable for analysis of fixed material. At present, 
this is the optimal way to detect EBV within HD lesions.
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HD tumours, therefore, can be subdivided into three groups on the basis of their 
EBV status. Due to the selected nature of the cases included in the study the exact 
proportion of cases in each group can only be estimated. In the first group, which 
comprises 33-50% cases, the EBV is present and expressed in RS cells. In the 
majority of these cases clonality of the EBV-infected cell population can be 
demonstrated. The EBV in this group of cases is likely to play a role in the disease 
process. We have designated as EBV-associated those cases in which clonal EBV 
genomes are detected and the EBV LMP-1 protein or EBER RNA are present in RS 
cells.
In the second group, which included approximately half of the cases, EBV is 
detectable using sensitive techniques but appears to be present in small 
lymphocytes. The distinction between localisation of EBV to the malignant cells and 
to the small lymphocytes is clearly necessary. The RNA in situ hybridisation method 
enables this distinction to be made.
EBV was not detectable in HD biopsy material in the third group which comprises 
only a small minority of cases.
Future studies of the pathogenesis of HD should take into account the EBV status of 
the lesions. The use of the above mentioned criteria to define EBV-associated HD 
cases should overcome confusion in the literature concerning the definition of an 
EBV-positive case.
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Chapter 5
Detection of EBV In paediatric Hodgkin's disease
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5.1 Introduction
Although HD is not common the high incidence of cases in young adulthood has 
generated a great deal of interest in both the biological and clinical aspects of this 
malignancy.
HD has a bimodal age incidence curve. In developed countries, HD is rare in 
childhood, however there is an increased incidence in young adults (Cartwright et 
ai., 1990). In developing countries higher rates of HD are observed in childhood
change (Correa & O' Conor, 1971, Alexander et al., 1991b). In both developed and 
developing countries the incidence of HD increases or plateaus in older age groups 
(McKinney et al., 1989). The patterns of age incidence in HD are described in more 
detail in section 1.3.4.
Examination of the age incidence data and other epidemiological features of HD led 
MacMahon (1966) to suggest that this disease comprises of three distinct disease 
entities, based on the age at clinical onset. HD in young adults was thought to be 
caused by an infectious agent. There is little additional data available for the 
paediatric age group (Gutensohn, 1982, Alexander etal., 1991a).
Studies investigating the epidemiological features of HD have resulted in the 
suggestion that young adult cases of HD occur as a host response to late primary 
exposure to a common infectious agent (Alexander et al., 1991a, Gutensohn & 
Cole, 1980). Similarity between the epidemiological features of HD and paralytic 
poliomyelitis-the polio model has been observed (Gutensohn & Cole, 1980). In
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and there is no adult peak (Correa & O'Conor, 1971). An intermediate age
31incidence pattern has been observed in countries undergoing socio-economic
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contrast to MacMahon's hypothesis, this model suggests that the same infectious 
agent is involved in young adult and childhood HD (see section 1.3.4).
These two hypotheses are consistent with HD in young adults being related to late 
exposure to a common infectious agent. Evidence to support an infectious aetiology 
for HD has been accumulating over a number of years. As demonstrated in the 
previous chapter of this thesis HD cases can now be designated as either EBV- 
associated oi non-associated based on the presence of EBV within RS cells. Using 
sensitive and reproducible in situ hybridisation methodology the localisation of EBV 
within RS cells in formalin-fixed HD tissues has enabled the study of increased 
numbers of cases from different age groups.
Only a limited number of paediatric HD cases have been studied previously using 
Southern blot hybridisation. In the present study a number of paediatric HD cases 
from the United Kingdom (UK) were examined for the presence of EBV. Cases of 
paediatric HD from Brazil and Saudi Arabia were also investigated.
The differences in EBV-positivity rates for Saudi Arabia and Brazil were compared 
with those of the UK cases. The results of EBV status of the cases from all three 
countries were statistically analysed with respect to age, sex and histological 
subtype. In order to study the polio model and MacMahon's hypothesis in relation to 
EBV, the proportion of EBV-associated cases of paediatric and young adult HD 
cases from the UK was compared.
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5,2 Materials and Methods
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5.2.1 Clinical samples
Tumour biopsy samples from HD cases under the age of 15 years were obtained 
from a number of pathological centres throughout the United Kingdom. In addition 
formalin fixed paraffin-embedded tissue sections from paediatric HD cases were 
received from Dr R. Pinto Paes, Patologia, Sao Paulo, Brazil and Dr N.A. Morad, 
King Saud University, Abha, Saudi Arabia.
In total 55 paediatric HD cases selected by country (18 females: 37 males) were 
included in this study. These included 22 cases from the UK, 25 cases from Sao 
Paulo, Brazil and 8  cases from Saudi Arabia. All of the cases from Brazil and Saudi 
Arabia were native to those countries, whereas one of the cases from the UK was of 
Asian origin. With the exception of a single UK case, from which no paraffin- 
embedded material was available, all cases were reviewed by Dr A.S. Krajewski, 
Consultant Pathologist, Edinburgh Royal Infirmary, Edinburgh. One case was 
considered to have a differential diagnosis of LDHD and anaplastic large cell 
lymphoma but was retained in the study. The cases were classified using the Rye 
classification system (Lukes et al., 1966); 24 NSHD, 24 MCHD cases, 4 LPHD and 
3 LDHD.
The cases from Brazil were all HIV-negative, however HIV testing was not carried 
out on the remaining cases for ethical reasons.
The features of the Sao Paulo region of Brazil suggested that this area may be 
representative of a developing country; the incidence of paediatric HD in males is
94
highest in the age group 5 to 9 years, the incidence of acute lymphoblastic 
leukaemia (ALL) is low, and a high incidence of non-Hodgkin's lymphoma (NHL) in 
young children is observed (Parkin et ai, 1988), In Saudi Arabia, no cancer registry 
exists but the features of ALL are similar to those described for Western countries 
(Roberts et ai, 1990).
5.2.2 Classification as EBV-associated or non-associated HD
The comparison of several different methods for detecting EBV in HD was reported 
in Chapter 4. From these data the optimal method of detecting EBV in HD was 
found to be EBER-1 RNA in situ hybridisation. All cases from Saudi Arabia and 
Brazil were examined using this assay. Several methods were used to analyse the 
UK paediatric HD cases and these are summarised in Table 5.1.
Fourteen of the UK cases were examined for the presence of EBV using Southern 
blot analysis and 13 were included in a previous report (Jarrett et a!., 1991a). In the 
present study 13 of these cases were investigated further using in situ hybridisation. 
Paraffin-embedded material was not available from the remaining case, however 
Southern blot analysis indicated that this case was EBV-positive. One of the 
additional 9 UK cases was investigated for the presence of EBV using 
immunohistochemical staining for the detection of EBV LMP-1 protein. In situ 
hybridisation was not carried out due to the lack of available material. Fifty three of 
the cases including all cases from Saudi Arabia and Brazil were examined using 
EBER in situ hybridisation.
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Table 5.1 Results of EBV analyses-UK paediatric HD cases
LRF case 
number
Age
(years)
Histological
subtype
Southern 
blot result
LMP-1* EBER-1*
387 14 MC C + +
698 7 MC C + +
702 1 0 NS NT + Z
927 13 NS C NT NT
936 5 MC + NT +
937 14 MC C + +
938 6 NS c + +
939 7 NS - - -
940 5 MC c + +
941 13 MC - + +
942 1 2 LD + + +
943 14 NS - - -
944 14 NS - - -
945 13 LP - - -
946 1 0 NS - - “
1092 11 NS NT - -
1178 11 NS NT “ NT
1185 7 NS NT + +
1 2 2 0 4 MC NT + +
1227 13 LD NT 4- +
1235 13 NS NT - -
1236 14 NS NT - -
NS, nodular sclerosis HD; MC, mixed cellularity HD; LD, lymphocyte depleted HD; LP, 
lymphocyte predominance HD
C, clonal EBV genomes; Z, tissue section not satisfactory, NT, not tested; +, positive; 
-, negative; * EBV within RS cells
5.2.3 Detection of EBV
All in situ investigations were carried out on formalin-fixed paraffin-embedded 
material.
5.2.3.1 in situ hybridisation
Using methodology described in sections 2.4 and 4.2.3, paraffin-embedded biopsy 
sections from HD cases were examined for the presence of EBV EBER RNA, which 
is abundantly transcribed in cells latently infected with EBV.
5.2.3.2 Immunohistochemical analysis
The expression of EBV LMP-1 was examined using a cocktail of monoclonal 
antibodies (CS1-4) reactive with the LMP-1 protein and an ABC method as 
described in section 2.3.6 and in more detail in section 3.2.2.
5.2.4 Statistical methods
The statistical analysis was carried out by Dr F.E. Alexander, Edinburgh University 
Medical School, Edinburgh. The statistical package EGRET was used throughout. 
Equality of proportions in single tables was tested using Fisher's exact test. In order 
to adjust for the influence of other factors (e.g. age and histological subtype) the 
tables were stratified and more general tests applied.
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5.3 Results
5.3.1 Detection of EBV in paediatric HD
In total 38 of the 55 paediatric cases were shown to be EBV-associated. The 
results are summarised in Table 5.2. EBV was detected in the RS cells in 35/53 
cases analysed by EBV EBER-1 in situ hybridisation. These results included 7/8 
and 18/25 cases from Saudi Arabia and Brazil, respectively. A high percentage of 
the RS cells in the biopsy tissue from both Brazil and Saudi Arabia stained positively 
as demonstrated in Figures 5.1 and 5.2. In the remaining cases scattered 
lymphocytes stained positively in the EBV EBER-1 in situ hybridisation assay.
Thirteen of the 22 UK cases, including the case with the differential diagnosis of 
anaplastic large cell lymphoma, were EBV positive. One case which was examined 
solely by immunohistochemical staining was positive and, as stated above the case 
which was examined by Southern blot analysis only was EBV positive. EBER-1 
expression in RS cells was detected in a single case which was scored as negative 
previously on the basis of Southern blot analysis.
5.3.2 EBV-association by country
The majority of cases from each of the three countries were EBV-associated (Figure 
5.3). The proportion of EBV-associated cases was higher in Saudi Arabia and 
Brazil than in the UK but differences between the three countries are not statistically 
significant (p=0.34 by Fisher's exact test). The cases from Brazil were younger than 
those from the UK (15/25 and 8/22, respectively being aged <10 years) and this was 
reflected in increased proportions of the HDMC subtype. The un stratified odds
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Table 5.2 EBV-association and histological subtype by country
in paediatric HD
HD subtype UK Brazil Saudi Arabia Total
NSHD 4/12 7/10 2 / 2 13/24
MCHD 7/7 1 0 / 1 2 5/5 22/24
LPHD 0 /1 0 / 2 0 /1 0/4
LDHD 2 / 2 1 /1 0 / 0 3/3
Total 13/22 18/25 7/8 38/55
NSHD, nodular sclerosis HD; MCHD, mixed cellularity HD; LPHD, lymphocyte 
predominance HD; LDHD, lymphocyte depleted HD
Figure 5.1 EBER RNA in situ hybridisation 
Case 1386
(Magnification xlOO)
Paraffin-embedded lymph node section from a 5 year old paediatric MCHD case 
from Saudi Arabia. EBER-1 RNA detected in RS cells. Note distinct nuclear 
localisation of EBER RNA. Alkaline phosphatase and NBT .
Figure 5.2 EBER RNA in situ hybridisation 
Case 2050
(Magnification x100)
Paraffin-embedded lymph node section from a 4 year old paediatric MCHD case 
from Brazil. EBER RNA is detected in RS cells. Note distinct nuclear localisation of 
EBER RNA. Alkaline phosphatase and NBT, not counterstained.
Figure 5.3 EBV-association by country 
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ratios (OR) for EBV-associatlon in Brazil cases (0R=1.54; 95% confidence 
limits=0.40-6.04) relative to the UK decreased to less than one when the data were 
adjusted for age and/or sex and/or histological subtype. These results show no 
evidence that children in Brazil are more likely to be EBV positive than UK cases if 
their age and sex are taken into account.
5.3.3 EBV-association by age
Cases were categorised into three age groups for this analysis, 1-4 years, 5-9 years 
and 10-14 years. In the youngest group 6/7 cases were EBV-associated; the single 
negative case was a 3 year old HDLP case from Saudi Arabia. In the 5-9 year old 
group 18/20 cases were EBV-associated, this decreased to 14/28 cases in the older 
group. This data is summarised in Figure 5.4. The effect of age on EBV- 
association between the age ranges 0-9 years and 10-14 years was tested 
(OR=0.12 for the 10-14 year age; 95% confidence limits=0.20-0.53, p=0.002). 
These results persisted when the data were stratified by sex or country or subtype 
(p=0.003). The differences in EBV association by age group are highly significant 
(p=0.004 by Fisher's exact test). This pattern was evident for the UK and Brazil 
cases when separate analyses were performed. Numbers were too small to permit 
a similar analysis of the cases from Saudi Arabia however the only negative case 
from Saudi Arabia was in the youngest group as mentioned above
The difference in EBV-association rate between the paediatric cases and those of a 
series of young adult HD (15-24 years) cases from the UK, in which 11/79 (13.9%) 
cases were EBV-positive, is highly statistically significant (p<0.001; Figure 5.5).
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Figure 5.4 EBV-association by age 
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Figure 5.5 EBV-association by age 
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5.3.4 EBV-association by histological subtype and sex
A smaller proportion of NSHD cases were EBV-associated as compared to MCHD 
and this difference was highly significant (OR=0.11 with 95% confidence limlt=0.01- 
0.63, p=0.008, Figure 5.6). EBV was not detected in the 4 LPHD cases examined, 
however all 3 of the LDHD cases were EBV-associated. Females were less likely to 
be EBV-positive than males (11/18 compared to 27/37) however this difference is 
not statistically significant (OR=0.59 with 95% confidence limits 0.15-2.32).
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Figure 5.6 EBV-association by histological subtype 
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5.4 Conclusions
In this study, examination of paediatric HD cases from three different geographical 
locales revealed that EBV was present within the RS cells of affected tissues in the 
majority of cases. These results substantiate our previous findings in this age group 
in which 7/13 (54%) of childhood HD cases from the UK were shown to be EBV- 
associated (Jarrett ef a/., 1991a).
Until recently, few studies had investigated the association between EBV and 
paediatric HD (Libetta et a/., 1990, Weinreb et a/., 1992, Coates et a/., 1993, 
Ambinder et aL, 1993, Khan ef a/., 1993a, Chang et ai, 1993a). Analyses from the f  
UK and United States of America (USA) indicated that EBV-positivity rates varied in 
paediatric HD cases. These results were dependant on the assay used to detect 
EBV in HD biopsy material (Weinreb et ai, 1992, Coates et ai, 1993, Ambinder et 
ai, 1993). In a UK series of paediatric HD cases, the expression of EBV LMP-1 
protein was detected in RS cells in 37/77 (48%) of cases (Weinreb et ai, 1992).
Similar levels of EBV-positivity were obtained on investigation of childhood HD 
cases in the USA (Ambinder et ai, 1993). Using a less sensitive assay system,
DNA in situ hybridisation, Coates et al. (1993) detected EBV-positivity in only 5/24 
(25%) of cases of paediatric HD. In general, a limited number of cases has been 
studied; the small number of cases reflects the rare presentation of HD in childhood 
in Western countries (Merk et ai, 1990, McWhirter & Petroschevsky, 1990, Stiller et 
ai, 1991).
Studies of EBV in fixed HD biopsy material from different countries have been 
possible through the use of recently developed in situ techniques. In this study a 
sensitive RNA in situ hybridisation assay was utilised to detect EBV in tumour
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tissue. This technology enabled the study of EBV-association in paediatric HD from 
two additional countries, Brazil and Saudi Arabia.
The proportion of EBV-associated cases was higher in Saudi Arabia and Brazil as 
compared to the UK although differences were not statistically significant. There is 
some support for the notion that higher EBV-association rates are related to 
differences in disease pattern as the odds ratio for EBV-association in Brazil 
compared to the UK decreased to <1 following adjustment for age and subtype. On 
comparison with the UK cases, the Brazilian cases were younger (mean age 10.6 
years) and the majority were of MCHD subtype. Although in this study Brazil is 
considered representative of a developing country it is possible that socio-economic 
development in the Sao Paulo area is leading to a shift in the disease pattern. 
These observations may explain the lower EBV-association rate in Brazil compared 
to that reported in other studies from Honduras and Peru (see below).
Consistent results have been reported during the investigation of EBV-positivity in 
HD cases from Honduras and Peru (Ambinder et ai, 1993, Chang et aL, 1993a). All 
of the childhood HD cases from Honduras were EBV-associated. In the same 
study, EBV was detected in only 9/25 (36%) of paediatric HD cases from the USA 
(Ambinder et aL, 1993). A study of HD in Peru was not designed specifically to 
investigate paediatric HD, although the age range of the cases was typical of that 
seen In developing countries (Kirchhoff et aL, 1980, Talvalkar, et al 1982, Merk et 
aL, 1990, Riyat, 1992). The proportion of paediatric HD cases <15 years of age was 
62% and all of these cases were EBV-associated (Chang eta!., 1993a).
Further analysis of the present data indicated that the incidence of EBV-association 
was much greater in cases under 10 years of age. Of the 27 cases examined in this
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age category 24 cases were EBV-associated. Thus HD in this group is clearly an 
EBV-associated disease. Overall, this study provides no evidence that paediatric 
HD, within each of the 5-year age groups defined above (see section 5.3.3), is more 
likely to be EBV-associated in developing countries than in developed countries. 
Fourteen years of age is conventionally taken as the upper limit of the paediatric 
age group but this need not reflect a biological distinction and there is likely to be an 
overlap between the childhood and young adult disease patterns around this age. 
In this study cases aged 13 and 14 years predominated within the 10-14 year age 
bracket. Given the decline in the proportion of EBV-associated cases in this group 
these cases may represent the start of the young adult age incidence peak. Indeed, 
the age of paediatric patients from the UK at clinical onset was older than observed 
in developing countries (Weinreb et a/., 1992, Khan et a/., 1993a, Coates et a/., 
1993). From this data it is important that the age distribution of cases, geographical 
locale and histology are taken into account when performing international 
comparisons.
Several studies including largely adult cases have shown an excess of EBV-positive 
cases within the MCHD subtype as compared to NSHD (Pallesen et a/., 1991a, 
Weiss etaL, 1991, Murray et aL, 1992a, Delsol et ai, 1992) and in three studies this 
difference has been shown to be statistically significant (Pallesen et a/., 1991a, 
Weiss et ai, 1991, Murray et ai, 1992a). The results of the present study indicate 
that this difference is also evident in paediatric populations. Mixed cellularity HD in 
Honduras, USA and Peru was highly EBV-associated (Chang et ai, 1993a, 
Ambinder et ai, 1993). In a study of HD cases from USA, Mexico City and Costa 
Rica, Gulley et ai (1994) also observed that MCHD subtype was strongly predictive 
of EBV-positivity in these cases. In keeping with other studies this study indicated 
that all of the LDHD cases were shown to be EBV-associated however, the LPHD
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cases were EBV-negative (Boiocchi et al., 1989, Pallesen et al., 1991a, Weiss et al., 
1991).
In order to determine whether the polio model was relevant to EBV in HD, the EBV- 
positivity rate of paediatric HD cases was compared with a young adult HD (15-24 
years) group from the UK (see Figure 5.5 and Chapter 6 ). Only 11/79 cases were 
EBV-associated in the young adult age group. The proportion of EBV-associated 
cases in the paediatric and young adults is markedly different (p<0 .0 0 1 ).
This study enabled the epidemiological features of HD to be analysed with respect 
to EBV. The significance of the above results are apparent when testing the polio 
model. The finding that EBV-association is significantly less frequent in young 
adults in a developed country indicates that an analogy between EBV and poliovirus 
cannot be used to explain the epidemiologic features of HD with respect to EBV. It 
does remain possible however that HD in young adults is related to an infectious 
agent for which the polio model does hold. The suggestion by MacMahon in 1966 
that different age groups may have different aetiologies would be supported by the 
results of this investigation of paediatric HD and the subsequent comparison with 
young adult HD from the UK.
There is no definitive evidence that EBV plays a causal role in HD however the 
available data suggest that it is likely to play a role in the pathogenesis of a 
proportion of cases. HD occurring in childhood, particularly under the age of 10 
years, is predominantly an EBV-associated disease in both developed and 
developing countries.
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Chapter 6
The relationship between EBV-association, age and histological
subtype in Hodgkin's disease
3'Sf:
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6.1 Introduction
An association between EBV and HD has now been established. Clonal EBV 
genomes have been detected in HD biopsies and the EBV latent genes LMP-1 
and EBERs have been localised to the Reed-Sternberg (RS) cells (Weiss et al., 
1987a, 1991, Pallesen et al., 1991a, Wu et al., 1990) (as described in Chapters 3 
and 4).
On the basis of the epidemiological features of HD, three distinct groups cases 
have been identified which correspond to the three age groups 0-14 years, 15-34 
years and >49 years. MacMahon proposed that the aetiology of HD in these age 
groups differed and that the disease in young adults was likely to have an 
infectious aetiology (MacMahon, 1966).
The risk factors associated with the development of HD in young adulthood are 
suggestive of a lack of early social contact in childhood (Vianna & Polan, 1978). In 
contrast, the risk of HD in older persons is not related to these epidemiological 
factors.
Few studies have examined the epidemiological features of HD with respect to 
EBV and age at clinical onset. Using Southern blot analysis, the relationship 
between age and EBV-positivity was investigated in a series of 95 HD cases 
referred to the LRF Virus Centre (Jarrett et ai, 1991a). In this preliminary study 
EBV-positivity rates differed significantly between different age groups. In the 
paediatric age group (<15 years; 7/13 cases) and the older age cases (>49 years; 
27/38 cases) the majority of cases were EBV positive. A low incidence of EBV- 
positive cases was found in young adult HD (6/36 cases), in particular in NSHD.
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In the previous chapter of this thesis, paediatric HD cases from the UK were 
further investigated for the presence of EBV using an RNA in situ hybridisation 
assay. Thirteen of the twenty-two UK cases were scored as EBV-positive. 
Examination of paediatric HD cases from the UK and other geographical locales 
indicated that cases <10 years of age were most likely to be EBV-associated. 
These data suggest that EBV is likely to be an important agent in paediatric HD.
As described above, epidemiological data suggest that the young adult age group 
is most likely to have an infectious aetiology (see sections 1.3.4 and 1.5.4). These 
cases represent the first age incidence peak in developed countries. The NSHD 
subtype is the most common form of HD in this age group (McKinney et al., 1989, 
see section 1.3.2.2). From our previous data these cases tend not to be EBV- 
associated (Jarrett et al., 1991a). From recent reports MCHD cases have also 
been shown to be more likely to be EBV-positive compared with NSHD cases 
(Pallesen etal., 1991a).
Following the publication of our first report which highlighted the association 
between EBV status and age of HD cases, some groups have reported similar 
findings (I. Lauder, personal communication). However, the majority of studies 
failed to detect this association (Boiocchi et al., 1989, Coates et at., 1991, 1993, 
Wright et al., 1991, Uhara et al., 1991, S. Poppema, personal communication, G. 
Pallesen, personal communication). We therefore decided to test the hypothesis 
that EBV status was associated with age and histological subtype in HD. In 
particular, the EBV-positivity rates in the 15-24 year and 50+ year age groups was 
examined.
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The EBER RNA in situ hybridisation assay has now been established as the 
preferred method of detecting EBV in HD tumour tissue (Armstrong et a!., 1992b, 
see Chapter 4). This method is both sensitive and reliable and allows the 
localisation of EBV to RS cells. Using this methodology, cases of HD referred to 
the LRF Virus Centre between 1992-1994 were Investigated for the presence of 
EBV. The distribution of EBV in these cases was subsequently analysed with 
respect to age at clinical diagnosis and histological subtype.
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6.2 Materials and Methods
6.2.1 Clinical samples
Lymph node biopsies from HD patients were referred to the LRF Virus Centre from 
a number of clinical centres. In total 175 HD cases were investigated. The cases 
were grouped according to age at clinical onset and histological subtype. Seventy- 
nine of the samples were from non-selected cases with HD, 83 were selected 
specifically for age and a further 13 cases were selected for both age and 
histological subtype.
There was age selection in two age groups. First, cases aged >44 years of age 
were selected in order to augment numbers in the older adult age group. 
Secondly, 62 cases from a study of young adult HD in the age group 15-24 years 
were included. Due to selection in this age group, the previously defined 15-34 
year old young adult group has been split into two for the analyses.
The cases were classified using the Rye classification system (Lukes et al., 1966) 
which included 18 LPHD, 48 MCHD, 12 LDHD and 93 NSHD cases. It was not 
possible to subclassify four of the cases.
6.2.2 Detection of EBV
Paraffin-embedded lymph node biopsies were obtained from all cases. Previous 
studies have indicated that HD cases which were EBV-positive by In situ studies or 
Southern blot hybridisation for the detection of clonal EBV genomes can now be 
designated as EBV-associated (see Chapter 4).
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6.2.2.1 Immunohistochemîcal analysis
in 62 cases the expression of LMP-1 was examined using a cocktail of monoclonal 
antibodies (CS1-4) (Rowe et al., 1987) using methodology described in sections 
2.3.6 and 3.2.2.
6.2.2.2 EBER RNA in s/fi/hybridisation
Lymph node biopsies from all cases were hybridised with a biotinylated 
oligonucleotide probe, specific for the EBV EBER-1 RNA, using methodology 
described in section 2.4 and 4.2.3.
6.2.3 Statistical analysis
The statistical analyses were carried out by Dr F.E. Alexander. The EBV status of 
the samples was analysed with respect to age and histological subtype with or 
without inclusion of LPHD cases. LPHD cases were analysed independently as 
this histological subtype is thought to be a distinct clinical entity (Nicholas et al., 
1990, Mason etal., 1994, as discussed in section 1.3.3.1). The statistical package 
EGRET was used throughout the analysis. The data were analysed using logistic 
regression which permitted adjustment for age and histological subtype.
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6.3 Results
Following examination of 175 cases of HD, 44 cases were found to be EBV- 
associated. Twenty of the 79 (25%) non-selected HD cases were EBV-positive.
6.3.1 Effect of age
The cases were analysed according to age at date of biopsy, 15-24 years, 25-34 
years and 50+ years of age. These particular age divisions were chosen because 
of the age selection criteria used. The distribution of EBV-associated cases by 
age, excluding LPHD cases in the 15-24 and 50+ year age groups, is shown in 
Figure 6.1. Samples which were selected on the basis of both age and 
histological subtype were excluded from the age analysis. Further analysis of the 
35-49 years age group was of limited value as case numbers in this age group 
were small and cases within the >44 years of age group were highly selected.
When LPHD cases were excluded from the analyses, 11 of the 76 (14.5%) HD 
cases were EBV-positive within the 15-24 year age group. EBV was detected in 4 
of the 14 (28.6%) cases within the 25-34 year age group. In the 50+ year age 
bracket, 23 of the 41 (56%) HD cases were EBV-associated. Overall, statistical 
analysis for the effect of age indicated that EBV-positivity increased with 
increasing age (Table 6.1). The differences in EBV-association by age group are 
highly significant (p<0 .0 0 1 ), and statistical significance was maintained when 
LPHD cases were included in the anaiyses.
The distribution of EBV-association by histoiogical subtype and age is illustrated in 
Figure 6.2. Overall, a smaller proportion of NSHD cases (6/40 EBV-positive) were
no
Figure 6.1 EBV-association by age
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Results of EBV-association in paediatric HD cases are 
described in Chapter 5. LPHD cases were excluded 
from the analysis of EBV-association in the 15-24 years  
and 50+ years age.
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EBV-associated compared with the MCHD (12/27 EBV-positive). The majority of I
cases within the young adult age range (15-24 years of age) were NSHD, however 
only 1/57 of these cases was EBV-positive. Following adjustment for histological 
subtype, the effect of age is still shown to be statistically significant (Table 6.1).
Comparison of EBV-association between the paediatric HD cases from the UK
'1
described in Chapter 5 and the young adult age group (15-24 years of age) 
showed a highly significant difference (p<0 .0 0 1 ).
6.4 Conclusions
The results of the present study emphasise the relationship between EBV- 
association and age in HD. Foilowing exclusion of LPHD cases in the analysis, 
the majority of older adult cases were shown to be EBV-associated. In contrast, 
young adult HD cases were less likely to be EBV-positive. These results confirm 
our previous findings that EBV is associated with a significant proportion of 
paediatric and older age HD cases, however young adult HD cases are generally 
non-EBV associated. It has been established from the present study that the 
relationship between EBV-association and age in HD is non-random.
As histological subtype and age are confounding variables they should not be 
analysed independently (Jarrett et al., 1991a). Therefore, it is important to record 
the method of case selection in order to allow accurate statistical examination. 
There is a general consensus that MCHD cases are more likely to be EBV-positive 
than NSHD (Weiss et al., 1987a, Boiocchi et al., 1989, Pallesen et a/., 1991a, 
Murray et al., 1992a). in contrast to our previous study (Jarrett et al., 1991a), we 
have detected EBV-positivity within a significant proportion of MCHD cases 
compared with NSHD cases. Analysis of the present data indicated that EBV- 
association by age was significant even when the data were adjusted for the effect 
of histological subtype. These findings are consistent with the epidemiological 
features of HD; the risk factors of developing HD are more strongly associated 
with age than histological subtype.
HD in older cases has been associated with a poor prognosis and survival rate as 
detailed in section 7.1. In this age group, the detection of EBV increased with 
increasing age. The majority of cases were EBV-positive aged 50+ years, in
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particular cases of MCHD and LDHD subtype. From previous studies, the 
epidemiological features of older HD cases are different from young adult HD 
cases and thus are not thought to be associated with a delayed reaction to a 
common infectious agent. It has been documented that older age cases may 
have a different host response to EBV. Older persons have been shown to have 
an overall decreased immune function which may result in an increase in viral load 
of EBV which in turn may increase the likelihood of developing EBV-associated 
HD.
As mentioned in section 6.1, the epidemiological features of HD in young adult are 
suggestive of an infectious aetiology. The majority of young adult cases are 
NSHD subtype, however these cases are non-EBV-associated. It was within this 
group of cases that most evidence for the involvement of another infectious agent 
has been proposed. Examination of the association between other oncogenic 
DNA viruses and HD is described in Chapter 8 .
Few studies have investigated the association between EBV and age (Boiocchi et 
al., 1989, Libetta et al., 1990, Uhara et al., 1991, Coates et a!., 1993) and the 
majority of reports have failed to detect any association by age in EBV-positive 
cases. One such study detected EBV In 25 of 77 cases of HD using 
immunohistochemîcal and in situ hybridisation techniques (Khan et al., 1993a). 
The EBV-positivity rates between the children, young adult cases and older age 
cases showed no statistical difference. Although there are differences in the 
distribution of cases by age and histological subtype between this study and the 
present study, these features of the cases cannot explain the discrepancies in 
EBV-association by age between the two studies. Due to the different selection 
criteria of cases direct comparisons between studies are difficult to interpret.
1 Î 3
In the present study, the age distribution of EBV positive cases supports the 
multiple aetiology hypothesis proposed by MacMahon (1966). The young adult 
NSHD cases therefore are likely to be a distinct clinical and epidemiological group 
which should be studied in greater detail in future studies of HD.
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Chapter 7
Prognostic significance of EBV-association in Hodgkin's disease
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7,1 Introduction
In general, patients with Hodgkin's disease (HD) have a good prognosis with 60% 
surviving disease-free at 10 years (Proctor et al., 1991). Despite improvements in 
the treatment of HD, there are still a number of cases with poor clinical outcome. It 
is necessary to identify these cases in order to initiate alternative treatment regimes 
early in disease. In order to identify these cases, a prognostic index was devised at 
the Royal Victoria Infirmary, Newcastle-Upon-Tyne which incorporates 
haemoglobin, peripheral blood absolute lymphocyte count, clinical stage (Ann Arbor) 
and age (as a quadratic function) (Proctor etal., 1991). This index will identify those 
patients of different Ann Arbor stages who have a 75% chance of dying of HD within 
four years of diagnosis.
As discussed in detail elsewhere in this thesis, EBV is involved in a proportion of 
cases of HD (Weiss etal., 1987a, Paliesen etal., 1991a, Jarrett et al., 1991a, Delsol 
et al., 1992). However, EBV is detectable within the RS cells of only 40-50% of 
cases and these cases have been defined as EBV-associated (Armstrong et al., 
1992b, see Chapter 4). A number of studies have reported that MCHD cases are 
more likely to be EBV-associated than NSHD cases (Weiss et al., 1987a, 1989, 
Staal etal., 1989, Pallesen et al., 1991a, Herbst etal., 1991a, Murray et al., 1992a). 
In some studies, poor clinical outcome has been associated with older age and also 
with MCHD histology (Walker et al., 1990). We therefore speculated that EBV- 
association might be associated with a poorer prognosis.
Using immunohistochemîcal and in situ hybridisation techniques, EBV has been 
reliably detected within paraffin-embedded biopsy material (Pallesen et al., 1991a, 
Herbst et al., 1991a, Wu et a!., 1990, Weiss et al., 1991, Delsol etal., 1992, Khan et
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al., 1992). EBV LMP-1 antibodies and probes for the detection of EBV EBERs are 
now commercially available and can be used in routine testing of HD cases (see 
Chapters 3 and 4 of this thesis). The present study was devised to assess whether 
there is a relationship between EBV-positivity and clinical outcome, and also to 
assess whether EBV positivity could be usefully incorporated into the prognostic 
index as an additional variable.
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7.2 Materials and Methods
7.2.1 Clinical samples
Cases of HD diagnosed over a 13 year period (1976-1989) in the same Pathology 
laboratory at the Royal Victoria Infirmary, Newcastle-Upon-Tyne (RVI) were 
identified by Dr Anne Lennard and Dr Brian Angus. Fifty-nine patients were 
included in the study: 35 males, 24 females. Sixteen patients had Stage I, 13 Stage 
II, 19 Stage III and 11 Stage IV disease. The prognostic indexes were calculated on 
prospectively collected data, but do not include additional weighting for bulk disease 
as this information was not available.
The index has not been validated on seven patients under the age of 15 years. 
Lymph nodes from all 59 patients were examined by the same pathologist (BA). 
There were 27 NSHD, 28 MCHD, 3 LPHD and one case of LDHD. In subsequent 
analyses the cases were classified as NSHD or all other sub-types (AOS).
All cases were treated at the RVI. Early stage disease was treated with 
radiotherapy alone. Later stage or bulky disease was treated with a four drug 
regimen (chlorambucil, vinblastine, procarbazine and prednisolone), plus or minus 
radiotherapy. Minimum follow-up was 48 months.
7.2.2 Detection of EBV
Sections from paraffin-embedded lymph node biopsies were investigated for the 
presence of EBV using immunohistochemical and in situ hybridisation techniques 
(see sections 3.2.2 and 4.2.3). The results of the EBV analyses of 27 of these
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cases were included in a previous report which compared the above techniques 
(Armstrong et al., 1992b and Chapter 4 of this thesis).
7.2.3 Statistical analysis
The statistical analyses were carried out by Dr F.E. Alexander. The EBV status of 
the samples was analysed with respect to age, histological subtype, remission, total 
and disease-free survival and prognostic index. The statistical package EGRET 
was used throughout. Cases who never achieved remission were classified by EBV 
status; 2 x 2  tables were analysed with and without age stratification using exact 
methods. The Cox proportional hazard method was used to compare survival from 
the date of diagnosis with EBV-association. For analysis of disease-free survival, 
cases who never attained remission were classified as having failed at time = 1 
month. Multivariate analyses permitted adjustment for age and prognostic index. 
In the tables hazard ratios for EBV-association and 95% confidence limits are 
provided. A hazard ratio of 1.00 indicates that survival in the two groups is identical 
whilst a hazard ratio of less than 1.00 corresponds to improved prognosis of EBV- 
associated disease. Survival curves are based on Kaplen-Meier estimates of 
survival probabilities.
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7.3 Results
In total 21 ot the 59 HD cases were found to be EBV-associated. There was almost 
complete concordance between the results of the 2 assays for EBV; in one case the 
LMP-1 protein was present in RS cells but EBER-1 was not detected and in another 
case EBER-1 was detected in the absence of the LMP-1 protein. The cases were 
categorised into three age groups, paediatric 1-14 years, young adult 15-34 years 
and older >35 years of age.
Prognosis differed by age and by histological subtype although the latter differences 
were slight. All the paediatric cases included in this sample achieved full remission 
and experienced disease-free survival for the duration of follow-up. it follows that 
these cases contribute no information to any age-adjusted analyses of the effect of 
EBV status on survival. Within the young adult age group (15-34 years) relapse 
was more common for the NSHD cases than the remainder of this age group 
although the differences did not approach statistical significance. Four of the eight 
relapsers in this group would now be defined as high index, or poor risk patients and 
would receive more aggressive treatment from diagnosis. The oldest age group 
had poorest prognosis.
7.3.1 Remission by EBV-status
The EBV status and age group of the patients who achieved remission are shown in 
Table 7.1. A slightly higher proportion of EBV-associated cases, compared to EBV- 
negative cases, achieved remission however the number of cases who failed to 
achieve remission was small and the difference does not approach statistical 
significance (p=0.81). The results are influenced by the paediatric group, all of
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Table 7.1 Proportion of cases achieving remission by EBV status and age
Age (years)
0-14 15-34 >35 TOTAL
EBV-positive 4/4 1 1 / 1 1 4/6 19/21
EBV-neqative 3/3 22127 7/8 32/38
which achieved remission, and the young adult group, within which all the EBV- 
associated cases achieved remission. The number of older adult cases is small but 
there is no evidence of a higher remission rate in the EBV-associated cases in this 
age group.
7.3.2 Survival by EBV-status
There is weak evidence of improved disease-free survival and total survival for the 
EBV-associated cases when no adjustment for age is included in the model (Figures 
7.1a and 7.1b and Table 7.2). Following stratification by age (Table 7,2) some 
differences in total survival remain, although confidence intervals are wide, however 
differences in disease-free survival are no longer apparent (Figures 7.1a and 7.1b). 
When the adult age groups are analysed separately there is no consistent pattern 
with some indication that the EBV-associated cases have improved survival in the 
young adult group but not in the older group. There were only six HD deaths in the 
young adults (5 cases of NSHD and one case of AOS) and none of these was EBV- 
associated.
7.3.3 Prognostic index
Values of the prognostic index were slightly higher (indicating poor prognosis) for 
the EBV-associated cases. When the data were tested for an independent 
additional contribution to prognosis, EBV status was statistically significant for total 
survival but not for disease-free survival. Stratification by age group reduced the 
magnitude of the contribution and removed its statistical significance.
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Figure 7.1a Disease-free survival by EBV status 
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Table 7.2 Disease-free survival of EBV-associated cases
Stratified by 
age
Hazard ratio for 
EBV-positivity
95%
Confidence
Limit
Disease-free survival NO 0.76 0.27-2.15
Total survival NO 0.56 0 .1 1 -2 . 6 8
Disease-free survival YES 0.93 0.32-2.65
Total survival YES 0.56 0.11-2.73
7.4 Conclusions
In this study, we analysed the effect of EBV status on clinical outcome in HD. Of the 
59 cases examined, 21 (35%) were categorised as EBV-associated.
There was no evidence of an association between EBV status and survival which 
was apparent at all ages. Weak associations were observed within specific age 
groups but were not statistically significant and may be attributed to chance. In the 
young adult group the EBV-associated cases were more likely to achieve remission 
and had improved survival. The study provides no evidence to support the 
hypothesis that EBV-associated cases of HD have a less favourable clinical 
outcome than EBV-negative cases. It is possible that EBV-status may provide a 
subtle improvement to the prognostic index. However we feel that these effects are 
more likely to be attributed to the interplay of chance, small numbers and specific 
combinations of clinically disparate age groups.
Two previous studies specifically designed to address the association between EBV 
status and clinical outcome have reached similar conclusions (Vestlev et a/., 1992, 
Fellbaum et al., 1992). Vestlev et al. (1992) examined samples from 6 6  Danish 
patients using immunohistochemistry and LMP-1 antibodies to detect EBV. Their 
results indicated that LMP-positivity was not a useful prognostic marker. Fellbaum 
et al. (1992) analysed 130 cases using the polymerase chain reaction (PCR) and 
reported that EBV positivity did not influence survival time. We have found, 
however, that PCR is less reliable than in situ hybridisation techniques for 
determining whether cases are EBV-associated (Armstrong et ai., 1992b and 
Chapter 4).
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The analysis ot the EBV status of HD tumours using immunohistochemistry or in situ 
hybridisation is straightforward and reliable and reagents are readily available. 
Examination of larger numbers of cases will establish whether EBV-associated 
cases form a distinct subgroup of HD cases. However, the results of the present 
study emphasise that the detection of EBV in individual HD cases is not a clinically 
useful prognostic marker.
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Chapter 8
Absence of oncogenic DNA viruses In Hodgkin's disease
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8.1 Introduction
It is clear from the studies described in the previous chapters of this thesis that 
EBV is involved in a proportion of cases of HD. Young adult HD cases are least 
likely to be EBV-associated (Jarrett et al., 1991a, see Chapter 6 ). However, it is 
within this age group that there is most evidence for involvement of an infectious 
agent in HD.
Investigation of HD cases for an association with infectious agents has 
concentrated mainly on the antibody response to viral antigens with particular 
reference to the herpesviruses (Catalano & Goldman, 1972, Henderson et a!., 
1973, Langenhuysen et a!., 1974, Hesse et al., 1977). Raised antibody levels to 
HSV -1 and -2 (Catalano & Goldman, 1972, Hesse et a!., 1977), HCMV 
(Langenhuysen et al., 1974) and VZV (Henderson et al., 1973) have been 
observed in HD, although results for HSV-1 and HCMV are not consistent 
between studies (Levine et al., 1971, Hesse et al., 1977, Evans & Gutensohn, 
1984). There is no molecular evidence to support a role for these viruses in the 
aetiology of HD (Weiss et al., 1987a, Coates etal., 1991, Uhara etal., 1990).
The recently identified HHV- 6  and HHV-7 have a worldwide distribution and have 
been shown to be lymphotropic (Salahuddin et al., 1986, Frenkel et al., 1990). 
Neither virus has been directly associated with any malignant disease in vivo. 
Recent serological studies have observed elevated antibody titres to HHV- 6  in 
several lymphoproliferative diseases. In a case-control study Clark et al. (1990) 
reported elevated antibody titres to this virus in HD cases and increases relative 
to controls were most marked in young adults. At present, molecular studies 
have failed to directly link HHV- 6  with HD (Jarrett etal., 1988, Torelli et al., 1991, 
Compels et al., 1993). From these results it has been suggested that elevated 
titres to HHV- 6  in HD may be due to reactivation of the virus; alternatively the
125
virus may be acting as a marker for another infection which is directly involved in 
HD. HHV-7 is a candidate for the latter role.
In order to eliminate the involvement of known viruses in HD we specifically 
targeted members of the Adenovirus, Polyomavirus and Herpesvirus families for 
investigation using a Southern blot assay. These DNA viruses have not been 
associated with any malignancies in humans. However, the E1A gene of 
adenovirus, SV40 large T antigen, and polyoma viruses including the LPV have 
all been shown to have transforming ability in vitro (Ruley, 1983, Colby & Shenk, 
1982, Gallimore etal., 1974, Takemoto etal., 1982) and have the ability to cause 
tumours in experimental animals (reviewed by Brady & Salzman, 1986).
Clinical samples from cases of HD, previously studied for the presence of EBV, 
NHL and reactive conditions were further examined for the presence of 
adenovirus, SV40, LPV and HHV-7.
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8.2 Materials and Methods
8.2.1 Clinical samples
Lymph node samples from 25 cases of Hodgkin's disease were investigated for 
the presence of the El A gene of adenovirus, SV40, LPV and HHV-7. Cases 
were classified according to the Rye classification system (Lukes et al., 1966) 
and included 15 cases of NSHD, 7 cases of MCHD, one case of LDHD and one 
case of LPHD.
Twenty three samples of NHL were also included in the study. These cases 
included low and high grade lymphomas and three cases of angioimmunoblastic 
lymphadenopathy (AILD). In addition 18 reactive conditions were examined 
which included 1 2  reactive lymph nodes from paediatric patients, two cases of 
systemic lupus erythematosus (8 LE), two cases of Sjogren's syndrome and two 
cases of lymphadenopathy of unknown cause.
DNA was extracted from all samples using the procedures described in section 
2 .2.1.
The HHV-7 molecular analyses were carried out on samples included in this 
survey. Experiments were carried out by Dr Ruth Jarrett and Alice Gallagher in 
collaboration with Dr Z. Berneman, Hématologie, Univ. Ziekenhuis Antwerpen, 
Edegem, Belgium.
8.2.2 Analysis of high molecular weight DNA
The restriction endonuclease digestion of DNA, separation of DNA fragments 
and Southern blot hybridisation procedures are described in detail in section 2.6.
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Briefly, ten \xg of DNA were digested with the restriction enzyme Hind III or Pst I 
(Life Technologies Inc., Paisley, UK) and incubated overnight at 37^C. The 
restriction endonuclease digested high molecular weight DNA was separated on 
a 0.8% agarose gel in TBE buffer (section 2.6.2, Appendix I). Placental DNA 
was included as a negative control. Positive controls included plasmid DNA 
which was digested and diluted to a level equivalent to a single copy gene 
present in a 10pg sample of genomic DNA.
The high molecular weight DNA was transferred to nylon membrane (Hybond N, 
Amersham International pic, Little Chalfont, UK) using a Southern blot procedure 
(section 2.6.3).
8.2.3 Preparation of DNA probes
Using standard procedures, plasmid DNA was prepared as described in sections 
2.5.1-2.5.3.
8.2.3.1 Adenovirus El A probe
The pLAI construct contains the Bgl IID fragment of adenovirus type 5 from 
nucleotide 1 to 3322, cloned between the EcoR I and BamH I sites of pATI 53. 
The plasmid pLEI A, supplied by Dr V Mautner, Institute of Virology, University of 
Glasgow is truncated at nucleotide 1704 and contains the entire E1A gene but no 
E1B coding sequences (Dery et al., 1987). The plasmid DNA was digested with 
the restriction enzyme Hinc II (Life Technologies Inc., Paisley, UK) which yielded 
an El A region probe of 1.7 kb. The plasmid DNA fragment was gel purified as 
described in section 2.5.3.I.
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5.2.3.2 Lymphotropic papovavirus (LPV)
The biologically active molecular clone of LPV strain K38 (pL6 ) was kindly 
provided by Dr M. Pawlita, Institit fur Virusforschung, Hiedelberg, Germany. The 
plasmid DNA was digested with the restriction enzyme BamH I (Life 
Technologies Inc., Paisley, UK) which generated a complete LPV probe of 5.1 
kb. The plasmid DNA fragment was gel purified as described in section 2.5.3.1.
5.2.3.3 SV40
Supercoiled circular SV40 DNA derived from strain 776, propagated in BSC-1 
cells, was supplied by Life Technologies Inc. This DNA was linearised with 
BamH I (Life Technologies Inc., Paisley, UK).
8.2.3.4 pBR322
Following digestion with the restriction enzyme Pst I (Life Technologies Inc., 
Paisley, UK), pBR322 was used as probe in order to determine whether 
contaminating plasmid sequences were present in DNA samples.
8.2.3.5 TCRp gene probe
In order to assess the integrity of the DNA under analysis, the TCRp region 
probe, C91p, a cDNA clone of the p chain obtained from the HTLV-1 infected cell 
line C91PL (Gledhill eî al., 1990) was utilised in these investigations. To obtain a 
probe for the TCRp constant region the plasmid was digested with EcoR I and 
Xho I (both Life Technologies Inc., Paisley, UK) to generate a constant region 
probe of 900bp. The plasmid DNA fragment was gel purified as described in 
section 2.5.3.
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8.2.4 Radioactive labelling of DNA
This procedure has been summarised in section 2.5.4. Plasmid inserts from the 
E1A gene of adenovirus, LPV and TCRp, linearised pBR322 and SV40 were 
radio-labelled with a^^p dCTP using a random priming procedure (Multiprime 
labelling kit, Amersham International pic, Little Chalfont, UK).
8.2.5 Molecular analysis
The nylon filters were hybridised with the radio-labelled probes (see section 
2.5.4) under conditions calculated by the formula:
Tm=81.5 + 16.6logM + 0.41(%G+C)-500/n-0.61(F)
M is the ionic strength in moles/L, G+C is the percentage of G and C, n is the 
length of probe and F is the percentage formamide in the hybridisation solution. 
For every 1% mismatching of bases in a DNA duplex the T|^ is reduced by 1°C
The Trn calculated for pLE1A, pL6 , pBR322 and TCRp probes was 
approximately 92^0. The hybridisation kinetics have been shown to be optimal 
at approximately 25°C below the T^  ^ for dsDNA probes, thus the filters were 
hybridised at 65°C in 3x SSC (Appendix I) in the absence of formamide. The 
filters were washed as detailed in section 2.6.4 and placed in a cassette 
containing an intensifying screen.
130
8.3 Results
The detection of viruses in HD, NHL and reactive conditions is summarised in 
Table 8.1. Previous results indicated that EBV was detected in Reed-Sternberg 
(RS) cells in 14 of these cases of HD.
in order to test the integrity of the sample DNA the TCRp probe was hybridised 
to the filters. Only cases which had clearly visible bands on autoradiographic film 
were retained in the study.
identified four cases which gave a signal on the autoradiographic film after one to 
seven days exposure. The four cases detailed above were further investigated 
using the restriction enzyme Pst I (Life Technologies Inc., Paisley, UK) and 
hybridised with the pBR322 probe. The bands identified on the original blots 
were shown to be due to plasmid sequences contaminating the DNA samples.
Subsequent analysis using the LPV and SV40 probes failed to detect these 
viruses in any of the clinical samples tested.
From a total of 50 cases of HD which included all 25 cases analysed in this 
study, there was no evidence of HHV-7 sequences in any clinical samples 
(R.Jarrett and Z. Berneman, personal communication).
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Initial screening of DNA samples for the presence of adenovirus type 5 El A gene
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8.4 Conclusions
It has been suggested that another infectious agent may be involved in the 
pathogenesis of young adult HD. This study was designed to examine the 
presence of the herpesvirus, HHV-7, adenovirus and polyomaviruses in HD. The 
experimental method chosen was Southern blot hybridisation which has been 
previously been shown to allow detection of a single genome if present in - 2 % of 
cells of a DNA sample derived from 1 x 1 0 ^ cells. In HD, the putative malignant 
cell population of RS cells are present in only 1-5% of the total cellular infiltrate. 
The sensitivity of the Southern blot assay is thus on the borderline for detection 
of virus in RS cells. The Southern blot assay therefore is suitable for use as an 
initial screening technique. The increased sensitivity associated with PCR 
methodology would overcome the problems associated with detection of virus in 
HD samples. However, the use of this assay to screen samples in this first 
instance may fail to detect defective or related viruses. The ideal method of 
detecting virus in HD requires sensitivity and the ability to demonstrate the 
cellular localisation of the virus.
This study examined the presence of adenovirus and polyomaviruses in human 
malignant disease at a molecular level. These viruses were specifically chosen 
due to their ability to transform mammalian cells (see sections 1.4.4, 1.4.5 and 
1.4.6)
The ElA and BIB region of adenovirus codes for the transformation function of 
the virus (Sambrook et al., 1974). The El A sequence of adenovirus is well 
conserved over the different subtypes of adenovirus. Despite the oncogenic 
potential of these viruses in cell culture and animal models there was no 
evidence for adenovirus sequences in any of the HD, NHL and reactive
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conditions investigated in the present study. Further studies are now underway 
to investigate these cases using the E1A gene from adenovirus type 12.
During the search for potential infectious agents which may be important in the 
aetiology of HD, we studied members of the papovavirus family: LPV and SV40. 
It has previously been reported that human sera have antibodies that react with 
LPV of African green monkeys (Brade et al., 1980, Takemoto et al., 1982), 
however no human equivalent virus has been isolated. In order to eliminate 
these viruses from our investigations for a novel viral agent we studied both HD 
and NHL cases. To date we have not detected these viruses in any clinical 
sample.
Other candidate viruses include members of the herpesvirus family. The most 
thoroughly examined human herpesvirus is EBV and this virus has been 
associated with a proportion of cases of HD and NHL. As stated previously, EBV 
was detected in a proportion of these cases of HD.
Two herpesviruses, HHV- 6  and 7, have recently been isolated and they have 
been shown to be distinct from other herpesviruses at the molecular level. The 
initial isolation of HHV- 6  from six patients with various lymphoproliferative 
diseases (Salahuddin et al., 1986) suggested that there may be an association 
between HHV- 6  and lymphoproliferative disease. The oncogenic potential of 
HHV- 6  was reported by Razzaque (1990). HHV- 6  has the ability to transform 
NIH 3T3 cells and these transformed cells cause tumours in nude mice. This 
oncogenic potential of HHV- 6  is in keeping with the majority of herpesviruses 
(reviewed by MacNab, 1987), although the viral oncogenes in HSV-1, HSV-2 and 
CMV have not been identified (Cameron et al., 1985, Galloway etal., 1984).
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HHV- 6  DNA sequences have been detected in tissue samples from patients with 
malignant disease (Jarrett et al., 1988, Josephs et al., 1988). However, HHV- 6  
sequences were not detected in any of the HD or NHL cases in this series using 
Southern blot analysis (R. Jarrett, personal communication). In contrast to these 
findings, using a PCR technique, Torelli et al. (1991) detected HHV- 6  DNA in 3 of 
65 HD cases, however HHV- 6  was absent in the 41 NHL cases studied (G. 
Torelli, personal communication). HHV- 6  DNA was observed in only two of these 
cases using a Southern blot analysis. It has been shown previously that the 
sensitivity of PCR enables amplification of HHV- 6  sequences which are present 
in infected lymphocytes and therefore a direct role for HHV- 6  has still to be 
clarified. The detection of HHV- 6  within RS cells in HD using in situ hybridisation 
would clarify the role of HHV- 6  in lymphoproliferative disease. One such study 
detected HHV- 6  positive cells in lymphocytes, however the virus was not present 
in RS cells (Krueger etal., 1989).
HHV-7 was isolated by Frenkel et al. (1990), from stimulated, purified CD4+ T 
cells from a healthy individual. Further isolates from chronic fatigue syndrome 
and saliva from healthy persons (Berneman et al., 1992, D. Clark, personal 
communication) have been reported. There does appear to be a widespread 
distribution of the virus and infection occurs early in childhood. Serological 
studies have shown elevated titres to HHV-7 in non EBV-associated cases of 
HD, however these differences did not reach statistical significance (R.Jarrett, 
personal communication). In this study, in collaboration with Dr Z. Berneman, 
there was no evidence of HHV-7 infection in cases of HD or NHL.
In conclusion the lack of known potentially oncogenic DNA viruses in HD, NHL 
and reactive conditions has strengthened the evidence that an as yet unidentified 
virus may be involved in the non EBV-associated HD cases. Studies to identify
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novel viral sequences from single RS cells are now ongoing in the LRF Virus 
centre.
135
Chapter 9 
General Discussion
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it is only recently that molecular evidence linking EBV with HD has been reported. 
As discussed in section 1.5.4, EBV genomes have been detected in a proportion of 
HD biopsies using Southern blot hybridisation. Despite the presence of clonal EBV 
genomes in HD cases, it has been recognised that the detection of viral nucleic acid 
in samples from affected tissues is not sufficient to establish a relationship between 
a virus and disease (section 1 .6 ).
HD is an unusual malignancy in which the tumour cells, RS cells, constitute only a 
minority of the tumour mass (section 1.3.2). Thus, the detection of EBV in RS cells 
would strongly support an aetiological role for EBV in HD. In view of this, the initial 
investigations of this project were designed to determine the cellular localisation of 
EBV within HD biopsy material (Chapters 3 and 4).
The demonstration of the EBV latent gene product, LMP-1 exclusively in RS cells in 
HD has indicated that EBV is localised to the malignant cells in HD. The 
transcription and translation of a latent gene, with oncogenic potential, in RS cells 
supports the idea that EBV is likely to be involved in the disease process in HD 
(Chapter 3). Further support for this concept was presented by the expression of 
LMP-1 in the majority of HD cases previously shown to have clonal EBV genomes.
Using immunohistochemicai staining expression of LMP-1 was detected in RS cells, 
in the absence of EBNA-2 expression. Due to a lack of effective antibodies for the 
other EBV latent genes, Deacon et al, (1993) examined the pattern of EBV latent 
gene expression in EBV-positive HD at the transcriptional level. A distinct and 
consistent pattern of viral transcription was identified which included the expression 
of EBNA-1, LMP-1, LMP-2A and 2B. As EBNA-1 is required for the maintenance of 
the viral genome in episomal form, it was assumed that the EBNA-1 protein was
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expressed in HD however until recently there was no direct evidence tor this. 
EBNA-1 expression in RS cells has now been confirmed in a proportion of HD cases 
using a monoclonal antibody (P. Murray, personal communication). Overall, these 
results indicate that the pattern of EBV latent gene expression in HD is similar to 
that seen in the epithelial malignancy, NPC. This pattern of latency is distinct from 
other patterns of EBV latency observed in EBV-associated malignancies, in vivo 
(see section 1.4.5). The latency pattern associated with HD, consisting of EBNA-1, 
LMP-1 and LMP-2, has been described as Lat II (Figure 9.1). The BZLF-1 protein, 
an early lytic cycle protein, has only been detected within the nuclei of a minority of 
RS cells within a minority of HD cases (Pallesen et ai., 1991b, Brousset et ai., 
1993a). Thus in the majority of cases of HD, EBV infection in RS cells is tightly 
latent. In general, the pattern of EBV latent gene expression is less heterogeneous 
in HD than in other EBV-associated malignancies.
In order to further elucidate the role of LMP-1 in HD, the expression of LMP-1 was 
correlated with the presence of various cellular genes. From previous work on B- 
cells in vitro, LMP-1 has been shown to have the ability to induce a number of 
cellular genes including CD23, CD40 and bcl-2. It is clear from the results 
presented in Chapter 3 that CD23 is rarely detected in RS cells. Furthermore, there 
is no correlation between the detection of CD23 and LMP-1 expression in RS cells. 
As discussed in Chapter 3, the absence of EBNA-2 expression in HD may a 
significant factor in the lack of upregulation of CD23.
Expression of the LMP-1 protein has been shown to induce the expression of bcl-2 
and this in turn is thought to contribute to the development of tumours by the 
inhibition of apoptosis thereby increasing cell survival. Although the t(14;18) 
translocation which is involved in the dysregulation of bcl- 2  has been detected in a
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Figure 9.1 Patterns of EBV latent gene expression
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small number of HD cases, bcl-2 expression has not been consistently detected in 
RS cells (Chapter 3). It would appear that the expression of bcl-2 as a result of 
induction by LMP-1 or the t(14;18) translocation was not consistently detected in 
HD.
CD40, a member of the nerve growth family receptor family, has also been 
investigated in HD. CD40 has been shown to mediate several effects on B-cells in 
vitro including prevention of apoptosis in germinal centres (Liu etal., 1989) which is 
accompanied by the expression of bcl-2. Despite high levels of CD40 expression in 
RS cells, the expression of CD40 was not shown to correlate with either bcl-2 or 
LMP-1 expression (O'Grady etal., 1994). Although these studies have not clarified 
the role of LMP-1 in HD, the results suggest that LMP-1 acts on cellular genes in HD 
in a manner distinct from that described in B-cells in vitro.
One specific feature of LMP-1 which requires further investigation is the finding that 
LMP-1 protein is highly Immunogenic and has the ability to generate EBV-specific 
cytotoxic T lymphocyte (CTL) reponses in healthy individuals (Murray et a i, 1988, 
1992b). The expression of LMP-1 in HD would imply that there is an immune defect 
in HD, a concept suggested in previous studies (Kumar & Penny, 1982). The 
possibility that the downregulation of the immunodominant EBNA-3 family of 
proteins in HD may help RS cells evade EBV-specific CTL surveillance has been 
proposed. However since LMP-1 and LMP-2, which are both immunogenic, are 
both present in HD, it is unclear how RS cells evade immune-destruction. One 
possibility may be through variations in LMP-1 sequence which may represent less 
immunogenic forms of EBV (Knecht et ai, 1993).
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The LMP-2 peptide epitope presented by HLA A2.1 has recently been identified 
(Lee etal., 1993). As LMP-2 is present in RS cells, studies have been designed to 
determine the prevalence of HLA A2 in HD. It has been suggested that EBV- 
positive HD may be more prevalent among HLA A2-negative persons. Poppema & 
Visser (1994a) recently reported that the expression of HLA A2 in HD did not 
correlate with EBV status.
The suggestion that a defect in HLA class I expression in HD may account for the 
lack of a CTL response has also been investigated. In a recent study, strong 
staining for HLA class II in RS cells was evident, however HLA class I expression 
was absent in most cases (Poppema & Visser, 1994b). These results require 
further investigation as this may be an important mechanism through which RS cells 
escape immune recognition.
Comparison of techniques to detect EBV in HD material indicated that the RNA in 
situ hybridisation is the most useful, sensitive and reliable method of determining 
EBV latent infection. From the results of the studies described in Chapter 4, HD 
cases which were EBV-positive either by in situ studies or Southern blot 
hybridisation for the detection of clonal EBV genomes were designated EBV- 
associated. As the EBER RNA is present consistently in all RS cells of EBV-positive 
HD cases, this assay is ideal for the investigation of the epidemiological aspects of 
HD in relation to EBV.
The heterogeneous nature of HD has been highlighted by the detection of EBV in 
specific groups of cases. EBV was associated with paediatric HD cases <10 years 
of age, older adult cases and MCHD cases (Chapters 5 and 6 , Armstrong et al., 
1993). Paediatric HD cases from different geographical locales were strongly EBV-
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associated which leads us to believe that EBV is important in the pathogenesis of 
HD in these cases. A poorer prognosis has been associated with older age and 
MCHD cases. However, in the present studies described in Chapter 7, EBV was not 
shown to be a useful prognostic marker In HD (Armstrong etal., 1994),
The identification of EBV within specific subgroups of HD suggests that this disease 
may comprise of a range of conditions which have various aetiologies, some of 
which are strongly associated with EBV. This situation is similar to that observed in 
BL where eBL is strongly associated with EBV however in a proportion of cases of 
BL the virus is not detected in the tumour cells. In BL the presence of the myc 
translocation, as described in section 1.5.1, is detected in both EBV-positive and 
EBV-negative BL cases. It is likely that EBV is one step in a multi-step process 
leading to development of a tumour.
Although the epidemiological features of HD suggest that young adult HD is most 
likely to be caused by an infectious agent (section 1.3.4), this group of cases is less 
frequently associated with EBV (see Chapter 6 ). We speculate that another as yet 
unidentified infectious agent may be Involved in these cases.
The above observation prompted the studies described in Chapter 8 . Viruses with 
known oncogenic potential were specifically chosen for investigation. The failure to 
detect these viruses in HD samples may be because they are present at low copy 
number. Therefore an assay which incoporates the extreme sensitivity required to 
detect a single copy viral gene within a tumour cell population of HD is essential. 
An assay which allows the amplification of low copy viral DNA combined with the 
added advantage of the localisation of the virus to malignant cells would be 
particularly useful in situations, such as HHV-6 , where the virus has been detected
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previously in the reactive infiltrate of HD. One such assay has recently been 
described, PCR //7 s/ft/hybridisation (Hasse etal., 1991).
From the above data, there is no absolute proof that EBV is directly involved in the 
pathogenesis of HD. There is a growing list of diseases in which EBV has been 
detected including Ki-1 anaplastic large cell lymphoma (Herbst et al., 1991b, 
Carbone et al., 1993), gastric carcinoma with lymphoid stroma (Oda et al., 1993), 
lethal midline granuloma (HarabuchI etal., 1990, Borisch et al., 1993), pyrothorax- 
associated pleural lymphoma (Fukayama et al., 1993) and enteropathy-associated 
T-cell lymphoma (Pan etal., 1993). EBV has not been detected in lymphomatoid 
papulosis (Kadin et al., 1993), hairy cell leukaemia or monocytoid B-cell lymphoma 
(Chang et al., 1993b) although an infectious aetiology is suspected for these 
conditions.
Due to the scarcity of RS cells in HD tumour tissue and a lack of a distinct 
immunophenotype for these cells, there are problems associated with the study of 
HD material. Few cell lines have been derived from HD biopsy material and those 
which have been successfully cultured tend to have originated from late stage HD 
material (V. Diehl, personal communication). To date, no animal model for HD has 
been established. Recently, the severe combined immunedeficient (SCID) mouse, 
transplanted with HD biopsy material, was examined as a potential model system 
for HD. All of the mice produced tumours which had a B-cell phenotype and 
resembled EBV-positive human B-cell lymphoproliferations (Kapp et al., 1993, A. 
Krajewski, personal communication). It was thought that this animal model would 
allow investigation of RS cells independent from a host response, however these 
EBV-positive tumours are more likely to have been derived from EBV-infected small 
bystander lymphocytes present within the cellular infiltrate. These studies indicate
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that the SCID mouse model for HD is not an adequate system to determine the 
histogenesis of RS cells.
The above observations indicate that it is particularly difficult to propagate RS cells 
in culture therefore it would appear that another method of examination of HD 
biopsy material is required. Analysis at the single cell level, where the RS cells are 
investigated independently of the cellular infiltrate, has been recently reported. 
Trumper et al. (1993) described a single-cell based PCR technique in which cDNA 
sequences from single RS cells were analysed. This technique showed that the 
expression pattern of lineage markers in RS cells was heterogeneous between 
cases and that single RS cells coexpressed genes characteristic of several 
haematopoietic lineages, in addition, mutation in exon 7 of the p53 gene was 
present in five out of seven single RS cells from the one case studied. It has 
previously been shown using immunohistochemicai methods that p53 is 
overexpressed in HD. These results highlight the possibility that mutant p53 may be 
involved in the neoplastic process in a proportion of HD cases. There was no 
correlation of p53 with the EBV status of HD lesions (Niedobitek etal., 1993).
Further application of the single cell PCR method has allowed the investigation of 
the origin of the malignant cells in HD. Using a single cell PCR method, Roth et al. 
(1994) examined the presence of IgH gene rearrangements in RS cells. This group 
failed to detect Ig gene rearrangements in single RS cells. However using a similar 
strategy two groups recently reported rearrangements of Ig genes in single RS cells 
(H.Stein and ML. Hansmann, personal communication to R. Jarrett). These 
techniques may allow the identification of an interaction between epidemiological, 
environmental and genetic events in HD.
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The application of the single cell PCR assay, as mentioned above, to HD tumour 
biopsy material would assist in the identification of novel viral sequences at the RNA 
level in single RS cells specifically in non EBV-associated cases. These studies are 
now underway at the LRF virus centre.
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Appendix I 
Buffers and Solutions
TNE buffer for purification of high Sodium chloride
molecular weight DNA Tris pH 8
EDTA adjusted to pH 8
TE buffer
TAE buffer
Tris pH 8 
EDTA pH 8
Trie base 
Sodium acetate 
Sodium chloride 
EDTA adjusted to pH 8
Iris base 
Boric acid
EDTA adjusted to pH 8
Sodium hydroxide 
Sodium chloride 
adjusted to >pH 12
Tris base 
Sodium chloride 
Cone. HOI 
adjusted to pH 8
Elution buffer for removal of DNA fragments Sodium chloride 
from DEAE membrane Tris pH 9EDTA
TBE buffer
Alkali buffer
Neutralising buffer
ssc
Denhardt's solution (lOOx)
Southern hybridisation buffer
Sodium chloride 
Sodium citrate
Ficoll
Bovine serum albumin 
Polyvinyl Pyloridine (PVP)
Formamide 
Denhardt's solution 
Sodium dodecyl sulphate 
Iris pH 7.4 
EDTA pH 8 
SSC
Dextran sulphate 
Genebloc
144mM
lOmM
ImM
lOmM
ImM
40mM
20mM
20mM
2mM
90mM
90mM
2.25mM
0.5M
1.5M
0.5M
3M
3.3%
1M
50mM
ImM
0.15M 
0.015M
2%
2%
2%
As appropriate
5x
0.1%
50mM
lOmM
3x
10%
250pgAnL
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Appendix II
Solutions for immunohistochemicai staining I
TBS Sodium chloride 
Tris pH 7.6
0.15M
0.05M
Lugol's Iodine solution Iodine
Potassium iodide
40mM
120mM
Scotts Tap Water substitute Potassium bicarbonate (w/v) 
(STWS) Magnesium sulphate (w/v)
0 .2%
2%
Fast red substrate Naphthol AS-BI phosphate 
Dimethyl formamide (v/v) 
Tris pH 8.2 
Levamisole 
add Fast red TR salt
40mg/200mL
0.5%
0.1M
5mM
Img/mL
NBT/BCIP substrate Tris pH 9 
Sodium chloride 
Magnesium chloride 
add NBT 
add BCIP
0.1M
0.1M
5mM
0.33mg/mL
0.16mg/mL
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Appendix I I  cont’d
Solutions tor Immunohistochemicai staining II
Stock solution of NBT
Stock solution of BCIP
NBT
Dimethyl formamide 
BCIP
Dimethyl formamide
75mg/mL
75%
50mg/mL
100%
Mayer's haematoxylin Haematoxylin In IL distilled water 
Potassium or aluminium sulphate 
Citric acid 
Chloral hydrate 
Sodium lodate
0 .1%
5%
0 .1%
5%
0.02%
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Appendix HI
Solutions for in situ hybridisation
Pronase buffer Tris pH 7.5 EDTA pH 8
50mM
5mM
Glycine buffer Tris pH 7.5 
Sodium chloride 
Glycine
0.1M
0.1M
2mg/mL
Prehybridisation solution Sodium phosphate Denhardt's solution 
Dextran sulphate
20mM
1 x
10%
Hybridisation buffer Formamide 
Dextran sulphate 
Sodium phosphate pH 7.4 
SSC
Denhardt's solution 
Genebloc 
yeast tRNA
As appropriate 
10%
20mM
3x
1x
lOOpg/mL 
125pg/mL
Antibody buffer BSA
Tris pH 7.5 
Sodium chloride 
Magnesium chloride 
Brij 35 (w/v)
0.1%
0.1M
0.1M
5mM
0.25%
Wash solution 1 Tris pH 7.5 
Sodium chloride 
Triton-X 100 
Magnesium chloride
0.1M 
0.1M 
0 .01% 
5m M
Wash solution 2 Tris pH 9 
Sodium chloride 
Magnesium chloride
0.1M
0.1M
5mM
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Appendix IV
Solutions for growth and alkaline lysis of bacteria
Luria-Bertani (LB) medium
SOC medium
L-agar 
STE buffer
Solution 1
Solution 2 
Solution 3
Lysozyme solution 
PCI9
Sodium chloride 
Bacto-tryptone 
Bacto-yeast extract 
adjusted to pH 7
Bacto-tryptone 
Bacto-yeast extract 
Sodium chloride 
Potassium chloride 
Magnesium deride 
Glucose 
adjusted to pH 7
LB medium with Bacto-agar 
added
Sodium chloride 
Tris pH 8
EDTA adjusted to pH 8
Tris pH 8 
EDTA pH 8 
glucose
Sodium hydroxide 
SDS
Potassium acetate (5M) 
glacial acetic acid 
deionised water
lysozyme in HgO
phenol 
chloroform 
isoamyl alcohol
170mM
1%
0.5%
2%
0.5%
10mM
2.5mM
10mM
20mM
1.5%
0.1M
lOmM
ImM
25mM
lOmM
50mM
0.2M
1%
60mls 
11 mis 
28.5mls
5mg/mL
50%
48%
2%
:
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Appendix V
Coating glass slides using 3-aminopropyltriethoxysilane (APES)
Prior to coating with the APES solution, the glass slides were soaked in 10% Decon 
at room temperature overnight, rinsed under tap water for at least one hour and 
dried overnight at 65^C. The slides were immersed in a 2% solution of APES in 
acetone for five seconds, rinsed in acetone, washed in distilled water and dried at 
3 7 0 c  overnight. The slides were wrapped in foil and stored at room temperature.
Preparation of diethyl pyrocarbonate(DEPG)-treatment of water
Deionised water was treated with 0.1% diethyl pyrocarbonate (DEPC) and 
autoclaved for 20 minutes at 15 lb/square inch on liquid cycle.
Preparation of pronase
A stock solution of pronase at 20mg/mL was pretreated at 37%  for two hours to 
eliminate the DNase present. The solution was aliquoted and stored at -20OC.
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Appendix VI
Mixing table for Tris buffers
The stated quantities are for 500mL of a 1M solution which when diluted to 50mM at 
room temperature will be at the stated pH.
Tris Buffers PH7.5 pH8.0 pH8.2 PH9.0
Tris HCI 63.5q 44.4q 35.4g 7.6g
Tris base 11.8g 26.5q 33.4g 54.7g
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